2015N231 308_03 CONFIDENTIA L
The GlaxoSmithKline group of companies 201832
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title:201832: A Randomised, Double- Blind, Double -Dummy ,
Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25
mcg Once Daily  Versus Fluticasone Propi[INVESTIGATOR_16847] 250 mcg Twic e
Daily  in Adolescent and Adult Subjects with Asthma and
Exercise -Induced Bronchoconstriction
Compound Number: GW685698+GW642444
Development Phase: IV
Effective Date: 25-MAY -2016
Protocol Amendment Number:  3
Author (s):  
Copy right [ADDRESS_536145] dose of double -blinded study  medication in each 
Treatment Period. The purpose is to demonstrate that inhaled Fluticasone 
Furoate/Vilanterol (FF/VI)100/[ADDRESS_536146] 
exercise -induced bronchoconstriction (EIB ) compared with Fluticasone Propi[INVESTIGATOR_16847] (FP) 
250 mcg after 23 hours of treatment with blinded medication. In addition, it will allow for 
an evaluation of the presence and extent of tach yphylaxis. Separatel y, the study  title was 
revised to indicate the study is a ‘randomised’ study  with a ‘crossover’ design. Other 
minor corrections and edits were also made.
2015N231308_02 2015 -DEC -16 Amendment No. 2
This protocol is being amended to increase the screen failure rate to 20% (from 10%) and 
the run- in failure r ate to 70% (from 55%). This takes into consideration the challenge of 
enrolling EIB subjects with Sy mptomatic Allergic Rhinitis (SAR) at screening and also 
the challeng e for subjects to demonstrate a decrease in FEV1 of ≥20% at one time point 
within 30 minutes of the end of the exercise challenge at Visit 2; after taking fluticasone 
propi[INVESTIGATOR_424270]- in period. The amendment also 
allows subjects with sy mptomatic allergic rhinitis at screening to be treated with 
intranasal corticosteroids for up to four weeks, followed by  a repeat screening visit to 
determine eligibility  prior to entry  into the study . Subjects with sy mptomatic allergic 
rhinitis during the study  may  be treated with intranasal corticosteroids at a constant dose 
for the duration of the study . 
The time window for the repeat exercise challenge has been extended from 24 -48 hours 
to up to one week; taking into consideration the challenge for subjects to return within [ADDRESS_536147].
Tobacco/ma rijuana use and pregnancy  (which were omitted in error in the original 
protocol) have been added as exclusion criteria.
The secondary  endpoint for time to recovery  has been changed to a binary  endpoint 
defining recovery  as those subjects who have a [ADDRESS_536148] -exercise FEV 1
measurement that is no more than 5% lower than their pre- exercise FEV 1. In addition, the 
statistical testing hierarchy has been changed to prioritise the maximal percentage FEV 1
reduction (primary  endpoint) and binary  recovery  endpoin ts following the [ADDRESS_536149] to visit timing:
Visit 2 (currentl y Da y 1) redefined as Day  0 and Visit 3 (currentl y Da y 2) redefined as 
Day 1.
Visit window around day 29 removed and footnote added.
Text regarding timing of visits clarified to ensure that the intention of the protocol i s 
clearl y reflected
Other changes were made as follows:
Subject number will be assigned at Pre -Screening following informed consent rather than 
at Visit 1
Nucala ™ added as a n example prohibited medication
Rescue medication supply  strategy  has been removed and the reader referred to the SRM
Confirmation that post exercise vital signs will be immediately  post exercise, not after [ADDRESS_536150].
[COMPANY_003]
[COMPANY_003]
2015N231308_03 CONFIDENTIA L
201832
5MEDICA L MONITOR/SPONS OR INFORM ATION PA GE
Medical Monitor/SAE Contact [CONTACT_7171]: 
Role Name [CONTACT_417536] -hours 
Phone/Cell/
Pager 
NumberFax 
NumberSite Address
Primary 
Medical 
Monitor   Not 
ApplicableStockley 
Park West, 
1-[ADDRESS_536151]  
information Medical 
monitor 
as above
Sponsor Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_536152]
Middlesex, TW8 9GS
[LOCATION_006]
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline Affiliate 
Company  (or designee). If applicable, the details of the alternative Sponsor and contact 
[CONTACT_424351].   
Regulatory  Agency  Identify ing Number(s): IND number for FF/VI (077855), IND 
number for FP (IND 044090).
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2015N231308_03 CONFIDENTIA L
[ADDRESS_536153] to ensure that site 
staff receives the appropriate information throughout the study . 
Investi gator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator Signature [CONTACT_1782]
2015N231308_03 CONFIDENTIA L
201832
7TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 201832 ...................................................... 11
2.INTRODUCTION ................................
.................................................................... 16
2.1. Background ................................................................................................ 16
2.2. Study Rationale .......................................................................................... 16
2.3. Brief Background ........................................................................................ 16
3.OBJECTIVE ........................................................................................................... 17
3.1. Primary Objective ....................................................................................... 17
4.ENDPOINTS .......................................................................................................... 17
4.1. Primary Endpoint ........................................................................................ 17
4.2. Secondary Endpoints .................................................................................. 17
4.3. Other Endpoints .......................................................................................... 17
4.4. Safety Endpoints ......................................................................................... 18
5.STUDY DESIGN .................................................................................................... 18
5.1. Overall Design ............................................................................................ 18
5.2. Treatment Arms and Duration ..................................................................... 20
5.3. Type and Number of Subjects ..................................................................... 21
5.4. Design Justification ..................................................................................... 21
5.5. Dose Justification ........................................................................................ 21
5.6. Benefit: Risk Assessment ........................................................................... 22
5.6.1. Risk A ssessment ......................................................................... 23
5.6.2. Risk assessment for FP 250mcg ................................................. 30
5.6.3. Benefit Assessment ..................................................................... 30
5.6.4. Overall Benefit: Risk Conclusion .................................................. 30
6.SELECTIO N OF STUDY POPULATIO N AND WITHDRA WAL CRI TERIA ............. 31
6.1. Screening Criteria ....................................................................................... 31
6.1.1. Inclusion Criteria .......................................................................... 31
6.1.2. Exclusion Criteria ......................................................................... 32
6.2. Randomization Criteria ............................................................................... 34
6.2.1. Inclusion Criteria .......................................................................... 34
6.2.2. Exclusion Criteria ......................................................................... 35
6.3. Screening/Baseline/Run -in Failures ............................................................ 35
6.4. Withdrawal/Stoppi[INVESTIGATOR_2121] ....................................................................... [ADDRESS_536154] to Follow up (Non- Attendance) ............................................. [ADDRESS_536155] Number .................................................... 41
7.2.2. Assignment of Treatment Number ............................................... 41
2015N231308_03 CONFIDENTIA L
201832
87.3. Blinding ....................................................................................................... 42
7.4. Packaging and Labeling .............................................................................. 42
7.5. Preparation/Handling/Storage/Accountability .............................................. [ADDRESS_536156] Malfunction............................................................. 43
7.7. Compli ance with Study Treatment Administration ....................................... 43
7.8. Treatment of Study Treatment Overdose .................................................... 43
7.9. Treatment after the End of the Study .......................................................... 44
7.10. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] .................................... 44
7.10.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 44
[IP_ADDRESS]. Permitted Asthma Medications ................................... 44
[IP_ADDRESS]. Permitted Non -Asthma Medications ........................... 44
7.10.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 45
[IP_ADDRESS]. Prohibited Non- Asthma Medications ........................... 46
8.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 46
8.1. Time and Events Table ............................................................................... 47
8.2. Critical Baseline Assessments .................................................................... 50
8.3. Efficacy ....................................................................................................... 50
8.3.1. Spi[INVESTIGATOR_038] ................................................................................... 50
[IP_ADDRESS]. Target FEV 1Calculations ........................................... 51
8.3.2. Exercise Challenge Testing ......................................................... 51
[IP_ADDRESS]. Worsening of Asthma during Exercise 
Challenge ................................................................... 52
8.3.3. Key Study Assessments .............................................................. 52
[IP_ADDRESS]. Visit 1 (Screening) ...................................................... 52
[IP_ADDRESS]. Visit 2 (Randomization) .............................................. 52
[IP_ADDRESS]. Visit 3 and Visit 6 ([ADDRESS_536157] Dose 
Exercise Challenge) ................................................... 53
[IP_ADDRESS]. Visit 4 and Visit 7 (Blinded Treatment Exercise 
Challenges) ................................................................ 54
[IP_ADDRESS]. Visit 5 ......................................................................... 54
8.3.4. Physical Activity Monitor .............................................................. 54
8.3.5. Asthma Control Questionnaire- 5 (ACQ -5).................................... 55
8.4. Safety ......................................................................................................... 55
8.4.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 56
[IP_ADDRESS]. Time period and Frequency for collecting AE 
and SAE information ................................................... 56
[IP_ADDRESS]. Method of Detecting AEs and SAEs ........................... 56
[IP_ADDRESS]. Follow -up of AEs and SAEs ........................................ 57
[IP_ADDRESS]. Cardiovascular and Death Events .............................. 57
[IP_ADDRESS]. Regulatory R eporting Requirements for SAEs ............ 57
8.4.2. Asthma Exacerbations ................................................................ .58
8.4.3. Pregnancy ................................................................................... 58
8.4.4. Physical Exams ........................................................................... 58
8.4.5. Vital Signs .................................................................................... 58
8.4.6. Electrocardiogram (ECG) ............................................................. 59
8.5. Genetics ..................................................................................................... 59
9.DATA MANAGEMENT ........................................................................................... 59
10.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .60
10.1. Hypotheses ................................................................................................ .60
2015N231308_03 CONFIDENTIA L
201832
910.2. Study Design Considerations ...................................................................... 61
10.2.1. Sample Size Assumptions ........................................................... 61
10.2.2. Sample Size Sensitivity ................................................................ 62
10.2.3. Sample Size Re- estimation .......................................................... 62
10.3. Data Analysis Considerations ..................................................................... 63
10.3.1. Analysis Populations .................................................................... 63
10.3.2. Analysis Data Sets ....................................................................... 63
10.3.3. Treatment Comparisons .............................................................. 63
[IP_ADDRESS]. Primary Comparisons of Interest ................................ 63
[IP_ADDRESS]. Other Comparisons of Interest .................................... 63
10.3.4. Interim Analysis ........................................................................... 64
10.4. Key Elements of Analysis Plan ................................................................... 64
10.4.1. Efficacy Analyses ......................................................................... 64
[IP_ADDRESS]. Primary Analysis ......................................................... 64
[IP_ADDRESS]. Secondary Analyses ................................................... 65
[IP_ADDRESS].1. Other Efficacy Analyses .......................... 65
10.4.2. Safety Analyses ........................................................................... 66
[IP_ADDRESS]. Extent of Exposure ..................................................... 66
[IP_ADDRESS]. Adverse Events (AEs) ................................................ 66
[IP_ADDRESS]. Exacerbations ............................................................. 66
10.4.3. Pharmacogenetic Analyses ......................................................... 66
11. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 66
11.1. Posting of Information on Publicly Available Cli nical Trial Registers............ 66
11.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 66
11.3. Quality Control (Study Monitoring) .............................................................. 67
11.4. Qual ity Assurance ....................................................................................... 68
11.5. Study and Site Closure ............................................................................... 68
11.6. Records Retention ...................................................................................... 68
11.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Av ailable Clinical Trials Registers and Publication ................. 69
12.REFERENCES ....................................................................................................... 70
13.APPENDICES ........................................................................................................ 72
13.1. Appendix 1 –Abbreviations and Trademarks .............................................. 72
13.2. Appendix 2: Liver Chemistry Stoppi[INVESTIGATOR_424271] .................................................................................................... 74
13.3. Appendix 3: Liver Safety Required Actions and Follow up 
Assessments .............................................................................................. 76
13.4. Appendix 4: Genetic Research ................................................................... 80
13.5. Appendix 5: Definition of and Procedures for Recording, Evaluating, 
Follow -Up and Reporting of Adverse Events ............................................... 83
13.5.1. Definition of Adverse Events ........................................................ 83
13.5.2. Definition of Serious Adverse Events ........................................... 84
13.5.3. Definition of Cardiovascular Events ............................................. 86
13.5.4. Recording of AEs and SAEs ........................................................ 86
13.5.5. Evaluating AEs and SAEs ............................................................ 87
13.5.6. Reporting of SAEs to [COMPANY_004] ........................................................... 88
2015N231308_03 CONFIDENTIA L
[PHONE_8791].6. Appendix 6: Modified List of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproductive Potential (FRP) and 
Collection of Pregnancy Informat ion........................................................... 90
13.6.1. Collection of Pregnancy Information ............................................ 90
13.7. Appendix 7 -Country Specific Requirements .............................................. 92
13.8. Appendix 8 –Protocol Changes .................................................................. 93
13.8.1. Protocol Amendment 01 .............................................................. 93
13.8.2. Protocol Amendment 02 ............................................................ 116
13.8.3. Protocol Amendment 03 (25 -MAY -2016) from Protocol 
Amendment 02 (16 -DEC- 2015) ................................................. 162
2015N231308_03 CONFIDENTIA L
201832
111. PROTOCOL SYNOPSIS FOR STUDY 201832
Rationale
For man y patients with symptomatic asthma, physical exertion is often a precipi[INVESTIGATOR_424272]. Although vary ing in methodology  and criteria, early studies showed that as many  
as 90% of asthmatic patients have br onchoconstriction after exercise. In subjects with 
symptoms of persistent asthma, exercise and other forms of phy sical activity  represent 
only one of many  triggers that lead to worsening sy mptoms. 
Chronic treatment with inhaled corticosteroids (ICS) has b een shown to reduce the 
severit y of asthma associated with exercise. However, some patients continue to 
demonstrate asthma s ymptoms and a decrease in lung function during exercise even 
while receiving ICS. In patients with persistent asthma, improvements i n protection from 
exercise -induced bronchoconstriction (EIB) with ICS/long- acting beta 2-agonist (L ABA) 
combination product Fluticasone propi[INVESTIGATOR_16847] (FP )/salmeterol (ADVAIRTM) have been 
demonstrated. However, differences between FP/salmeterol and FP monothera py have 
not consistently  been observed.  In a stud y that evaluated the effect of FP/salmeterol 
compared with FP over the 12 hour dosing interval, a large percentage of subjects in both 
the FP/salmeterol (18%) and FP (36% and 33% at Day  1 and Week 4, respec tively ) 
treatment arms failed to complete the second exercise challenge test 8.[ADDRESS_536158] EIB towards the end of the 12 hour dosing 
interval. 
FF/V I (Fluticasone furoate/Vilanterol) , a new ICS/L ABA combinati on treatment, is 
dosed once dail y and has demonstrated significant bronchodilation over 24 hours. The 
purpose of this study  is to determine if the once -daily  administration of FF/VI  
demonstrates improved protection from EIB over ICS alone (FP) over the [ADDRESS_536159] of fluticasone furoate/vilanterol (FF/VI) 100/25 mcg 
once -daily compared with fluticasone propi[INVESTIGATOR_16847] (FP) [ADDRESS_536160] 
exercise -induced bronchoconstriction in adolescent and adult subjects aged 12 to 50 with 
persistent asthma 
Primary  Endpoint
Maximal percent decrease from pre -exercise FEV 1(Forced Expi[INVESTIGATOR_424273] ) following exercise challenge at [ADDRESS_536161] evening dose at the end 
of the 2-week treatment period
2015N231308_03 CONFIDENTIA L
201832
12Secondary  Endpoints
Maximal percent decrease from pre -exercise FEV 1following exercise challenge at 
[ADDRESS_536162] evening dose at the end of the 2 -week treatment period
Proportion of subjects with a [ADDRESS_536163]- challenge FEV 1thatwas no more than 
5% lower than their pre -exercise FEV 1following the exercise challenge at [ADDRESS_536164] evening dose at the end of the 2-week treatment period 
Weighted mean for percentage decrease from pre -exercise FEV 1following exercise 
challenge at [ADDRESS_536165] evening dose (weighted mean 0- 60 min) at 
the end of the 2-week treatment period
Other Endpoints
Categorical treatment response evaluation of the percentage of subjects who 
demonstrate a decrease from pre-exercise cha llenge FEV1 (at [ADDRESS_536166] evening dose at the end of the 2 -week treatment period) of:
o<10%, 
o≥10% to <20%, 
o≥20% 
Maximal percent decrease from treatment period baseline FEV 1following exercise 
challenge at [ADDRESS_536167] evening dose at the end of the 2 -week 
treatment period
Mean change from baseline in Asthma Control Questionnaire-5 (ACQ -5) score at the 
end of the 2- week treatment period.
Percentage of subjects controlled, defined as an ACQ -5 score ≤0.75, at the end of the 
2-week treatment period. 
Percentage of subjects achieving an improvement of ≥0.5 or greater in ACQ -5 score 
at the end of the 2 -week treatment.
Change in ph ysical activity  measures as assessed by  a biosensor (SenseWear 
Armband) in terms of physical activity endpoints (e.g. dail y step count, Metabolic 
Equivalent of Tasks (METs), sleep duration)
Proportion of subjects with a [ADDRESS_536168] -challenge FEV 1that was no more than 
5% lower than their pre -exercise FEV 1following the exercise challenge at [ADDRESS_536169] evening dose at the end of the 2- week treatment period. Repeat for 
the 10,15,45 and 60 minute ti me points. 
Safet y Endpoints
Adverse events 
2015N231308_03 CONFIDENTIA L
[ADDRESS_536170] udy visits (Visit 0 to Visit 7) over the course of the study  and a 
follow up phone call approximately  a week after Visit 7. Visits 1, 2, 3, 5 and 6 are 
evening visits that will be conducted between 5PM and 11PM. Visit 4 and Visit 7 are also 
evening visits that will begin between 5PM and 11PM and continue over a period of 
approximately  24 hours. Subjects will be required to attend three clinic visits during this 
24-hour period.
Standardized exercise challenge testing (using a treadmill) will be conducted at Visit 2 
for eligibility  determination, Visit 3 and Visit 6 (after [ADDRESS_536171] treatment dose 
in each Treatment Period); and at [ADDRESS_536172] evening dose at Visits 4 and 7. 
Spi[INVESTIGATOR_424274] (Visit 1), and pre -dose at Visit 5, and prior to 
each exercise challenge at Visits 2, 3, 4, 6 and 7. Serial spi[INVESTIGATOR_038]  (6 time points over 60 
minutes) as FEV 1only will be conducted after each exercise challenge test. At Visit 2, 
subjects must demonstrate a decrease in FEV 1of ≥20% when compared to the FEV [ADDRESS_536173] -challenge.  Subjects who achieve a decrease in FEV 1of 
15% to <20% may  continue taking their dail y run -in medication and repeat the eligibility  
exercise challenge and associated procedures once within a week of the original 
procedure. Subjects should be monitored until they  reach a recovery  level where their 
FEV 1value represents a 95% recovery  of the pre -exercise FEV 1 result.  Additional 
spi[INVESTIGATOR_424275] .
A Pre -Screening Visit (Visit 0) is included to obtain a signed Informed Consent, 
demograph y and to review concomitant medications, and may  be conducted on the same 
day as Visit 1, if appropriate. 
At Visit 1, subjects meeting eligibility  criteria and will enter a 4 week single- blinded run-
in period on fluticasone propi[INVESTIGATOR_16847] (FP) 250 mcg twice dail y (BD). Subjects with 
symptomatic allergic rhinitis at Vis it 1 (screening) may be treated for up to four weeks 
with intranasal corticosteroids followed b y a repeat screening visit to determine eligibility 
prior to entry  into the study . Onl y one repeat screening visit will be performed following 
treatment with int ranasal corticosteroids. Subjects that continue to be symptomatic after 
up to four weeks of treatment will be excluded. Eligible subjects will enter the run -in 
period. Subjects who are asy mptomatic at screening, who become s ymptomatic during 
the study  will remain in the study  and may  be treated with intranasal corticosteroids at a 
constant dose for the duration of the study .
Albuterol/salbutamol will be issued for rescue use during the run -in, wash -out and 
treatment periods as needed.  Subjects will be instructed to contact [CONTACT_424352].  
All subjects will be given a paper diary  during the run- in, washout and treatment periods 
to record an y medical problems experienced during the stud y, an y medications taken, and 
rescue medicati on usage.
2015N231308_03 CONFIDENTIA L
201832
14A screening electrocardiogram (ECG) and a complete phy sical examination will be 
conducted at Visit 1. Vital signs including pulse rate and s ystolic and diastolic blood 
pressure will be obtained at each clinic visit, including an y Earl y Withdrawal visit. At all 
time points where both vital signs and spi[INVESTIGATOR_424276], vital signs will be done 
before the spriometry  measurement. At visits where the exercise challenge is performed, 
vitals will be measured before (prior to the pre- exercise spi[INVESTIGATOR_038] ) and after the exercise 
challenge. 
Asthma control will be assessed using the ACQ- 5 at Visits 2, 4, 5 and 7.
Physical activity  levels will be monitored to assess activity  outside the clinic with the use 
of a ph ysical activity  monitor (SenseWear Armba nd accelerometer) worn for 7 day s prior 
to Visit 2 (baseline), for 7 days prior to Visit 4 (during the last week of Treatment Period 
1), for 7 days prior to Visit 5, and for 7 day s prior to Visit 7 (during the last week of 
Treatment Period 2).  Subjects un willing or unable to participate in dail y physical activity 
monitoring may  still participate in the study , if appropriate.
A follow up phone call will be conducted approximately  7 day s after Visit 7.
Treatment A rms and Duration
Two treatment arms will be e mploy ed for the study : 
FF/V I 100/25 mcg QD via ELLIPTA + Placebo BD via Diskus
FP 250 mcg BD via Diskus + Placebo QD via ELLIPTA
As this is a [ADDRESS_536174] approximately  7-days after completing 
Treatment Period 2. The total dur ation of study  participation is approximately  11 weeks; 
and up to 15 weeks for subjects with SAR at screening who may  need to be treated with 
intranasal corticosteroids followed by  a repeat screening visit.
Type and Number of Subjects
Approximately  275 subjects with persistent asthma with evidence of EIB and current use 
of a low -to moderate -dose inhaled corticosteroid (I CS) will be screened in order to 
randomize 66 subjects, assuming a 20% screen failure rate and 70% run -in failure rate. 
This is to achieve 56 evaluable subjects completing the exercise challenges and the FEV 1
evaluations at the end of both treatment periods. This calculation assumes a 15% 
withdrawal rate during the study .  
2015N231308_03 CONFIDENTIA L
201832
15Analysis
The primary  treatment comparison will be between the FF/VI combination and FP and 
will be performed using the intent- to-treat (ITT) Population. Demonstration of efficacy  
for the treatments will be based on a h ypothesis testing approach whereb y the null 
hypothesis is that there is no difference between the populati on treatment groups and the 
alternative h ypothesis is that there is a difference between the population treatment 
groups.  
The primary  endpoint will be defined as the maximal percent decrease from pre -exercise 
FEV 1at [ADDRESS_536175] -exercise minimum 
FEV 1measurements and mean maximal percent decrease from pre- exercise values will 
be summarized with descriptive statistics by  [CONTACT_1570]. A linear mixed model will 
be fitted that includes the following covariates: treatment, subject -level mean of the FEV 1 
period baselines (mean of the [ADDRESS_536176]), centered period -level 
baseline FEV 1(period baselines centered usin g subject -level mean of the FEV 1period 
baselines), gender, age and treatment period as fixed effects, and a random intercept for 
each subject.
A 2-sided 5% probability associated with incorrectly  rejecting the null hy pothesis 
(significance level) is consi dered acceptable for this study .  In order to account for 
multiplicity , the primary  hypothesis test on the primary endpoint for the ITT population 
will act as a gatekeeper for all other h ypothesis tests using the secondary  endpoints, 
where these tests will proceed in a pre -defined order. If a given statistical test fails to 
reject the null h ypothesis of no population treatment group difference at the significance 
level of 0.05, then all tests lower down the hierarchy  will be interpreted as descriptive 
only.  
2015N231308_03 CONFIDENTIA L
201832
162. INTRODUCTION
2.1. Background
For man y patients with symptomatic asthma, physical exertion is often a precipi[INVESTIGATOR_424272]. Although vary ing in methodology  and criteria, early studies showed that as many  
as 90% of asthmatic patients have bronchoconstriction a fter exercise [ McFadden, 1994; 
Poppi[CONTACT_3019] , 1970]. I n subjects with sy mptoms of persistent asthma, exercise and other forms 
of phy sical activit y represent only one of man y trigger s that lead to worsening s ymptoms. 
Chronic treatment with inhaled corticosteroids (ICS) has been shown to reduce the 
severit y of asthma associated with exercise. However, some patients continue to 
demonstrate asthma s ymptoms and a decrease in lung functio n during exercise even 
while receiving ICS. The addition of a long- acting beta 2-agonist (LABA) to I CS has been 
considered as a possible treatment in these cases. International guidelines such as those 
issued by  [CONTACT_424353] (GINA) [ GINA, 2015] and the National Heart 
Lung and Blood Institute (NHLBI) [ NIH, 2007] advocate the use of inhaled L ABA in 
combination with I CS as maintenance therapy  in asthma for subjects who remain 
symptomatic on low -to mid -dose I CS. 
2.2. Stud y Rationale
In patients with persistent asthma, improvements in protection from exercise -induced 
bronchoconstriction (EIB) with I CS/LABA combination product Fluticasone propi[INVESTIGATOR_16847]
(FP)/salmeterol ( Advair™ ) have been demonstrated [ Murray , 2011; 
Pearlman , 2009; 
Weiler , 2005]. However, differences between FP/salmeterol and FP monotherap y have 
not consistently  been observed [ Murray , 2011; Weiler , 2005]. I n a stud y that evaluated 
the effect of FP/salmeterol compared to FP over the 12 hour dosing interval [ Weiler , 
2005], a large percentage of subjects in both the FP/salmeterol (18%) and FP (36% and 
33% at Day  1 and Week 4, respectivel y) treatment arms failed to complete the second 
exercise challenge test 8.[ADDRESS_536177] EIB 
towards the end of the 12 hour dosing interval. 
FF/V I, a new ICS/L ABA combination treatment, is administered once daily and has 
demonstrated significant bronchodilation over 24 hours. The purpose of this study  is to 
determine if the once- daily  administration of FF/VI demonstrates improved protection 
from EIB over ICS alone (FP) over the entire 24 -hour dosing interval.
2.3. Brief Background
Fluticasone furoate (FF) is a novel glucocorticoid approved in the US for use as a once -
daily  inhaled treatment for asthma.  
Vilanterol (VI) is an orally inhaled LABA. The inhaled fixed -dose combination of once-
daily  VI and FF is approved in the US for the maintenance treatment of asthma in adults 
aged 18 and older, and in the European Union and other regions in adults and adolescents 
≥12 y ears of age. The FF/VI  100/25 mcg combination is being developed globally  as a 
2015N231308_03 CONFIDENTIA L
201832
17once -daily therap y for the long -term maintenance treatment of asthma in adults and 
children ≥5 y ears of age. The inhaled fixed- dose combination of FF and VI is 
administered via the Ellipta Dry Powder Inhaler (DPI).  
Information on the ph ysical, chemical, and pharmaceutical properties of FF alone, VI 
(GW642444) alone, and FF/VI in combination may be found in the respective 
Invest igator Brochures (IB).
3. OBJECTIVE
3.1. Primary  Objective
To evaluate the protective effect of fluticasone furoate/vilanterol (FF/VI) 100/25 mcg 
once -daily compared with fluticasone propi[INVESTIGATOR_16847] (FP) [ADDRESS_536178] 
exercise -induced bronchoconstriction in adolescent and adult subjects aged 12 to 50 with 
persistent asthma.
4. ENDPOINTS
4.1. Primary  Endpoint
Maximal percent decrease from pre -exercise FEV 1following exercise challenge at 
[ADDRESS_536179] evening dose at the end of the 2 -week treatment period
4.2. Secondary Endpoints
Maximal percent decrease from pre -exercise FEV 1following exercise challenge at 
[ADDRESS_536180] evening dose at the end of the 2 -week treatment period
Proportion of subjects with a [ADDRESS_536181]- challenge FEV 1that was no more than 
5% lower than their pre -exercise FEV 1following the exercise challenge at [ADDRESS_536182] evening dose at the end of the 2-week treatment period 
Weighted mean for percentage decrease from pre -exercise FEV 1following exercise 
challenge at [ADDRESS_536183] evening dose (weighted mean 0 -60 min) at 
the end of the 2-week treatment period
4.3. Other Endpoints
Categorical treatment response evaluation of the percentage of subjects who
demonstrate a decrease from pre- exercise challenge FEV 1(at [ADDRESS_536184] evening dose at the end of the 2- week treatment period) of:
o<10%, 
o≥10% to <20%, 
o≥20% 
2015N231308_03 CONFIDENTIA L
201832
18Maximal percent decrease from treatment period baseline FEV1 following exercise 
challenge at [ADDRESS_536185] evening dose at the end of the 2 -week 
treatment period.
Mean change from baseline in Asthma Control Questionnaire - 5 (ACQ -5) score at 
the end of the 2-week treatment period. 
Percentage of subjects controlled, defined as an ACQ -5 score ≤0.75, at the end of the 
2-week treatment period. 
Perce ntage of subjects achieving an improvement of ≥0.5 or greater in ACQ -5 score 
at the end of the 2 -week treatment. 
Change in ph ysical activity  measures as assessed by  a biosensor (SenseWear 
Armband) in terms of physical activity endpoints (e.g. dail y step c ount, Metabolic 
Equivalent of Tasks (METs), sleep duration).
Proportion of subjects with a [ADDRESS_536186]- challenge FEV 1that was no more than 
5% lower than their pre -exercise FEV 1following the exercise challenge at [ADDRESS_536187] evening dose at the end of the 2 -week treatment period. Repeat for 
the 10, 15, 45 and 60 minute time points. 
4.4. Safet y Endpoints
Adverse events 
5. STUDY DESIGN
5.1. Overall Design
This is a multicenter, randomized, double -blind, double -dummy , crossover study  with 
two 2 -week tre atment periods separated by  a 2-week wash- out period. Subjects will 
participate in up to eight study  visits (Visit 0 to Visit 7) over the course of the study  and a 
follow up phone call approximately  a week after Visit 7. Visits 1, 2, 3, 5 and 6 are 
evening visits that will be conducted between 5PM and 11PM. Visit 4 and Visit 7 are also 
evening visits that will begin between 5PM and 11PM and continue over a period of 
approximately  24 hours. Subjects will be required to attend three clinic visits during this 
24-hour period.
Standardized exercise challenge testing (using a treadmill) will be conducted at Visit 2 
for eligibility  determination, Visit 3 and Visit 6 (after [ADDRESS_536188] dose in each 
Treatment Period); and at [ADDRESS_536189] evening dos e at Visits 4 and 7. 
Spi[INVESTIGATOR_424274] (Visit 1), and pre -dose at Visit 5 and prior to 
each exercise challenge at Visits 2, 3, 4, 6 and 7. Serial spi[INVESTIGATOR_038]  (6 time points over 60 
minutes) as FEV 1only will be conducted after each exercise challenge test. At Visit 2, 
subjects must demonstrate a decrease in FEV 1of ≥20% when compared to the FEV [ADDRESS_536190] -challenge.  Subje cts who achieve a decrease in FEV 1of 
15% to <20% may  continue taking their dail y run -in medication and repeat the eligibility  
2015N231308_03 CONFIDENTIA L
201832
19exercise challenge and associated procedures once within a week of the original 
procedure. Subjects should be monitored until the y reach a recovery  level where their 
FEV 1value represents a 95% recovery  of the pre -exercise FEV 1 result.  Additional 
spi[INVESTIGATOR_424275] . 
A Pre -Screening Visit (Visit 0) is included to obtain a signed Informed Consent (I CF), 
demograph y and to review concomitant medications, and may  be conducted on the same 
day as Visit 1, if appropriate. 
At Visit 1, subjects meeting eligibility  criteria will enter a 4- week single -blinded run- in 
period on fluticasone p ropi[INVESTIGATOR_16847] (FP) 250 mcg twice dail y (BD). Subjects with 
symptomatic allergic rhinitis at Visit 1 (screening) may  be treated for up to four weeks 
with intranasal corticosteroids followed b y a repeat screening visit to determine eligibility 
prior to entry  into the study . Onl y onerepeat screening visit will be performed following 
treatment with intranasal corticosteroids. Subjects that continue to be sy mptomatic after 
up to four weeks of treatment will be excluded. Eligible subjects will enter the run -in 
perio d. Subjects who are asy mptomatic at screening, who become s ymptomatic during 
the study  will remain in the study  and may  be treated with intranasal corticosteroids at a 
constant dose for the duration of the study .
Albuterol/salbutamol will be issued for res cue use during the run -in, wash -out and 
treatment periods as needed.  Subjects will be instructed to contact [CONTACT_424352].  
All subjects will be given a paper diary  during the run- in, washout and treatment periods 
to record an y medical problems experienced during the stud y, an y medications taken, and 
rescue medication usage.
2015N231308_03 CONFIDENTIA L
201832
20A screening electrocardiogram (ECG) and a complete phy sical examination will be 
conducted at Visit 1. Vital signs including pulse rate and s ystolic and dia stolic blood 
pressure will be obtained at each clinic visit, including an y Earl y Withdrawal visit. At all 
time points where both vital signs and spi[INVESTIGATOR_424276], vital signs will be done 
before the sp irometry  measurement. At visits where the exerc ise challenge is performed, 
vitals will be measured before (prior to the pre- exercise spi[INVESTIGATOR_038] ) and after the exercise 
challenge. 
Asthma control will be assessed using the ACQ- 5 at Visits 2, 4, 5 and 7.
Physical activity  levels will be monitored to asse ss activity  outside the clinic [ Mitchell , 
2014] using a phy sical activity  monitor (SenseWear Armband accelerometer) worn for 7 
days prior to Visit 2 (baseline), for 7 day s prior to Visit 4 (during the last week of 
Treatment Period 1), for 7 day s prior to Visit 5, and for 7 day s prior to Visit 7 (during the 
last week of Treatment Period 2). Subjects unwilling or unable to participate in daily  
physical activity  monitoring may  still participate in the study , if appropri ate. See Study  
Reference Manual (SRM) for additional details.
A follow up phone call will be conducted approximately  [ADDRESS_536191] a repeat screening visit after 
treatment with intranasal corticosteroids.
There are no plans to routinely  provide any  of the study  treatments for compassionate use 
following stud y completion, as asthma treatments including ICS/ LABA combination 
products are available worldwide.
Supplementary  study  conduct information not mandated to be present in this protocol is 
provided in the SRM. The SRM will provide the site personnel with administrative and 
detailed technical information th at does not impact subject safet y.
5.2. Treatment A rms and Duration
Two treatment arms will be employ ed for the study : 
FF/V I 100/25 mcg QD via ELLIPTA + Placebo BD via Diskus
FP 250 mcg BD via Diskus + Placebo QD via ELLIPTA
As this is a [ADDRESS_536192] approximately  7-days after 
completing Treatment Period 2. The total duration of study  participation is approximately  
2015N231308_03 CONFIDENTIA L
[PHONE_8792] weeks; and up to [ADDRESS_536193] 
been using a low -to moderate -dose ICS as a part of their asthma maintenance treatment.
Assuming a 20% screen failure rate and 70% run -in failure rate, approximately  [ADDRESS_536194] completed both the exercise challenges and 
spi[INVESTIGATOR_424277]. This calculation assumes a 
15% withdrawal rate during the stud y.  
5.4. Design Justification
The study  design is based on the practice parameters for assessing EIB developed by  [CONTACT_424354] I mmunology  [Weiler , 2010], 
American Thoracic society  clinical practice guideline [ Parsons , 2013], EMA ( European 
Medicines Agency ) Note on Gu idance on Clinical I nvestigation of Medicinal Products 
for Treatment of Asthma [ EMA , 2013] and FDA Draft Guidance for the Development of 
Drugs for Exercise -Induced Bronchospasm [ FDA Guidance for Industry , 2002].  
A randomized, double- blind, double dummy , cross -over design is a well -
validated means 
to assess the efficacy  and safet y of two treatment groups. A cross -over design was chosen 
to reduce the impact of confounding variables, and allow for between and within group 
comparisons. The expectation that mild to moderate patients with EIB would alread y be 
using an ICS necessitated standardization of baseline I CS therap y and eliminates the need 
for use of a placebo comparator.  Considering a 4 -week run- in period on FP, two weeks 
of treatment with FF/VI followed by  [CONTACT_424355] 
a treatment effect for this within-subject comparison. A two- week washout period is 
adequate to wash out the L ABA, VI, prior to Treatment Period 2.
FP was chosen as the “gold standard” ICS active comparator as its ability  to prevent EIB 
has been previously  characterized and FF is not currentl y commercially available outside 
of the US.
The primary  endpoint of maxim al percent decrease from pre -exercise baseline FEV 1is a 
well-established measure of EIB and is consistent with agency  guidance and established 
practice parameters. Exercise challenge testing at 12, and [ADDRESS_536195] for 
the interventions.
5.5. Dose Justification
The inhaled FF/VI 100/25 mcg dose combination corresponds to the dose approved in the 
US (adults) and EU (adults and adolescents) for the treatment o f asthma corresponding to 
low to moderate ICS/LABA asthma therap y. FF100 is deemed a low/mid strength ICS.
2015N231308_03 CONFIDENTIA L
201832
225.6. Benefit: Risk A ssessment
Summaries of findings from both clinical and non-clinical studies conducted with FF 
(GW685698)/VI (GW642444) can be found in the corresponding Investigator’s Brochure 
and in the RELVAR/BREO™ ELLIPTA Prescribing Information for countries in which 
FF/V I is approved for marketing. For the FP section, information is taken from the label 
of FLOVENT ACCUHALER/DISKUS.
The following se ction outlines the risk assessment and mitigation strategy  for this 
protocol: 
2015N231308_03 CONFIDENTIA L
201832
235.6.1. Risk A ssessment
For FF/VI the following risks and the mitigation strategy  as applicable to asthma patients were taken from the summary  of saf ety concerns 
in the European Union –Risk Management Plan (EU -RMP). For FF/VI the data/rationale for the risk were derived from the 2014 
Investigator’s Brochure, from an integrated anal ysis of key RELVAR studies (Integrated Summary  of Safet y for Fluticasone 
Furoate/Vilanterol v02 DBL 31 Jan 2014), from the RMP version 6.2 and in the RELVAR/BREO ELLIPTA Prescribing Information for 
countries in which FF/VI is approved for marketing.
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) [FF/VI] 
Pneumonia in patients with asthma The incidence of pneumonia in patients with 
asthma was uncommon. The incidence (adjusted 
for exposure) seen with FF/VI 100/25 microgram 
strength (8.5/1000 patient years) was similar to 
placebo (9.3/ 1000 patient years). No risk factors 
were identified.
In an analysis performed on the 18 key studies in 
subjects with asthma pneumonia  was reported 
by 0.5% (13 of 2369) of subjects who received 
FF/VI 100/25 subjects and 0.2% (2 of 1070) of 
subjects who re ceived placebo.aThe risk of pneumonia in asthma patients is very 
low and is consistent with the risk of other ICS.  
Subjects are not at an increased risk in this 
study, since they enter the study stable on an 
existing ICS treatment. Subjects are alerted t o 
the potential risk of pneumonia in the informed 
consent. Investigators are informed of the risk in 
Section 1.2.3 (Asthma Clinical Studies) and 
Section 5.3.3 (Safety in Asthma Clinical Studies) 
of the IB. Subjects with concurrent respi[INVESTIGATOR_424278] e xcluded from the study.
Asthma related intubations and deaths This is a class effect of LABA in asthma. This 
has not been observed for FF/VI.
An FDA meta -analysis of LABA vs. no LABA 
(60,954 patients in 110 trials) by [CONTACT_424356] a 
composite endpoint of asthma -related deaths, 
intubations, and hospi[INVESTIGATOR_602] (asthma Subjects with a history of life- threatening asthma 
are excluded from the study. 
2015N231308_03 CONFIDENTIA L
201832
24Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
composite index) showed a statistically 
significant difference among age groups.  The 
composite event incidence difference for all ages 
was 6.3 events per 1000 patient -years (95% 
confidence i nterval [CI]: 2.2 -10.3) with LABAs 
compared with no LABA use. Among the 15,192 
patients with concurrent ICS use, the incidence 
difference was 0.4 events per 1000 patient -years 
(95% CI: - 3.8 to 4.6).  The authors noted a trend 
of greater excess risk with LABA among the 
younger age groups [ McMahon , 2011].
Serious cardiovascular events In an analysis performed on the [ADDRESS_536196] been reported in 
patients exposed to FF/VI. Seven events in FF/VI 
100/25 and one event in FF/VI 200/25. This 
represents an incidence less than 1% in the 
asthmatic patients exposed to FF/VI.a
The e vents reported include atrial fibrillation, 
acute coronary syndrome, coronary artery 
disease, hypertension, myocardial ischemia, 
tachyarrhythmia and tachycardia.Subjects with existing serious cardiovascular 
disease and/or abnormal ECG findings are 
exclude d from the study. Investigators are made 
aware of the potential class effects of LABAs and 
are advised to exercise caution for subjects with 
existing serious cardiovascular disease (Section 
6.3 [Warnings and Precautions] of the IB).
Hypersensitivity No F F/VI drug related hypersensitivity was noted 
in clinical trials.
Spontaneous reports of hypersensitivity 
reactions have been reported in post -marketing Subjects will be informed about the risk of 
hypersensitivity in the informed consent. 
Subjects will be advised to seek medical 
treatment if any signs of hypersensitivity occur.
Subjects with milk protein allergy or known 
2015N231308_03 CONFIDENTIA L
201832
25Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
data for FF/VI. A possible causal association 
cannot be ruled out based on the temporal 
association between drug administration and 
hypersensitivity events including anaphylactic 
reaction, angioedema, urticaria, pruritis and rash.hypersensitivity to FF, VI, the classes ICS or 
beta-agonist or any ingredient of the IP 
preparation will be excluded from participating in 
the study. Investigators are informed of the risk 
in Section 6.2 (Contraindications) of the IB.
Decreased bone mineral density and associated 
fracturesRisk of fracture has been associated with oral 
corticosteroids. It is unclear if inhaled 
corticosteroids carry the same risk. 
There were few events associated with bone 
disorders or fractures reported during the asthma 
development program. These events tended to 
be those associated with trauma. 
Currently the risk of reduced bone mineral 
density has not been observed in the asthm a 
population [ Jones, 2002]. In addition specific 
assessments in adolescents with asthma have 
not demonstrated an effect on bone mineral 
density, when controlled for growth [ König , 1993; 
Turpeinen , 2010].
In an analysis performed on the 18 key studies in 
subjects with asthma bone fractures were 
reported by <1% (16 of 2369) of subjects who 
received FF/VI 100/25.aSubjects will be informed abou t the risk of 
decreased bone mineral density and bone 
fractures in the informed consent. Investigators 
are made aware of the potential for this ICS 
class effect. Subjects will be advised to seek 
medical treatment if any signs of decreased bone 
mineral density or fractures occur.
2015N231308_03 CONFIDENTIA L
201832
26Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Adrenal Suppression This is considered a class effect of ICS. 
Preclinical studies showed that FF effects are 
comparable with other corticosteroids. No 
studies have shown a clinically relevant effect of 
FF/VI on the hypothalamic -pi[INVESTIGATOR_424279] 
(HPA) at the 100/25 strength. This includes a 
formal HPA study (HZA106851), using 24 -hour 
serum cortisol measurements, and multiple 
studies with chronic obstructive pulmonary 
disorder (COPD) and asthma subjects which 
monitored urinary c ortisol.Subjects will be informed about the risk of 
adrenal suppression in the informed consent. 
Investigators are made aware of the potential for 
this class effect in Section 6.3 (Warnings and 
Precautions) of the IB. I f systematic symptom s
appear, invest igators should implement an 
appropriate treatment while observing the 
subject’s’ asthma symptoms.
Corticosteroid associated eye disorders This is considered a class effect of ICS. 
Preclinical studies showed FF at high dose 
comparable to other high dose corticosteroids. In 
study HZA106839 (FF/VI, FF and FP in subjects 
with asthma), formal ophthalmic assessments 
were conducted (including LOCS III evaluations 
for ocular opacities) throughout the study. This 
study showed no apparent effects on lens 
opacificat ion, compared to baseline. During 
studies in both subjects with asthma and COPD, 
no associated affect on ocular disorders was 
observed.Subjects will be informed about the risk of
corticosteroid associated eye disorders in the 
informed consent. Subjects wi ll be advised to 
seek medical treatment if any signs of eye 
disorder occur .Investigators are made aware of 
the potential for this class effect in Section 
[IP_ADDRESS] (Ophthalmic Effects) of the IB.
Study Design and Procedures
Exercise -induced bronchoconstr iction following 
exercise challenge testingThis study specifically recruits a s tudy population 
which demonstrates a minimal level of exercise -Exercise challenges may be s topped at any time 
during the assessment for worsening asthma. 
(Guidelines for treatment are provided in the 
2015N231308_03 CONFIDENTIA L
201832
27Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
induced bronchoconstriction ( ≥20% decrease 
from their pre -exercise FEV 1). However, more 
severe bronchoconstriction is possible following 
exercise challenge testing.study reference manual [SRM].) 
If a subject's FEV 1decreases to ≥40% from 
their pre -exercise FEV 1following exercise 
challenge, he/she must receive rescue therapy. If 
he/she requires rescue therapy with anything 
other than MDI (Metered Dose Inhaler )or 
nebulized albuterol/salbutamol or ipratropi[INVESTIGATOR_1890] 
(secondarily) following the exercise challenge 
assessment, he/she will not be allowed to 
continue in the study. 
Subjects will be monitored until their FEV 1 
reaches ≥95% of their pre -exercise FEV 1. 
Rescue Albuterol/salbutamol may be given 
during recovery.
Cardiovascular stress resulting from exercise Rigorous exercise can lead to heart attack, 
stroke and even death. Subjects with existing serious cardiovascular 
disease and abnormal ECG findings are 
excluded from the study. Investigators are made 
aware of the potential class effects of LABAs and 
are advised to exercise caution for subjects with 
existing serious cardiovascular disease (Section 
6.3 [Warnings and Precaut ions] of the IB).
Musculoskelatal injury resulting from exercise 
challenge testingMusculoskelatal injury is a risk of exercise on a 
treadmill.The exercise challenge will begin gradually to 
allow the subject to warm up over [ADDRESS_536197] in order 
to prevent a fall. Subjects will be instructed to 
2015N231308_03 CONFIDENTIA L
201832
28Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
challenge testing treadmill, with an air mask and heart rate 
monitor. Subjects unfamiliar with treadmill usage 
or with wearing equipment while on t he treadmill 
could become unbalanced and fall.refrain from holding on to the support railings 
during the challenge. At least one staff member 
will be behi nd and within reach of the
subject throughout the challenge. It is 
recommended that 3 staff members should 
facilitate the challenge procedures.
Unknown risks to an embryo, fetus (unborn 
baby) or nursing infantThere are no studies with FF/VI or the indiv idual 
components (FF and VI) in pregnant women.As specified in the protocol:
Women who are pregnant, lactating or are 
planning on becoming pregnant during the 
study are not eligible to participate in this 
study.
Female subjects must be postmenopausal or 
using a highly effective method for avoidance 
of pregnancy while in this study.
If a female subject becomes pregnant during 
the study, she should let the study doctor 
know immediately. The study medication will 
be stopped.
For women of child -bearing potenti al, a urine 
pregnancy test will be performed at Screening 
(Visit 1). For enrolled subjects, a urine 
pregnancy test will be performed at 
Screening, randomization, Visit [ADDRESS_536198]. The result will 
be reported to the site study staff during the 
2015N231308_03 CONFIDENTIA L
201832
29Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Follow -Up Phone Contact.
Asthma symptoms may worsen during the study As specified in the protocol:
The use of certain asthma medications is 
excluded prior to and during the study.
After Visit 1, the use of rescue medication 
(albuterol/salbu tamol) must be withheld for at 
least 6 hours prior to and during each clinic 
visit.
Patients will be placed on an ICS alone 
treatment during the run -in period and 
possibly during the treatment period.The informed consent advises the subject to:
Talk to th e study doctor about the excluded 
medications before deciding and consenting 
to participate in the study.
Use the rescue medication 
(albuterol/salbutamol) if asthma symptoms 
worsen.
Notify the study doctor or staff if his/her 
asthma symptoms worsen or do n ot get better 
after using the rescue medication.
Go immediately to the emergency 
department/seek medical attention if the 
symptoms are severe.
Shortness of breath, coughing, lightheadedness 
or fainting, and/or chest tightness during the 
spi[INVESTIGATOR_424280]. As specified in the informed consent form for this 
study, if any of these symptoms should happen 
to the subject, he/she will receive medical 
treatment.
a. RELVAR studies summarized include FFA109684, FFA109685, FFA109687, B2C109575, HZA106827, HZ A106829, HZA113091, HZA113714, HZA113719, HZA116863, 
HZA106837, HZA106839, HZA106851, FFA112059, FFA114496, FFA115283, FFA115285, B2C112060.
2015N231308_03 CONFIDENTIA L
201832
305.6.2. Risk assessment for FP 250mcg
FLOVENT/FLIXOTIDE is a marketed drug that contains the ICS fluticasone propi[INVESTIGATOR_16847]
(FP 250 mcg). A similar profile of undesirable effects as reported for ICS may  occur with 
FP. Since FLOVENT/FLIXOTIDE contains an ICS (FP), the risk mitigation strategies 
for FF (ICS) as mentioned in Section 5.6.[ADDRESS_536199] label.
5.6.3. Benefit A ssessment
Combined treatment with I CS and LABA has been shown to be more effective than the 
individual components in asthma, leading to the development of fixed dose combination 
inhalers. The use of ICS/LABA combinations is now well established in international 
treatment guidelines for moderate to severe persistent asthma patients for whom 
treatment with I CS alone is not sufficient. 
In patients with persistent asthma, improvements in protection from EIB with I CS/LABA 
combination product FP/salmeterol ( Advair ) have been demonstrated [ Murray , 2011; 
Pearlman, 2009; Weiler , 2005].  Once -daily FF/VI 100/[ADDRESS_536200] for the treatment of persistent asthma 
and has a recognized safety  profile. 
5.6.4. Overall Benefit: Risk Conclusion
GlaxoSmithKline ([COMPANY_004]) has assessed this study  for any  potential risks that a subject may  
experience. The investigational product (IP) FF/VI has an acceptable safet y profile for 
clinical use and there are no significant associated risks. This conclusion is supported by  
[CONTACT_424357] y performed clinical studies with the products in he althy  
volunteers and subjects with Asthma and COPD. The ICS (FP) described above will be 
used at a dose and frequency that is approved for the treatment of Asthma and has an 
acceptable safet y profile for use. This conclusion is supported by [CONTACT_424357] y 
performed clinical studies and post- marketing experience (see local label).
Adverse effects that could be associated with the use of FF/VI and FP will be closel y 
monitored. A safet y criterion outlining details for subject withdrawal is included in the 
protocol (Section 6.4, Withdrawal Criteria). A thorough summary  and evaluation of the 
available pre -clinical data can be found in the IB. Routine safet y anal ysis of this study  
will be conducted b y the compan y.
Taking into account the measures taken to minimize risk to subjects participating in this 
study , the potential risks identified in association with FF/VI and FP are justified by  [CONTACT_424358].
2015N231308_03 CONFIDENTIA L
[ADDRESS_536201] label or IB/IB 
supplement(s).
Deviations from inclusion and exclusion criteria are not allowed because they can 
potentially  jeopardize the scientific integrity  of the study , regulatory  acceptability  or 
subject safet y. Therefore, adherence to the criteria as specified in the protocol is essential.
6.1. Screening Criteria
6.1.1. Inclusion Criteria
A subject will be eligible for inclusion in this study onl y if all of the following criteria 
apply :
1.Informed consent: Subjects must give their signed and dated written informed 
consent to participate prior to commencing an y study  related activities.
2.Age Range:   12 to 50 y ears of age, inclusive, at Visit 1 (Screening).  
3.Diagnosis:   A diagnosis of asthma, as defined b y the National Institutes of Health 
[NIH, 2007], for at least 12 weeks prior to Visit 1. 
4.Asthma Severity: Subjects must have a pre -bronchodilator FEV 1of ≥70% of the 
predicted normal value. Predicted values will be based upon Global Lung 
Function Initiative (GLI) [ Quanjer , 2012] equations for spi[INVESTIGATOR_424281].
5.Evidence of EIB: Subjects must answer “Yes” to at least 2 of the following 3 
questions reflecting on the previous 12 months:
Are you short of breath during exercise or other physical exertion?
Do y ou wheeze after exercise or other phy sical exertion?
Do y ou cough after exercise or other phy sical exe rtion?
6.Concurrent Anti -Asthma Therapy:   Subjects must be taking low -to moderate -
dose inhaled steroids for 12 weeks prior to Visit 1 in order to participate with no 
change in dose for the 4 weeks prior to Visit 1.  Example dosages considered 
appropriate fo r study  participation are outlined in the SRM.
7.Gender: Subjects may  be male or an eligible female. 
A female is eligible to enter and participate in the study  if she is of:
Non-child bearing potential (i.e., phy siologically  incapable of becoming 
pregnant, including an y female who is post -menopausal or surgically  sterile). 
Surgicall y sterile females are defined as those with a documented h ysterectomy  
2015N231308_03 CONFIDENTIA L
201832
32and/or bilateral oophorectomy  or tubal ligation. Post -menopausal females are 
defined as being amenorrhoeic fo r greater than 1 year with an appropriate clinical 
profile, e.g., age appropriate, > [ADDRESS_536202] at screening, and agrees to 
acceptable contraceptive me thods approved in their local country , when used 
consistently  and correctly  (i.e., in accordance with the approved product label and 
the instructions of the physician for the duration of the study –screening to 
follow -up contact). See Appendix 5 . 
8.Albuterol/salbutamol Use:   All subjects must be able to replace their current 
short -acting beta 2-agonist (SABA) with albuterol/salbutamol, to be used only  on 
an as -needed basis for the duration of the study .  Each subject mus t be judged 
capable of withholding albuterol/salbutamol for at least 6 hours prior to 
performing spi[INVESTIGATOR_424282].
9.Physical Capacity : Each subject must be phy sically  able to perform the exercise 
challenges on a treadmill when bronchodilators have be en withheld.
6.1.2. Exclusion Criteria
A subject will not be eligible for inclusion in this study  if an y of the following criteria 
apply :
1.Intermittent Asthma, Seasonal Asthma, or Exercise -Induced 
Bronchoconstriction Only:   Subjects with only  intermittent or seasonal asthma 
or only  exercise -induced asthma are excluded from participation in this study .
2.History of Life -threatening Asthma:  Defined for this protocol as an asthma 
epi[INVESTIGATOR_28302]/or was associated with hypercapnia, 
respi[INVESTIGATOR_424283] t or h ypoxic seizures within the last 10 years. 
3.Asthma Exacerbation:   Any asthma exacerbation requiring oral corticosteroids 
within 12 weeks of Visit 1 or that resulted in an overnight hospi[INVESTIGATOR_424284] 6 mon ths prior to Visit 1.
4.Symptomatic Allergic Rhinitis:  Subjects with sy mptomatic allergic rhinitis at 
Visit 1 may  be treated for up to four weeks with intranasal corticosteroids 
followed b y a repeat screening visit to determine eligibility prior to entry in to the 
study . Subjects that continue to be s ymptomatic after up to four weeks of 
treatment will be excluded. 
5.12-Lead Electrocardiogram (ECG):  A subject is not eligible if he/she has an 
abnormal, clinicall y significant ECG as determined by [CONTACT_20616] r at the 
Screening V isit. 
6.Pregnancy: Women who are pregnant or lactating or are planning on becoming 
pregnant during the study.
2015N231308_03 CONFIDENTIA L
201832
337.Respi[INVESTIGATOR_60623]: Culture -documented or suspected bacterial or viral 
infection of the upper or lower respi[INVESTIGATOR_53121], sinus or middle ear that is not 
resolved within [ADDRESS_536203]’s asthma status 
or the subject’s abilit y to participate in the stud y. 
8.Conc urrent Respi[INVESTIGATOR_31753]: A subject must not have current evidence of: 
a.Atelectasis 
b.Bronchopulmonary  dysplasia 
c.Chronic bronchitis 
d.Chronic obstructive pulmonary  disease (current or past diagnosis including 
asthma/COPD overlap)
e.Pneumonia 
f.Pneumothorax 
g.Interstitial lung disease 
h.Or an y evidence of concurrent respi[INVESTIGATOR_44034] 
9.Other Concurrent Diseases/Abnormalities:  A subject must not have any  
clinically  significant, uncontrolled condition, or disease state that, in the opi[INVESTIGATOR_8574], would put the safet y of the subject at risk through study 
participation or would confound the interpretation of the efficacy  results if the 
condition/disease exacerbated during the stud y.
The list of additional excluded conditions/disease s includes, but is not limited to, 
the following:
Table 1 Excluded Conditions/Diseases
Addison's disease hypertension1 (uncontrolled)
aortic aneurysm (clinically significant) immunologic compromise
cardiac arrhythmia (clinically significant) malignancy2 (current)
congestive heart failure peptic ulcer (recent or poorly controlled)
coronary heart disease (clinically significant) renal disease
Cushing's disease stroke within 3 months of Visit 1
diabetes mellitus (uncontrolled) thyroid disorder (uncontrolled)
drug or alcohol abuse (recent history) tuberculosis (current or untreated3)
hematological disease
1. Two or more measurements with systolic pressure >160mmHg or diastolic pressure >100mmHg
2. A history of malignancy is acceptab le only if subject has been in remission for one year prior to Visit 1 
(remission = no current evidence of malignancy and no treatment for the malignancy in the 12 months 
prior to Visit 1)
3. Subjects with a history of tuberculosis infection who have complete d an appropriate course of 
antituberculosis treatment may be suitable for study entry provided that there is no clinical suspi[INVESTIGATOR_424285].
2015N231308_03 CONFIDENTIA L
[PHONE_8793].Investigational Medications:   A subject must not have used an y investigational 
drug within 30 day s prior to Visit 1 or within five half -lives (t½) of the prior 
investigational stud y, whichever is longer of the two periods. 
11.Allergies:
a)Drug Allergy:   Any adverse reaction including immediate or delay ed 
hypersensitivity  to an y beta 2-agonist, sy mpat homimetic drug, or any  
intranasal, inhaled, or s ystemic corticosteroid therapy, or excipi[INVESTIGATOR_424286]/VI  100/25 or FP 250 (i.e., drug, lactose or magnesium stearate).
b)Milk Protein Allergy: History  of severe milk protein allergy .
c)Latex Allergy: Histor y of allergy  or sensitivity  to latex that in the opi[INVESTIGATOR_424287]’s participation in the study .
12.Concomitant Medication:   Administration of prescription or non -prescription 
medication that would significantly  affect th e course of asthma, or interact with 
study  drug (see Prohibited Medication Section 7.[ADDRESS_536204] of prohibited 
medications and washout times required prior to Visit 1).
13.Immunosuppressive Medications: A subject must not be using or require the 
use of immunosuppressive medications during the study .
14.Compliance:   A subject will not be eligible if he/she or his/her parent or legal 
guardian has an y infirmity, disability, disease, or geographical location which 
seems likely  (in the opi[INVESTIGATOR_871]) to impair compliance with any  
aspect of this study  protocol
15.Tobacco/Marijuana Use: Current tobacco smoker or has a smoking history  of 
≥10 pack- years (20 cigarettes/day  for 10 y ears). A subject may  not have used 
inhaled tobacco products or inhaled marijuana within the past 3 months (e.g., 
cigarettes, cigars, electronic cigarettes, or pi[INVESTIGATOR_28303]).
16.Affiliation with Investigator’s Site:   A subject will not be eligible for this study  
if he/she is an immediate family member of the participating investigator, sub 
investigator, stud y coordinator or an employee of the participating investigator.
6.2. Randomization Criteria
At the end of the run -in period, a subject will be eligible for Randomization to double-
blinded study  treatment if he/she meets all the following criteria at Visit 2. 
6.2.1. Inclusion Criteria
1.Physical Capacity: All subjects must be phy sically  able to perform the exercise 
challenges on a treadmill with specific consideration of an y health changes since 
Visit 1.
2.FEV1Target : Subjects must demonstrate a decrease in FEV 1of 20% at one 
time point within 30 minutes of the end of a standardized exercise challenge.  
Subjects who achieve a decrease in FEV 1of 15% to <20% may  continue taking 
2015N231308_03 CONFIDENTIA L
201832
35their daily  run-in medication a nd repeat the eligibility  exercise challenge and 
associated procedures once within a week of the original procedure.
6.2.2. Exclusion Criteria
1.Pregnancy: Positive urine pregnancy  test at Visit 2.
2.Asthma Medication Changes:  Changes in asthma medication after Visi t 1 
(excluding albuterol/salbutamol inhalation aerosol provided at Visit 1) are not 
permitted.
3.Prohibited Medication:   Use of an y prohibited medications (Section 7.10.2 ) 
during the run- in period or at Visit 2.
4.R
espi[INVESTIGATOR_83078]:  Occurrence of a culture -documented or suspected 
bacterial or viral infection of the upper or lower respi[INVESTIGATOR_53121], sinus or middle 
ear during the run -in period that led to a change in asthma management or, in the 
opi[INVESTIGATOR_871], is expected to affect the subject’s asthma status or the 
subject’s ability  to participate in the study .
5.Asthma Exacerbation :  Evidence of a severe exacerbation, defined as 
deterioration of asthma requiring the use of s ystemic corticosteroids (tablets, 
suspension, or injection) for at least 3 days or an in- patient hospi[INVESTIGATOR_424288] (ED) visit due to asthma that required s ystemic 
corticosteroids between Visits 1 and 2.
6.3. Screening/Baseline/Run-in Failures
In order to ensure t ransparent reporting of screen failure subjects, meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements, and respond to 
queries from Regulatory  authorities, a minimal set of screen failure information is 
required including De mograph y, Screen Failure reason details, Eligibility Criteria, and 
any Serious Adverse Events.
A subject who is assigned a subject number, has signed the informed consent, and has 
completed at least one study  procedure, but does not enter the run- in period of the study  
is considered a ‘screen failure’.  
A subject who completes the screening visit and is dispensed FP 250 mcg, 
albuterol/salbutamol for rescue use, and a medical conditions diary  card is considered to 
have entered the run -in period.  A subject who has entered the run -in period, but is not 
randomized to study  treatment medication, is classified as a ‘run -in failure’.  
At a minimum, the following information will be collected for subjects who fail 
screening or run- in:
1.Demographic information for race, age and gender
2.Reason for screen/run -in failure (screen/run-in failure eCRF page, 
inclusion/exclusion criteria eCRF page, and randomization criteria eCRF page 
[if applicable])
2015N231308_03 CONFIDENTIA L
[ADDRESS_536205] a repeat screening visit after 
treatment with intranasal corticosteroids.
6.4. Withdrawal/Stoppi[INVESTIGATOR_2121]
A subject may  withdraw from study  treatment at any  time at his/her own request, or may  
be withdrawn at an y time at the discretion of the investigator for safet y, behavioural or 
administrative reasons. Once withdrawn from the investigational product a subject will be 
considered withdrawn from the study . Subjects who are withdrawn from the study  may  
be replaced at the discretion of the Sponsor.  The primary  reason for withdrawal will be 
recorded in the eCRF.
6.4.1. Study Specific Withdrawal Criteria
A Subject will be withdrawn from the stud y if any of the following withdrawal criteria 
are met:
1.Liver Chemistry: Meets any  of the protocol- defined liver chemistry  stoppi[INVESTIGATOR_31732] (see Appendix 2 ).
Liver chemistry stoppi[INVESTIGATOR_301131] y and evaluate liver event etiology (in alignment 
with the FDA premarketing clinical liver safety  guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformatio
n/Guidances/UCM174090.pdf
If the liver chemis try stoppi[INVESTIGATOR_424289] , treatment restart or rechallenge is not permitted.
2.Severe Asthma Exacerbation
Subjects who experience a severe asthma exacerbation at any  time during the study  must 
be withdrawn from the study .  Asevere exacerbation is defined as deterioration of asthma 
requiring the use of s ystemic corticosteroids (tablets, suspension, or injection) for at least 
3 day s or an in -patient hospi[INVESTIGATOR_424290] s ystemic corticosteroids during the study . 
3.Worsening of Asthma requiring additional treatment
Subjects requiring rescue therap y with an ything other than MDI or nebulized 
albuterol/salbutamol or ipratropi[INVESTIGATOR_1890] (secondaril y) following the exercise ch allenge 
assessment should be withdrawn.
NOTE: If a subject's FEV 1decreases to ≥40% from their pre- exercise FEV 1
following exercise challenge, he/she must receive rescue therap y. If he/she 
requires rescue therap y with any thing other than MDI  or nebulized 
2015N231308_03 CONFIDENTIA L
201832
37albuterol/salbutamol or ipratropi[INVESTIGATOR_1890] (secondaril y) following the exercise 
challenge assessment, he/she is not allowed to continue in the study
Subjects who experience asthma worsening outside of the exercise challenges 
which, in the opi[INVESTIGATOR_73829], requires additional asthma treatment 
other than study  medication or study  supplied albuterol/salbutamol should be 
withdrawn. 
4.Pregnancy: Positive urine pregnancy  test
5.ECG :Discontinuation is required i f any  of the following ECG criteria are met 
during the study :
QTcF>500 msec or uncorrected QT>600 msec 
Change from baseline: QTcF> 60msec
For patients with underl ying bundle branch block , follow the discontinuation 
criteria listed below:
Baseline QTc with Bundle 
Branch BlockDiscontinuation QTc with 
Bundl e Branch Block
< 450 msec > 500 msec
450 –480 msec ≥ 530 msec 
The same QT correction formula must be used for each individual subject to 
determine eligibility  for and discontinuation from the study .  This formula 
may not be changed or substituted once the subject has been enrolled.
For example, if a sub ject is eligible for the protocol based on QTcB , then 
QTcB must be used for discontinuation of this individual subject as well.
Once the QT correction formula has been chosen for a subject’s eligibility , 
the same formula must continue to be used for that s ubject for all QTc data 
being collected for data analysis .  Safety  ECGs and other non -protocol 
specified ECGs are an exception.  
The QTc should be based on single or averaged QTc values of triplicate 
electrocardiograms obtained over a brief (e.g., 5 -10 mi nute) recording period.  
Details on performing ECG assessments can be found in Section 8.4.6 .
6.4.2. Reasons for Study  Withdrawal
The primary  reason for Study  Withdrawal will be recorded in the eCRF and any  data 
collected up until the point of withdrawal will be used in the data analy ses.
2015N231308_03 CONFIDENTIA L
201832
38General reasons for withdrawal may  include: 
1.Adverse event 
2.Withdrew consent
3.Lost to follow -up 
4.Protocol deviation impacting safety
5.Lack of efficacy
6.Subject reached protocol -defined w ithdrawal criteria
Liver function
Asthma Exacerbation
Asthma Worsening
Pregnancy
ECG
7.Non-compliance 
8.Injury  during the exercise challenge
9.Study  closed/terminated
6.4.3. Lost to Follow up (Non- Attendance)
The following actions must be taken in relation to a subjec t who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact [CONTACT_131993]- schedule the missed visit as 
soon as possible. 
The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
continue in the study . 
In cases where the subject is deemed ‘lost to follow up’, the investigator or 
designee must make every effort to regain contact [CONTACT_1155] (where 
possible, [ADDRESS_536206]’s last 
known mailing address or local equivalent methods). These contact [CONTACT_131994]’s medical record. 
Should the subject continue to be unreachable, only the n will he/she be considered 
to have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
6.4.4. Early  Withdrawal Visit
Subjects may  withdraw or be withdrawn from the study  for any  reason. If withdrawal 
occurs, the investigator must make every  effort to have the subject return to the clinic as 
soon as possible after the subject stopped study  medication for an Earl y Withdrawal 
(EW) Visit (ideally within 24 hours).  At withdrawal, all study  medications and other 
2015N231308_03 CONFIDENTIA L
[ADDRESS_536207] (Time andEvents 
Table Table 3 ).  In the event a subject withdraws at, or during, a scheduled visit, an Early  
Withdrawal Visit is not required.  However, all study  procedures scheduled at an Early
Withdrawal Visit must be performed at this visit instead.  A follow -up phone contact 
[CONTACT_69551] 7 day s (± 2 day s) after the Early  Withdrawal Visit.
Following completion of these procedures, the subject will be discharged from the study .  
Upon completi on of the Earl y Withdrawal Visit, each subject may resume any asthma 
medications deemed appropriate b y the investigator for the management of the subject.
In the event that a subject is withdrawn from the study  due to an adverse event, the 
investigator must attempt to follow the subject until the adverse event has either resolved 
or has become clinicall y insignificant.
6.5. Subject and Study  Completion
A completed subject is one who has completed all phases of the stud y including the 
follow -up phone contact. 
The end of the stud y is defined as the last subject’s last contact.
7. STUDY TREA TMENT
7.1. Investigational Product and Other Study  Treatment
The term ‘stud y treatment’ is used throughout the protocol to describe an y combination 
of products received b y the subject a s per the protocol design. Study  treatment may  
therefore refer to the individual study  treatments or the combination of those study  
treatments.
Albuterol/salbutamol will be given to all subjects to use throughout the study to treat 
acute asthma s ymptoms as needed per product label. Only  study -supplied 
albuterol/salbutamol should be used for rescue during the stud y. Rescue usage will be 
recorded once dail y in the subject’s paper diary. Do not record albuterol/salbutamol 
use in the eCRF.
Albuterol/salbutamol inhalation aerosol will be supplied as detailed in the SRM .
2015N231308_03 CONFIDENTIA L
[ADDRESS_536208] name: [CONTACT_424373]/
Vilanterol
100/25 mcgFluticasone Propi[INVESTIGATOR_16847]
250 mcgPlacebo ELLIPTA Placebo DISKUS/ 
ACCUHALER
Formulation: First strip: FF 100 mcg 
blended with lactose
Second strip: VI [ADDRESS_536209] strip: lactose
Second strip: blend of 
lactose and magnesium 
stearate Lactose
Dosage form: ELLIPTA –
30 doses per deviceDISKUS/
ACCUH ALER – 60 
doses per deviceELLIPTA –
30 doses per deviceDISKUS/
ACCUHALER –60 
doses per device
Unit dose 
strength(s)/Dosage 
level(s):100/25 mcg per 
actuation250 mcg per actuation NA NA
Route of Administration Inhaled Inhaled Inhaled Inhaled
Dosing instructions: Once daily in the 
eveningTwice daily; once in the 
morning and once in 
the eveningOnce daily in the 
eveningTwice daily; once in the 
morning and once in 
the evening
FF= fluticasone furoate; VI = vilanterol; FP = fluticasone propi[INVESTIGATOR_16847]; mcg = micrograms; NA = not applicable
2015N231308_03 CONFIDENTIA L
201832
417.2. Treatment A ssignment
Subjects will be assigned in a 1:1 ratio to the following treatment sequences ( Table 2) in 
accordance with the randomization schedule generated b y Cli nical Statistics, prior to the 
start of the study , using validated internal software:
Table 2 Treatment A ssignment
Treatment 
SequenceTreatment Period 1 Washout Treatment Period 2
1 FF/V I 100/25 mcg QD 
via Ellipta + Placebo 
BD via DiskusFP 250 mcg BD FP 250 mcg BD via 
Diskus + Placebo QD via 
Ellipta
2 FP 250 mcg BD via 
Diskus + Placebo QD 
via ElliptaFP 250 mcg BD FF/V I 100/25 mcg once 
daily  (QD) via Ellipta + 
Placebo BD via Diskus
7.2.1. Assignment of Subject Number
At the Pre -screen V isit, a unique Subject Number (CRF number) will be assigned to an y 
subject who has given informed consent. The unique Subject Number will be used to 
identify  individual subjects during the course of the study . 
All subjects that have a repeat screening vis it following treatment for s ymptomatic 
allergic rhinitis will continue to use the same subject number assigned at the original 
screening visit.
7.2.2. Assignment of Treatment Number
Subjects meeting the randomization eligibility  criteria at Visit 2 will be randomized to a 
treatment group through an Interactive Response Technology  (IRT). The IRT will 
confirm the subject’s CRF number (Subject Number) and provide two additional 
numbers:
A randomization number will be assigned from a randomization schedule 
generated b y Clinical Statistics, prior to the start of the study, using validated 
internal software. Once assigned, this number must not be reassigned to any 
other subject in the study.
Two treatment pack numbers will be provided that identifies the single blinded 
study medication (Diskus) and double- blind study  medication (ELLIPTA and 
Diskus) that should be dispensed to the subject from the investigator’s inventory
2015N231308_03 CONFIDENTIA L
201832
427.3. Blinding
Subjects will be single blinded to the study  medication given in the run -in and washout 
perio ds. Investigators and site staff will be unblinded to the run -in and washout 
medication. 
The treatment periods will be double -blind, double -dummy  study  and the following will 
apply : 
The investigator or treating ph ysician may  unblind a subject’s treatment
assignment only in the case of an emergency OR in the event of a serious 
medical condition when knowledge of the stud y treatment is essential for the 
appropriate clinical management or welfare of the subject as judged b y the 
investigator. 
Investigators h ave direct access to the subject’s individual study  treatment. 
It is preferred (but not required) that the investigator first contacts the Medical 
Monitor or appropriate [COMPANY_004] study  personnel to discuss options before unblinding 
the subject’s treatment assi gnment. 
If [COMPANY_004] personnel are not contact[CONTACT_222201], the investigator must 
notify  [COMPANY_004] as soon as possible after unblinding, but without revealing the 
treatment assignment of the unblinded subject, unless that information is 
important for the safety  of subjects currently  in the study . 
The date and reason for the unblinding must be fully  documented in the eCRF 
[COMPANY_004]’s Global Clinical Safet y and Pharmacovigilance (GCSP) staff may unblind 
the treatment assignment for an y subject with a Serious Adv erse Event (SAE). If 
the SAE requires that an expedited regulatory  report be sent to one or more 
regulatory agencies, a copy  of the report, identifying the subject’s treatment 
assignment, may  be sent to investigators in accordance with local regulations 
and/or [COMPANY_004] policy .
7.4. Packaging and Labeling
The contents of the label will be in accordance with all applicable regulatory  
requirements.
7.5. Preparation/Handling/Storage/A ccountability
No special preparation of study  treatment is required. Eligible subjects will b e taught 
proper use of the Diskus inhaler and administer their first dose of inhaled FP [ADDRESS_536210] doses from each inhaler (active and place bo) at the visit. 
Only  subjects enrolled in the study  may  receive study  treatment and onl y 
authorized site staff may  supply  or administer study  treatment.  All study  
treatments must be stored in a secure environmentally  controlled and monitored 
2015N231308_03 CONFIDENTIA L
201832
43(manual or automated) area in accordance with the labelled storage conditions 
with access limited to the investigator and authorized site staff. 
The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study  treatm ent accountability , reconciliation, and 
record maintenance (i.e. receipt, reconciliation and final disposition records).  
Further guidance and information for final disposition of unused study  treatment 
are provided in the SRM. 
Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safety risks to site staff . Take adequate precautions to 
avoid direct ey e or skin contact [CONTACT_23968]. In the case 
of unintentional occupational e xposure notify  the monitor, Medical Monitor 
and/or [COMPANY_004] study  contact.
A Material Safety  Data Sheet (MSDS)/equivalent document describing 
occupational hazards and recommended handling precautions either will be 
provided to the investigator, where this is re quired by  [CONTACT_1207], or is available 
upon request from [COMPANY_004].
7.6. Investigational Product Malfunction
Any investigational product inhaler that fails to function properl y must be identified to 
[COMPANY_004] personnel for return to [COMPANY_004] for testing. Details of the failure w ill be documented in 
the eCRF. The subject should return the inhaler to the clinic as soon as possible to avoid 
missing an y doses. The site will then contact [CONTACT_23983]’s internal IVRS (also known as the 
Registration and Medication Ordering Sy stem [RAMOS] NG) and obtain a new 
treatment pack number for this subject and dispense a new stud y medication kit from the 
site's investigational product supply , as instructed per the IVRS. 
7.7. Compliance with Study  Treatment A dministration
Subject compliance with study  medicatio n will be assessed at all visits (including at Earl y 
Withdrawal) via review of the dose counters on the ELLIPTA and DI SKUS inhalers. 
This information will be recorded in the eCRF. Subjects who are not compliant with run -
in medication administration or stud y drug administration should be counselled on 
appropriate dosing of study  drug and this counselling should be noted in the source 
documentation. Subjects who demonstrate <80% compliance may  be withdrawn from the 
study  upon consultation with the Sponsor. 
7.8. Treatment of Study  Treatment Overdose
For this study , an overdose will be defined as the subject receiving any  amount of 
investigational product greater than the maximum dose permitted b y the protocol, which 
results in clinical signs or sy mptoms.
[COMPANY_004] does not recommend specific treatment for an overdose. 
2015N231308_03 CONFIDENTIA L
201832
44In the event of an overdose the investigator [or treating phy sician] should use their 
discretion as to whether other treatment is warranted and contact [CONTACT_1689]. 
Decisions regarding dose interrup tions or modifications will be made by  [CONTACT_424359].
7.9. Treatment after the End of the Study
Subjects will not receive any  additional treatment from [COMPANY_004] after complet ion of the 
study  as other treatment options are available for persistent asthma. The investigator is 
responsible for ensuring that consideration has been given to the post -study  care of the 
subject’s medical condition, whether or not [COMPANY_004] is providing speci fic post -study  
treatment. At the end of Visit 7, investigators should prescribe asthma medication 
appropriate to the severity  of the subject’s asthma in accordance with asthma guidelines 
[GINA, 2015; NI H, 2007]. Do not record asthma medications started on or after the 
final clinic visit in the eCRF.
7.10. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_424291], doses, and regimens of the asthma medications taken during the [ADDRESS_536211] be recorded in the Concomitant Medications section in the eCRF.
All concomitant medications taken during the study will be recorded in the eCRF. The 
minimum requirement is for the reporting of the drug name [CONTACT_424374]. 
Study  provided albuterol/salbutamol should NOT be recorded in the eCRF.
Asthma medications taken after the final clinic visit will not be recorded in the eCRF.
7.10.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]
[IP_ADDRESS]. Permitted A sthma Medications
1.Short -acting β 2-Agonist: Subjects will receive albuterol/salbutamol inhalation 
aerosol at Visit 1 for rescue use throughout the run -in, washout and treatment 
periods. Subjects should be able to withhold albuterol/salbutamol at least 6 hours 
prior to spi[INVESTIGATOR_424292]. 
2.Anticholinergic Rescue: Ipratropi[INVESTIGATOR_424293] a secondary  treatment for 
rescue purposes at the exercise challenges. All other anticholinergic use is prohibited 
during the stud y.
[IP_ADDRESS]. Permitted Non -Asthma Medications
The following non -asthma medications are permitted. This list is not all inclusive. For 
any questions contact [CONTACT_1689].
2015N231308_03 CONFIDENTIA L
201832
45Cardioselective beta- blockers (stable dose) and ophthalmic beta -blockers: 
Administer with caution as they  may  block bronchodilatory  effects of beta -agonists 
and produce se vere bronchospasm.
Strong cytochrome P450 3A4 inhibitors (e.g. ketoconazole, ritonavir, 
clarithromycin): Use with caution . May  cause sy stemic corticosteroid and 
cardiovascular effects.
Tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs):
Adm inister with extreme caution as they  may  potentiate the effects of beta -
agonists on the vascular system.
Diuretics: Caution is advised in the co -administration of beta -agonists with non 
potassium –sparing diuretics.
Decongestants: Subjects may  take deconges tants during the study  except during the 
24 hours prior to ECG measurements.
Antihistamines: Short -acting and long -acting antihistamines are allowed to control 
symptoms of allergic disorders, however are not permitted the week prior to 
exercise testing. Inaddition, antihistamine ey e drops are allowed during the study . 
Subjects should be reminded to avoid taking any antihistamines a week before 
each exercise challenge procedure.
Intranasal corticosteroids: Subjects may  take intranasal corticosteroids to con trol 
symptoms of allergic disorders as long as the dose remains constant for the duration 
of the study .
Topi[INVESTIGATOR_11930]: Subjects may  use topi[INVESTIGATOR_11930] ( ≤ 1% 
hydrocortisone) for dermatological diseases.
Influenza and/or pneumonia vaccination.
All medications for other disorders as long as the dose remains constant wherever 
possible and their use is not expected to affect the subjects’ lung function or safet y 
assessments.
7.10.2. Prohibited Medications and Non- Drug Therapi[INVESTIGATOR_424294]:
Within 12 weeks of Visit 1 and durin g the study:
Systemic (oral, parenteral or depot) corticosteroids
Anti- IgE (e.g. Xolair , Nucala ™)
Within 2 weeks of Visit 1 and during the study:
Theophy llines
Oral long- acting beta 2-agonists ( LABA) (e.g., bambuterol)
2015N231308_03 CONFIDENTIA L
201832
46Within 1 week of Visit 1 and during the study:
Anti-leukotrienes including suppressors of leukotriene production and antagonists
1 Da y Prior to Visit 1 and during the study:
Inhaled long -acting beta 2-agonists
Anticholinergics 
Use of anticholinergics are not permitted except for the use of ipratropi[INVESTIGATOR_424295] 
(secondary  to albuterol/salbutamol) at exercise challenges, if required. 
Ketotifen
Nedocromil sodium
Sodium cromogly cate
[IP_ADDRESS]. Prohibited Non -Asthma Medications
A subject may  not use any  other prescription or non- prescription medication which may  
affect the course of asthma or interact with sy mpathomimetic amines beginning at the 
respective time points defined below and during the remainder of the stud y.
Immunosuppressive medications: A subject must not be using or require the use of 
immunosuppressive medications during the stud y.
Prior use of study medication/other investigational dru gs:Subjects who have 
received an investigational drug within 30 day s of entry  into this study  (Screening), 
or within [ADDRESS_536212]’s treatment must not be changed merel y for the purpose of e nabling the 
subject’s participation in the study .
8. STUDY A SSESSMENTS A ND PROCEDURES
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the stud y design requirements, including those 
specif ied in the Time and Events Table, are essential and required for stud y conduct.
This section lists the procedures and parameters of each planned study assessment.  The 
exact timing of each assessment is listed in the Time andEvents Table Table 3.
2015N231308_03 CONFIDENTIA L
201832
478.1. Time and Events Table
Table 3 Time and Events Table
ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 212
Randomization3 412, 14 512 6 712, 14
Week -4 0 0 2 4 4 6 7
Treatment Day -26 to -30 
days0 118 14 (-2/+2) 
days28 (-2/+2) 
days2918 42 (-2/+2) 
days47 to 
[ADDRESS_536213] Demography X
Medical History (including CV) X
Disease (Asthma) History X
Medication History X X
Smoking history/status X
Inclusion/Exclusion Criteria X
Evidence of EIB X
Efficacy Assessments
Spi[INVESTIGATOR_038] (full F EV1 and FVC) X X2 X2 X2 X X2 X2 X
Exercise Challenge Testing 
(Treadmill)X3, [ADDRESS_536214] SenseWear accelerometer X X
Safety Assessments
Concomitant Medication X X X X X X X X X X7
2015N231308_03 CONFIDENTIA L
201832
48ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 212
Randomization3 412, 14 512 6 712, 14
Week -4 0 0 2 4 4 6 7
Treatment Day -26 to -30 
days0 118 14 (-2/+2) 
days28 (-2/+2) 
days2918 42 (-2/+2) 
days47 to 
[ADDRESS_536215] Fluticasone Propi[INVESTIGATOR_16847] X X
Dispense Rescue16
Albuterol/salbutamolX X X X X X
Collect Rescue 
Albuterol/salbutamolX X X X
Dispense IP X11 X
Assess study drug  compliance X X X X X X X
Collect IP X X X
2015N231308_03 CONFIDENTIA L
201832
491. Genetics saliva sample collected at Visit 2 (following Randomization) or at any scheduled visit thereafter. Genetics consent MUST be obtained PRIOR to 
collection of the Genetics sample.  
2. Pre-exercise spi[INVESTIGATOR_038] (full FEV 1 and forced vital capacity (FVC) testing), conducted immediately pre -exercise (and after vital signs), if applicable. Subject 
should have withheld albuterol/salbutamol within previous [ADDRESS_536216] demonstrate a 
decrease in FEV 1of 20% at one time point within [ADDRESS_536217] -exercise challenges. Longer monitoring may be required for those subjects 
who do not return to 95% of baseline FEV 1values within [ADDRESS_536218]. 
8. Vital signs will be collected before (prior to the pre -exercise spi[INVESTIGATOR_038]) and after each exercise challenge test.
9. Adverse Event and Serious Adverse Events to be collected from the start of study Dru g (Visit 1) until the follow up contact. However, any SAE related to study 
participation will be     recorded from the time of Informed Consent 
10. Review medical conditions diary card, including an assessment of any potential change in exercise capacity
11. An unblinding card will be dispensed along with double blind IP.
12. Subjects will be contact[CONTACT_5143] [ADDRESS_536219].
14. Visit 4 and Visit 7 will begin between 5PM and 11PM and continue over a period of approximately 24 hours. Subjects will retur n to the clinic at 12 hours (±1 
hour) and 23 h ours (±1 hour) (after the evening dose of study medication from the evening visit) for an exercise challenge procedure.
15. Subjects will be contact[CONTACT_5143] [ADDRESS_536220] and re -dispense rescue as needed from Visit 1
17.   Subjects who achieve a decrease in FEV 1of 15 % to <20% may continue taking their daily run -in medication and repeat the eligibility exercise challenge and 
associated procedures once within a week of the original procedure.
18.   Visit [ADDRESS_536221] be performed on the day immediately followi ng Visit 5.
2015N231308_03 CONF IDENTIA L
201832
508.2. Critical Baseline A ssessments
During the pre -screeni ng visit (Visit 0); each subject will have the following information
collected:
1.Demographic history  (including gender, ethnic origin and date of birth)
2.Concomitant medication review
3.Adverse event assessment
The following data will be captured at Visit 1:
1. M edical/medication/family  history  will be assessed as related to the 
inclusion/exclusion criteria listed in Section 6.1
2.Smoking history  
3.Asthma history  (including duration of asthma)
4.Evidence of E IB questions
5.Asthma and non -asthma concurrent medications
6.Concurrent medical conditions
7.Cardiovascular medical history /risk factors (as detailed in the eCRF) will be assessed 
at screening.
8.Reason for screen failure (if applicable)
9.Screening lung function
10.Vital signs (inc luding height and weight)
11.Serious Adverse Events related to study  participation
8.3. Efficacy
8.3.1. Spi[INVESTIGATOR_424296] 4 hours prior to the spi[INVESTIGATOR_96644]. 
FEV 1should be measured using spi[INVESTIGATOR_424297]  (ATS)/European Respi[INVESTIGATOR_21584] y 
(ERS) [ Miller , 2005]. All sites will use standardized spi[INVESTIGATOR_424298]. Full FEV 1and FVC will be conducted at Visit 1, and pre -dose at Visit 
5, and prior to each exercise challenge at Visits 2, 3, 4, 6 and 7. 
For full FEV 1and FVC testing at Screening and at randomisation (Visit 2), at least two 
valid and two repeatable (with no more than 8) efforts should be obtained using 
ATS/ERS guidelines. For all other visits where full FEV 1and FVC testing is performed 
(prior to each exercise test at visits 3, 4, 6 and 7), at least two val id efforts should be 
2015N231308_03 CONF IDENTIA L
[ADDRESS_536222] FEV 1and FVC should be recorded, even if they  
do not come from the same effort. 
Serial FEV 1 measurements only  (not FVC) will be conducted serially  as described in 
Time andEvents Table Table 3following each exercise challenge at Visits 2, 3, 4, [ADDRESS_536223] 70% of their predicted normal value to be eligible 
to take part in the stud y at Visit 1.
After Visit 1, subjects will alway s berequired to withhold their albuterol/salbutamol for 
at least [ADDRESS_536224] not administer study  drug prior to coming to the clinic on study  visit day s.
[IP_ADDRESS]. Target FEV 1Calculations
Three target FEV 1values will be calculated f rom the pre -exercise FEV [ADDRESS_536225] prior to exercise challenge 
testing: 
1.The FEV 1value that represents a ≥20% decrease in FEV 1, which is the 
eligibility  criterion. 
2.The FEV1 value that represents a ≥40% decrease in FEV1, which will serve as 
an alert for severe bronchoconstriction and need for administering rescue 
treatment. 
3.The FEV1 value that represents a ≥95% recovery  of the FEV1 result.  
Subjects should be monitored until they  reach a recovery  level where their FEV 1value 
represents a 95% recovery  of the pre -exercise FEV 1 result.  Additional spi[INVESTIGATOR_424299] (See Sect ion [IP_ADDRESS] ).
8.3.2. Exercise Challenge Testing
The exercise challenge test is a stepped challenge on a treadmill at a speed and incline 
that will allow the subject’s heart rate to reach between 80% to 95% of their maximum 
heart rate. All exercise challenges will be performed on a treadmill. During the exercise 
challenge, subjects will breathe medical grade dry  air at ambient temperature from a 
reservoir using a two -way non-rebreathing valve.
Subjects will exercise suff iciently  to attain a heart rate between 80 to 95% of their 
predicted maximum within 4 minutes and maintain this heart rate with exercise for an 
additional 6 minutes for a total of 10 minutes of exercise. The challenge will be followed 
immediately  by [CONTACT_28424][INVESTIGATOR_038]  (FEV 1efforts only ) at 6 time points over 60 minutes ( 5, 
10, 15, 30, [ADDRESS_536226]- exercise) . The information gained from the eligibility  
challenge(s) regarding incline and speed will be used to obtain the target heart rate in the 
subsequent exercise challenges.
2015N231308_03 CONF IDENTIA L
201832
52Exercise challenges should not be performed within 24 hours of exercise in cold air. 
Subjects should abstain from drinking beverages with high caffeine content such as tea or 
coffee for 4 hours prior to the exercise challenge. 
Additional instructions on exercise challenge testing can be found in the SRM.
[IP_ADDRESS]. Worsening of A sthma during Exercise Challenge
Exercise challenges may  be stopped at any  time during the assessment for worsening 
asthma. Guidelines for treatment are provided i n the SRM. 
If a subject's FEV 1decreases to ≥40% from their pre- exercise FEV 1following exercise 
challenge, he/she must receive rescue therap y. If he/she requires rescue therapy with 
anything other than MDI or nebulized albuterol/salbutamol or ipratropi[INVESTIGATOR_1890] (secondaril y) 
following the ex ercise challenge assessment, he/she is not allowed to continue in the 
study  (see Section 6.4.1). 
The subject should not leave the clinic until FEV 1returns to within 95% of the baseline 
FEV 1target recovery  value or the subject is judged medically  stable by  [CONTACT_424360].
8.3.3. Key Study  Assessments
Information regarding spi[INVESTIGATOR_038] , exercise testing, and study  medication dosing at Visits 
will be conducted as described below. All other assessment s will also be conducted as 
shown in Time andEvents Table Table 3
.
[IP_ADDRESS]. Visit 1 (Screening)
Spi[INVESTIGATOR_424300] 1 between 5:00 PM and 11:[ADDRESS_536227] pre -bronchodilator FEV 1of ≥ 70% of their predicted normal value to be 
eligible to take part in the study .  
[IP_ADDRESS]. Visit 2 (Randomization)
Treatment period 1 baseline FEV 1:Visit 2 begins between 5 PM and 11 PM and 
should begin at approximately  the same time as Visit 1 (±1 hour).  Spi[INVESTIGATOR_424301] 2 at approximately  the same time as at Visit 1 (±1 hour). The FEV 1
should be measured approximately  12 hours (±1 hour) after dosing with run- in 
medication (FP 250 mcg). At least two valid and two repeatable spi[INVESTIGATOR_424302].
From this spi[INVESTIGATOR_68333], the target FEV 1 values #2 and #3 (Section [IP_ADDRESS] ) should 
be determined based on the pre -exercise FEV 1. 
2015N231308_03 CONF IDENTIA L
201832
53Eligibility Exercise Challenge: After the pre -exercise baseline FEV [ADDRESS_536228]-exercise Serial Spi[INVESTIGATOR_038]: Following the eligibility  exercise challenge, serial 
spi[INVESTIGATOR_105222] (FEV 1) will be performed at 5, 10, 15, 30, [ADDRESS_536229] demonstrate a decrease in FEV 1of ≥20% 
when compared to the FEV 1obtained immediately pre -exercise for at least one of the 
post-exercise spi[INVESTIGATOR_424303] [ADDRESS_536230] -challenge.  Subjects 
who achieve a decrease in FEV 1of 15% to <20% may  continue taking their daily run-in 
medication and repeat the eligibility  exercise challenge once within a week. I n the event 
where a repeat visit is required for the exercise challenge, spi[INVESTIGATOR_424304] -and post - exercise challenge as de tailed in Table 3. 
In addition, ACQ- 5 and a review of concomitant medication and adverse events will be 
performed at the repeat visit. 
Dosing: Eligible subjects will administer their evening dose of double- blinded study  
medicatio n following the eligibility  exercise challenge/serial spi[INVESTIGATOR_038] . Evening dosing 
should occur between 5 PM and 11PM.
[IP_ADDRESS]. Visit 3 and Visit 6 ([ADDRESS_536231] Dose Exercise Challenge)
Visit 3 and Visit 6 begin sbetween 5 PM and 11 PM and should begin at app roximately  
the same time as Visit 1 (±1 hour).  These visits should begin prior to the subject’s 
evening dose on that visit day .
Pre-exercise FEV 1:Spi[INVESTIGATOR_424305] 3 and 6 at approximately  the 
same time as at Visit 1 (±1 hour). The F EV 1should be measured approximately  23 hours 
(±1 hour) after the first dose in each treatment period. At least two valid spi[INVESTIGATOR_424306].
From this spi[INVESTIGATOR_68333], the target FEV 1 values #2 and #3 ( Section [IP_ADDRESS] ) should 
be determined based on the pre -exercise FEV 1. 
Exercise Challenge: After the pre -exercise FEV [ADDRESS_536232]-exercise Serial Spi[INVESTIGATOR_038]: Following the eligibility  exercise challenge at each 
visit, serial spi[INVESTIGATOR_038]  (FEV 1) will be performed at 5, 10, 15, 30, [ADDRESS_536233]-
exercise.
Medication Dosing: At the end of Visits [ADDRESS_536234] evening 
dose exercise challenge/serial spi[INVESTIGATOR_038] , and prior to the subject’s leaving the clinic.
2015N231308_03 CONF IDENTIA L
201832
[IP_ADDRESS]. Visit 4 and Visit 7 (Blinded Treatment Exercise Challenges)
Visit 4 and Visit 7 begin between 5 PM and 11 PM and are conducted over 
approximately  24 hours. Subjects will be required to attend three clinic visits during each 
24-hour period for Visit 4 and Visit 7. The evening visit should begin at approxima tely 
the same time as Visit 1 (±1 hour).  
Dosing: At the beginning of Visit 4 and Visit 7, subjects will administer their evening 
doses of double -blinded study  medication in the clinic and the time of dosing will be 
recorded. In addition to administering the evening dose, vital signs will be measured and 
a review of concomitant medication and AEs performed.
Subjects will return to the clinic 12 (±1) hours and 23 (±1) hours after evening 
dosing for exercise challenge testing.
Pre-exercise FEV 1:At least two valid spi[INVESTIGATOR_424307] 1and FVC 
maneuvers should be obtained just prior to each exercise challenge.
From this spi[INVESTIGATOR_68333], the target FEV 1 values #2 and #3 (Section [IP_ADDRESS] ) should 
be de termined based on the pre -exercise FEV 1. 
Exercise challenge testing: Exercise challenge testing will occur at 12 (±1) hours and 23 
(±1) hours after administering the evening dose. (The 12 -hour exercise challenge and 
spi[INVESTIGATOR_424308]). 
Post-exercise Serial Spi[INVESTIGATOR_038]: Following the eligibility  exercise challenge at each 
visit, serial spi[INVESTIGATOR_038]  (FEV 1) will be performed at 5, 10, 15, 30, [ADDRESS_536235]-
exercise.
Washout Medication Dosing: At the end of Visit 4, the washout medication should be 
dispensed and first evening dose administered following completion of the [ADDRESS_536236] 
evening dose exercise challenge/serial spi[INVESTIGATOR_038] , and prior to the subject’s leaving the 
clinic.
[IP_ADDRESS]. Visit 5
Treatmen t period 2 baseline FEV 1:Spi[INVESTIGATOR_424300] 5 at 
approximately  the same time as at Visit 1 (±1 hour). The FEV 1should be measured 
approximately  12 hours (±1 hour) after dosing with the washout medication. At least two 
valid spi[INVESTIGATOR_424309].
Dosing: Subjects will administer their evening doses of double- blinded study  medication 
following the spi[INVESTIGATOR_038] .
8.3.4. Physical A ctivity Monitor
Subjects should refrain from significant changes in their exercise level (e.g., joining a
gym), except as instructed by  [CONTACT_093], for the duration of the study .
2015N231308_03 CONF IDENTIA L
201832
55A clinically  validated phy sical activity  monitor (accelerometer) will be used to measure 
specific levels of ph ysical activity . There will be 4 assessment periods, including an 
initial baseline assessment in order to provide a reliable estimate of habitual phy sical 
activity .The ph ysical activity  monitor will be worn by  [CONTACT_424361] 2, Visit 4, Visit 5 and Visit 7. Further details will be provided in the 
SRM.
Subjects will be contact[CONTACT_424362] 8- 9 day s prior to Visits 2, 4, 5 and 7 and 
reminded to wear the SenseWear Armband accelerometer for the 7 day s preceding these 
visits.
Physical activity  monitors will be shipped from each study  site directly  to [COMPANY_004] for 
analysis and interpretation or to an independent vendor, contracted by  [CONTACT_23983], blinded to 
treatment assignment, who will be responsible for transmitting the data to [COMPANY_004].
8.3.5. Asthma Control Questionnaire -5 (ACQ-5)
The ACQ -[ADDRESS_536237]’ asthma control that can be quickly  and easily  completed [ Juniper , 2005]. The 
questions are designed to be self -completed by  [CONTACT_423]. The five questions enquire 
about the frequency  and/or severit y of s ymptoms (nocturnal awakening on waking in the 
morning, activity  limitation, and shortness of breathe, wheeze). The response options for 
all these questions consist of a zero (no impairment/limitation) to six (total impairment/ 
limitation) scale.
The subject should be given a quiet area in which to complete the questionnaire. The 
investigator should ask the subject to complete th e questions as accurately  as possible. If 
the subject requests help or clarification with an y of the questions, he/she will be asked to 
re-read the instructions and give the answer that best reflects how he/she felt over the 
previous week. The subject sh ould be reassured that there are no right or wrong 
answers. The investigator should not provide the subject with any  answer or attempt to 
interpret an y portion of a question.
It is recommended that the ACQ -
[ADDRESS_536238]’s response. Adequate time 
should be allowed to complete all items on the ACQ-5.
8.4. Safet y
Safety  will be assessed, as indicated in the Time and Events Table Table 3, by [CONTACT_424363], a ph ysical examination at screening, and vital signs (s ystolic and diastolic blood 
pressure and heart rate [pulse] at each visit. A screening [ADDRESS_536239] x -ray should be conducted within 
48 hours.
Planned time points for all safety  assessments are listed in the Time and Events Table 
(Time and Events Table 3). 
8.4.1. Adverse Events (A E) and Serious A dverse Events (S AEs)
The definitions of an AE or SAE can be found in Appendix 5 .
The inves tigator and their designees are responsible for detecting, documenting and 
reporting events that meet the definition of an AE or SAE. 
[IP_ADDRESS]. Time period and Frequency  for collecting A E and SA E information
AEs and SAEs will be collected from the start of Study  Treatment (the start of the 
run-in period) until the follow -up contact (see Section [IP_ADDRESS]), at the time points 
specified in the Time and Events Table Table 3).
Medical occurrences that begin prior to the start of study  treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the eCRF.
Any SAEs assessed as related to study  participation (e.g., protocol- mandated 
procedures, invasive tests, or change in existing therapy ) or related to a [COMPANY_004] 
product will be recorded from the time a subject consents to participate in the 
study  up to and including any  follow -up contact. 
All SAEs will be recorded and reported to [COMPANY_004] within 24 ho urs, as indicated in 
Appendix 5 .
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects. However, if the investigator learns of an y SAE, including a death, at an y 
time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording, evaluating and assessing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to [COMPANY_004] are provided in 
Appendix 5 .
[IP_ADDRESS]. Method of Detecting AEs and SA Es
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y our last visit/contact?” 
2015N231308_03 CONF IDENTIA L
201832
57“Have you taken an y new m edicines, other than those provided in this study , since 
your last visit/contact?” 
[IP_ADDRESS]. Follo w-up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject at subsequent visits/contacts. All SAEs, and non -serious AEs of special interest 
(as defined in Section 5.6.1) will be followed until resolution, until the condition 
stabilizes, until the event is otherwise explained, or until the subject is lost to follow -up 
(as defined in Section 6.4). Further information on follow -up procedures is given in 
Appendix 5 .
[IP_ADDRESS]. Cardiovascular and Death Events
For an y cardiovascular events detailed in Appendix 5 and all deaths, whether or not they 
are considered SAEs, specific Cardiovascular (CV) and Death sections of the eCRF will 
be required to be completed. These sections include questions regarding cardiovascular
(including sudden cardiac death) and non- cardiovascular death.
The CV CRFs are presented as queries in response to reporting of certain CV Medical 
Dictionary  for Regulatory  Activities (MedDRA) terms. The CV information should be 
recorded in the specific cardiovascular section of the CRF within one week of receipt of a 
CV Event data query  prompting its completion.
The Death CRF is provided immediately
 after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one 
week of when the death is reported.
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_424364]- serious AEs related to 
study  treatment (even for non- interventional post -marketing studies ) is essential so that 
legal obligations and ethical responsibilities towards the safet y of subjects and the safety 
of a product under clinical investigation are met. 
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
An investigator who receiv es an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements.
2015N231308_03 CONF IDENTIA L
201832
588.4.2. Asthma Exacerbations
Severe asthma exacerbations should not be recorded as an AE unless they  meet the 
definition of an SAE (Section 13.5.2 ).  For the purposes of this study, severe asthma 
exacerbations will be collected and recorde d on the exacerbations log in the eCRF. The 
treatment details must also be recorded in the eCRF. 
The time period for collection of severe asthma exacerbations will begin from the time of 
randomization (first receipt of investigational product) and will en d after the 7 -day 
follow -up period has been completed.
8.4.3. Pregnancy
Details of all pregnancies in female subjects will be collected from the time the 
informed consent is signed (Visit 1) and until the follow up contact.
Any pregnancy  that occurs during stud y participation must be reported using a 
clinical trial pregnancy  form.  
If a pregnancy  is reported then the investigator should inform [COMPANY_004] within 2 weeks 
of learning of the pregnancy  and should follow the procedures outlined in Section 
13.6.1 .
Any SAE occurring in association with a pregnancy , brought to the investigator’s 
attention after the subject has completed the stud y and considered b y the investigator 
as possibly  related to the study  treatment, must be pro mptly  reported to [COMPANY_004].
8.4.4. Physical Exams
A detailed ph ysical examination including, but not limited to an evaluation of the 
lungs and cardiovascular sy stem, will be conducted at Visit 1.  I nvestigators 
should pay  special attention to clinical signs related to previous serious illnesses
Licensed practitioners who are listed on the Form [ADDRESS_536240]’s clinic notes. Whenever possible, the same person should 
perform the examination. 
If during routine clinical examination of the subject there is evidence of oral 
candidiasis infection, a culture can be taken and appropriat e therap y should be 
instituted at the discretion of the Investigator.
8.4.5. Vital Signs
Vital signs including pulse rate and sy stolic and diastolic blood pressure will be 
obtained at each clinic visit, including any  Earl y Withdrawal visit. 
Vital signs will be o btained after subjects have rested for approximately  [ADDRESS_536241] .
2015N231308_03 CONF IDENTIA L
201832
59At all time points where both vital signs and spi[INVESTIGATOR_424276], vital signs 
will be done before the spriometry  measurement. 
At visits where the exercise challenge is performed, vitals will be measured before 
(prior to the pre -exercise spi[INVESTIGATOR_038] ) and after the exercise challenge.
Heart rate will be measured during each exercise challenge. 
If there are an y clinicall y significant abnormalities noted, further examinations 
must be performed until the abnormalit y is resolved.  
8.4.6. Electrocardiogram (ECG)
A 12 -lead ECG will be performed and interpreted by  [CONTACT_15009]/her 
suitably  qualified designee at Visit 1. The ECG will be recorded after [ADDRESS_536242]; after vital signs and prior to performing spi[INVESTIGATOR_038] .
Investigators will use a site ECG machine and perform a manual readi ng of the 
ECG parameters to determine whether a subject meets the eligibility  criteria for 
enrolment in the study  at screening (Visit 1). 
The ECG interpretation including the paper trace will be maintained at the site 
within the source documentation.
8.5. Gene tics
Information regarding genetic research is included in Appendix 4 .
9. DATA MANAG EMENT
For this study , subject data will be entered into [COMPANY_004] defined CRFs, transmitted 
electronically  to [COMPANY_004] or designee and combined with data provided from other 
sources in a validated data sy stem.  
Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data, 
e.g., removing errors and inconsiste
ncies in the data.
Adverse events and concomitant medications terms will be coded using MedDRA 
(Medical Dictionary  for Regulatory  Activities) and an internal validated 
medication dictionary , [COMPANY_004]Drug.  
CRFs (including queries and audit trails) will be reta ined b y [COMPANY_004], and copi[INVESTIGATOR_131964] y.  Subject initials 
and full date of birth will not be collected or transmitted to [COMPANY_004] according to 
[COMPANY_004] policy .
For this study  subject data will be collected using [COMPANY_004] defined case report forms 
and combined with data provided from other sources in a validated data s ystem.
2015N231308_03 CONF IDENTIA L
201832
60Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data, 
e.g., removing errors and inconsistencies in the data.
Adverse events and concomitant medications terms will be coded using MedDRA 
(Medical Dictionary for Regulatory  Activities) and an internal validated 
medication dictionary , [COMPANY_004]Drug.  
Original CRFs will be retained by  [CONTACT_23983], while the investigator will retain a copy .  
Subject initials will not be collected or transmitted to [COMPANY_004] according to [COMPANY_004] 
policy .
10. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
10.1. Hypotheses
The primary  endpoint is the maximal per cent decrease in FEV 1following exercise 
challenge at [ADDRESS_536243] -dose at the end of the 2-week treatment period.  
The treatment comparison is the FF/VI combination versus FP.  Demonstration of 
efficacy  for this treatment comparison will be based on a h ypothesis testing approach 
whereb y the null hy pothesis is that there is no difference between treatment groups and 
the alternative h ypothesis is that there is a difference between treatment groups.  
A 2-sided 5% probability associated with incorrectly  rejecting the null hy pothesis 
(significance level) is considered acceptable for this study . In order to account for 
multiplicity , this primary hy pothesis test on the primary  endpoint for the ITT ( Intent -to-
Treat) population will act as a gatekeeper for all other h ypothesis tests using the 
secondary  endpoints, where these tests will proceed in a pre -defined order.
If the primary  hypothesis on the primary  endpoint for the ITT population is rejected then 
the following hierarchy of tests will be performed using th e ITT population; 
1.Test at the 5% level the null hypothesis that the true odds ratio between the two treatment 
groups of recovering to within 5% of pre -exercise FEV 1at the [ADDRESS_536244] at the 5% level the null hy pothesis that the true population difference 
between the treatment group means in maximal percent decrease in FEV 1from 
pre-exercise at [ADDRESS_536245] at the 5% level the null hypothesis that the true odds ratio between the two treatment 
groups of recovering to within 5% of pre -exercise FEV 1at the [ADDRESS_536246] at the 5% level the null hy pothesis that the true 
population difference between the treatment group means in weighted mean [ADDRESS_536247] at the 5% level the null hy pothesis that the true 
population difference between the treatment group means in weighted mean [ADDRESS_536248]-dose at the end of the 2 -week treatment period , given 
an assumed 20% screen failure rate, a 70% run- in failure rate, and a 15% withdrawal rate 
post-randomisation, a total of approximately  [ADDRESS_536249] 220 subjects will enter the run- in period, 
of which 66 subjects will be randomized, of which 56 subjects will be evaluable, that is 
completing the exercise challenges and the FEV 1evaluations at the end of both treatment 
periods . With 56 evaluable subjects this study  has approximately  90% power assuming a 
true population difference of 5% in maximal percent decrease in FEV 1between the two 
treatment groups.  This assumes a within- subject standard deviation (SD) of 8% where 
signifi cance is declared at the two -sided 5% significance level. 
Subjects will be centrall y randomized to one of the two treatment sequences shown 
below in Table 4 in a 1:1 ratio:
Table 4 Treatment Sequencing
Allocation 
ratioSequence Period 1 Period 2
1 1 FF/V I 100/25 mcg QD via 
Ellipta + Placebo BD via 
DiskusFP 250 mcg BD via Diskus + 
Placebo QD via Ellipta
1 2 FP 250 mcg BD via Diskus + 
Placebo QD via ElliptaFF/V I 100/25 mcg QD via 
Ellipta + Placebo BD via 
Diskus
2015N231308_03 CONF IDENTIA L
[PHONE_8794].2.2. Sample Size Sensitivity
To demonstrate the sensitivity  of the sample size calculation for this study , Table [ADDRESS_536250] Deviation 
(%)Power for the 
primary endpoint 
(%)
5 >99.[ADDRESS_536251] Deviation 
(%)Number of 
evaluable subjects 
5 24
6 33
7 44
8 56
9 71
10 87
11 104
Both Table 5 and Table 6 assume a true population difference of 5% between the two 
treatment groups.
10.2.3. Sample Size Re -estimation
Blinded sample size re -estimation will be conducted when approximately  50% of the 
subjects have completed their second exercise challenge. In order to assess the accuracy 
of the sample size assumption for the within- subject SD, the linear mixed model for the 
primary  anal ysis will be fitted to this blinded interim data, but with a dummy  variable to 
denote treatment group membership. If this suggests the original assumptions behind the 
sample size were incorrect, an adjustment may  be made to the planned number of 
subjects to be recruited.
2015N231308_03 CONF IDENTIA L
[PHONE_8795].3. Data Analysis Considerations
10.3.1. Analysis Populations
Three subject populations will be identified.
Total Population : This population will comprise of all subjects screened and for whom a 
record exists on the study  database and will be used for the tabulation and listing of 
reasons for withdrawal before randomization.
Intent -to-Treat (ITT) Population : The ITT Population will comprise all subjects 
randomized to treatment and who received at least one dose of trial medication.  
Randomized subjects will be assumed to have received trial medication unless definitive 
evidence to the contrary  exists.  This will constitute the primary  population for all 
analyses of efficacy  measures and safet y measures. Outcomes will be reported according 
to the randomized treatment allocation.
Per Protocol (PP) Population : The PP Population will consist of all subjects in the I TT
Population who do not have full protocol deviations.  Protocol deviations can either be 
full or partial.  Subjects with only  partial deviations will be considered part of the PP 
population but their data will be excluded from the date of their deviation u ntil either the 
end of the stud y or the end of the treatment period in which the deviation occurred.  The 
decision to exclude a subject, or part of their data, from the PP Population will be made 
prior to breaking the blind.  Protocol deviations that will lead to full or partial exclusion 
from the PP population will be detailed in the Reporting and Anal ysis Plan (RAP).  This 
population will be used for confirmatory  anal yses of the primary  efficacy  endpoint only .
10.3.2. Analysis Data Sets
Details of the derived dat a in anal ysis datasets to be created will be given in the RAP.
10.3.3. Treatment Comparisons
[IP_ADDRESS]. Primary  Comparisons of Interest
The primary  treatment comparison is the comparison of group means for the FF/VI 
combination and FP for the primary  endpoint of maximal perc ent decrease in FEV 1from 
pre-exercise at [ADDRESS_536252] -evening dose at the end of the 2 -week treatment period . This 
comparison is to be performed using the ITT Population.
[IP_ADDRESS]. Other Comparisons of Interest
The primary  treatment comparison of FF/VI combination v ersus FP for the primary  
endpoint will also be performed for the PP population.
In addition FF/VI combination will be compared to FP for the secondary  and other 
efficacy  endpoints.
2015N231308_03 CONF IDENTIA L
[PHONE_8796].3.4. Interim A nalysis
No interim anal ysis is planned.  
10.4. Key Elements of A nalysis Plan
Where possible, data from subjects who withdraw prematurely  from the study  will be 
included in an y anal yses. Specific details for inclusion will be detailed in the RAP but, in 
general, if a subject has completed a treatment period, including both exe rcise challenges 
and FEV 1evaluations, then the data for that period will be included in the anal ysis. 
Specificall y if a subject has completed the first exercise challenge at [ADDRESS_536253] the missing 23 hour time 
point.
Any tests for interactions will be 2 -sided a t the 10% level of significance.  In all cases, if 
any assumptions of the proposed methods of analy ses are not met, alternative methods of 
analyses will be used.
The baseline FEV 1for all endpoints will be the pre- treatment FEV 1value obtained at the 
start of each Treatment Period (Visit 2 or Visit 5).
10.4.1. Efficacy  Analyses
All efficacy  data will be summarized using means, standard deviations, medians and 
ranges for continuous variables and frequencies and percentages for categorical variables.
[IP_ADDRESS]. Primary  Analysis
The primary  efficacy  end point is maximal percent decrease from pre -exercise FEV [ADDRESS_536254] for covariate effects. The LMM will include the following covariates: treatment, 
subject -level mean of the pre-treatment FEV 1period baselines (mean of the [ADDRESS_536255]), centered period- level baseline FEV 1(period baselines centered 
using subject -level mean of the pre -treatment FEV 1period baselines), gender, age, 
treatment period and smoking history  as fixed effects, and a random intercept for each 
subject.  
2015N231308_03 CONF IDENTIA L
201832
65Details will be provided in the RAP of alternative anal yses methods to be used in the 
event that distributional assumptions do not hold (e.g. if the distribution appears to be 
heavily  skewed).
Mean post -exercise minimum FEV 1measurements and mean maximal percent decrease 
from pre -exercise FEV 1will be summarized with descriptive statistics by  [CONTACT_6490]. Summaries and analy ses for the primary  endpoint will be provided for both the 
ITT and PP populations.  
[IP_ADDRESS]. Secondary  Analyses
Summaries and anal yses for secondary  endpoints will be provided for the ITT population.  
Maximal percent decrease from pre -exercise FEV 1following exercise challenge (at [ADDRESS_536256] -dose at the end of the 2- week treatment period):
This endpoint will be summarized and anal yzed as for the primary  endpoint of maximal 
percent decrease from pre- exercise FEV 1following exercise challenge at [ADDRESS_536257] -challenge F EV 1that was no more than 
5% lower than their pre -exercise FEV 1following the exercise challenge at [ADDRESS_536258] evening dose at the end of the 2 -week treatment period
This endpoint will be analy sed using a logistic regression model separatel y for the 12 and 
23 hour challenges using the covariates baseline FEV 1, treatment group, gender, age, and 
smoking history .
Weighted mean 0 -60 minutes for percentage decrease from pre- exercise FEV 1after 
exercise (at [ADDRESS_536259] -dose at the end of the 2- week treatment 
period):
A comparison will be made of the estimated means of the two treatment groups in for 
weighted mean [ADDRESS_536260] for covariate effects. The LMM will include 
the following covariates: treatment, subject -level mean of the pre -treatment FEV 1 period 
baselines (mean of the [ADDRESS_536261]), centered period -level baseline 
FEV 1(period baselines centered using subj ect-level mean of the pre -treatment FEV 1
period baselines),  gender, age, treatment period and smoking history  as fixed effects, and 
a random intercept for each subject.  
[IP_ADDRESS].1. Other Efficacy Analyses
Other measures of efficacy include the evaluation of a categ orical treatment response 
evaluating the percentage of subjects who demonstrate a decrease from pre -exercise 
challenge FEV 1<10%, a decrease 10% to <20%, or a decrease 20%, and an evaluation 
of maximal percent decrease from  treatment period baseline in F EV 1(period baseline) 
following exercise challenge (at [ADDRESS_536262]- dose) .  Additional endpoints 
2015N231308_03 CONF IDENTIA L
[ADDRESS_536263]- challenge FEV 1that was no more than 5% lower than their 
pre-exercise FEV 1following the exercise challenge at [ADDRESS_536264] 
evening dose at the end of the 2-week treatment period (repeat for the 10, 15, 45 and 60 
minute time points).   
10.4.2. Safety  Analyses
Safety  will be assessed with clinical adverse events and asthma exacerbations.  
[IP_ADDRESS]. Extent of Exposure
The extent of exposure to study  drug will be summarized by  [CONTACT_1570].
[IP_ADDRESS]. Adverse Events (A Es)
Frequency  of adverse events will be tabulated by  [CONTACT_424365] n umber of 
subjects with events occurring during the treatment period.  Drug -related adverse events 
will be tabulated in the same manner.  Subject listings will include all reported adverse 
events, all adverse events rated as serious and all adverse events l eading to study  
discontinuation.
[IP_ADDRESS]. Exacerbations
The frequency  of subjects experiencing an asthma exacerbation during the treatment 
period will be tabulated by [CONTACT_1570].  A subject listing will include all reported 
exacerbations.
10.4.3. Pharmacogenetic A nalyses
See Appendix 4 for details about the PGx Analy sis Plan.
11. STUDY GOVERNANCE CON SIDERATIONS
11.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on p ublicly  available clinical trial 
registers before enrollment of subjects begins.
11.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, [COMPANY_004] will obtain favourable opi[INVESTIGATOR_1649]/approval from the 
appropriate r egulatory  agency  to conduct the study in accordance with I CH Good Clinical 
Practice (GCP) and applicable country -specific regulatory  requirements.
2015N231308_03 CONF IDENTIA L
201832
67The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
The study  will also be conducted in accordance with I CH Good Clinical Practice (GCP), 
all applicable subject privacy  requirements, and the guiding principles of the current 
version of the Declaration of Helsinki.  This includes, but is not limited to, the f ollowing:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of the study  protocol and 
amendments as applicable
Obtaining signed informed consent
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol 
deviations to I RB/IEC)
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, 
or both.
Signed informed consent must be obtained for each subject prior to participation 
in the study
The IEC/I RB, and where applicable the regulatory authority, approve the clinical 
protocol and all optional assessments, including genetic research.  
Optional assessments (including those in a separate protocol and/or under separate 
informed consent) and the clinical protocol should be concurrentl y submitted for 
approval unless regulation req uires separate submission.  
Approval of the optional assessments may  occur after approval is granted for the 
clinical protocol where required b y regulatory  authorities.  I n this situation, 
written approval of the clinical protocol should state that approv al of optional 
assessments is being deferred and the study , with the exception of the optional 
assessments, can be initiated.
11.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations including GCP, and [COMPANY_004] procedures, 
[COMPANY_004] monitors will contact [CONTACT_288627], study  requirements, and their responsibilities to satisfy  
regulatory , ethical, and [COMPANY_004] requirements.  
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which CRF will 
serve as the source document.
[COMPANY_004] will monitor the study  and site activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  
other study  agreements, GCP, and all applicable regulatory  requirements.
2015N231308_03 CONF IDENTIA L
201832
68The investigator and the head of the medical institution (where applicable) ag rees to 
allow the monitor direct access to all relevant documents
11.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, [COMPANY_004] 
may conduct a quality  assurance assessment and/or audit of the site records, and 
the regulator y agencies may  conduct a regulatory inspection at any  time during or 
after completion of the study . 
In the event of an assessment, audit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) dire ct access to all 
relevant documents and to allocate their time and the time of their staff to discuss 
the conduct of the stud y, any findings/relevant issues and to implement any 
corrective and/or preventative actions to address any  findings/issues identifi ed.
11.5. Stud y and Site Closure
Upon completion or premature discontinuation of the study , the [COMPANY_004] monitor will 
conduct site closure activities with the investigator or site staff, as appropriate, in 
accordance with applicable regulations including GCP, and [COMPANY_004] Standard 
Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or prematurel y discontinue this 
study  at an y time for reasons including, but not limited to, safety  or ethical issues 
or severe non -compliance. For multicenter studies, this can occur at one or more 
or at all sites.  
If [COMPANY_004] determines such action is needed, [COMPANY_004] will discuss the reasons for taking 
such action with the investigator or the head of the medical institution (where 
applicable).  When feasible, [COMPANY_004] will provide advance n otification to the 
investigator or the head of the medical institution, where applicable, of the 
impending action.
If the study is suspended or prematurely discontinued for safet y reasons, [COMPANY_004] will 
promptly  inform all investigators, heads of the medical in stitutions (where 
applicable) and/or institution(s) conducting the study . [COMPANY_004] will also promptly  
inform the relevant regulatory authorities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.  
If required b y appli cable regulations, the investigator or the head of the medical 
institution (where applicable) must inform the I RB/I EC promptl y and provide the 
reason for the suspension or premature discontinuation.
11.6. Records Retention
Following closure of the study , the investigator or the head of the medical 
institution (where applicable) must maintain all site study  records (except for 
those required b y local regulations to be maintained elsewhere), in a safe and 
secure location.  
2015N231308_03 CONF IDENTIA L
201832
69The records must be maintained to allow e asy and timely  retrieval, when needed 
(e.g., for a [COMPANY_004] audit or regulatory  inspection) and must be available for review 
in conjunction with assessment of the facilit y, supporting s ystems, and relevant 
site staff.  
Where permitted b y local laws/regulations or institutional policy , some or all of 
these records can be maintained in a format other than hard cop y (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all r eproductions are legible and are a true and 
accurate cop y of the original and meet accessibility and retrieval standards, 
including re -generating a hard cop y, if required.  Furthermore, the investigator 
must ensure there is an acceptable back -up of these r eproductions and that an 
acceptable qualit y control process exists for making these reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining these records to 
comply  with all applicable regulatory  requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study, as dictated by 
[CONTACT_65406], [COMPANY_004] 
standards/procedures, and/or institutional requirements.  
The investigator must notify  [COMPANY_004] of any changes in the archival arrangements, 
including, but not limited to, archival at an off- site facility  or transfer of 
ownership of the records in the event the investigator is no longer associated with 
the site.
11.7. Provision of Study  Results to Investigators, Posting of 
Information on Publically  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study report.  The investigator wi ll be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the ful l summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
[COMPANY_004] will provide the investigator with the randomization codes for their site only  after 
completion of the full statistica l analy sis.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript for publication will be in accordance with [COMPANY_004] Policy .
A manuscript will be progressed for publication in the scientific literature if th e results 
provide important scientific or medical knowledge.
2015N231308_03 CONF IDENTIA L
[PHONE_8797]. REFERENCES
European Medicines Agency  (EMA). Note for guidance on clinical investigation of 
medicinal products for treatment of asthma. 27Jun2013. CHMP/EWP/2922/01 Rev.1.
FDA Guidance for Industry : Exercise Induced Bronchospasm (EIB)—Development of 
Drugs to Prevent EIB, February  2002.
Global I nitiative for Asthma (GINA). Global Strategy for Asthma Management and 
Prevention. GI NA, www.ginasthma.org; 2015.
Hatcher RA, Trussell J, Nelson AL, Cates W J r, Stewart F, Kowal D, editors. 
Contraceptive Technology . 19th edition. [LOCATION_001]: Ardent Media, 2007 : 24. Table 3-2.
ICH guideline M3(R2) on non -clinical safety  studies for the conduct of human clinical 
trials and marketing authorisation for pharmaceutical s, 2009; EMA/CPMP/ICH/286/1995
Jones A, Fay  JK, Burr ML, Stone M, Hood K, Roberts G. Inhaled Corticosteroids Effects 
on Bone Metabolism in Asthma and Mild Chronic Obstructive Pulmonary Disease. 
Cochrane Database of Systemic Reviews. 2002;1:1 -21. 
Juniper E F, Svensson K, Mörk AC, Ståhl E. Modification of the Asthma Quality  of Life 
Questionnaire (standardised) in patients 12 y ears and older. Health and Quality of Life 
Outcomes. 2005; 3:58.
König P, Hillmana L, Cervantesa C, Levine C, Maloney  C, Douglass B , etal. Bone 
Metabolism in Children with Asthma Treated with Inhaled Beclomethasone 
Dipropi[INVESTIGATOR_16847]. The Journal of Paediatrics. 1993;122:219-226. 
McFadden ER, Gilbert IA. Exercise- induced asthma. N Engl J Med 1994;330:1362 -1367.
McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murph y D. Age and risks 
of FDA -approved long -acting 2-adrenergic receptor agonists. Pediatrics. 
2011;Nov;128(5):e1147 -54. 
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi F, Coates A, et al. 
Standardisation of spi[INVESTIGATOR_038] . Eur Respir J. 2005;26:319 -338. 
Mitchell KE, Johnson- Warrington V, Apps LD, Bankart LS, Williams JE, Rees K,et al. . 
A Self- Management Programme for COPD: a Randomised Controlled Trial. Eur Respir 
J. 2014;44:1538-1547. 
Murray  JJ, Waitkus- Edwards KR, Yancey  SW. Evaluation of Fluticasone Propi[INVESTIGATOR_424310]/Salmeterol Combination on Exercise in Pediatric and Adolescent 
Patients with Asthma. Open Resp Med J, 2011, 5, 11 -18.
National Institutes of Health (NIH). Guidelines for the Diagnosis and Manag ement of 
Asthma - Expert Panel Report 3 2007 . U.S. Department of Health and Human Services, 
Bethesda, MD; 2007. NIH Publication No. 07-4051.
2015N231308_03 CONF IDENTIA L
201832
71Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky  DA, Rundell KW, Hull JH, et al. 
An Official American Thoracic S ociet y Clinical Practice Guideline: Exercise -induced 
Bronchoconstriction. Am J Respir Crit Care Med 2013;187:1016–1027.
Pearlman D, Qaqundah P, Matz J, Yancey  SJ, Stempel DA, Ortega HG. Fluticasone 
Propi[INVESTIGATOR_16847]/Salmeterol and Exercise -Induced Asthma in Child ren With Persistent 
Asthma. Pediatric Pulm 2009;44:429 –435.
Poppi[CONTACT_3019] H, Muittari A, Kreus KE, Korhonen O, Vilhanen A. Exercise Asthma and 
Disodium Cromogly cate. Br Med J 1970;4:337- 339.
Quanjer P, Stanojevic S, Cole T, Baur X., Hall G, Enright P, et al. on behalf of the ERS 
Global L ung Function Initiative.  Multi -ethnic reference values for spi[INVESTIGATOR_105221] 3 -
95 year age range: the global lung function 2012 equations. Eur Respir J , 2012; 40: 
1324 –1343.
Turpeinen M, Pelkonen AS, Nikander K, Sorva R, Selroos O, Juntunen- Backman K,et al. 
. Bone mineral density  in children treated with daily  or periodical inhaled budesonide: the 
Helsinki Early  Intervention Childhood Asthma study . Paediatric Research. 
2010;68(2):169 -173. 
Weiler J, Anderson SD , Randolph C , Bonin i S, Craig TJ , Pearlman DS , et al. 
Pathogenesis, prevalence, diagnosis, and management of exercise -induced 
bronchoconstriction: a practice parameter. Ann Allerg Asthma Immunol 2010;105 (6 
Supp): S1- S47. 
Weiler J, Nathan RA, Rupp NT, Kalberg CJ; Emmett A, Dorinsky  PM. Effect of 
fluticasone/salmeterol administered via a single device on exercise -induced 
bronchospasm in patients with persistent asthma. Ann. Allergy Asthma Immunol. 
2005;94:65-72.
2015N231308_03 CONFIDENTIA L
[PHONE_8798]. APPENDICES
13.1. Appendix 1 –Abbreviations and Trademarks
Abbrev iations
ACQ Asthma Control Questionnaire -[ADDRESS_536265] Upper Limit of Normal
VI Vilanterol Trifenate (GW642444)
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_424366]/BREO
2015N231308_03 CONFIDENTIA L
[PHONE_8799].2. Appendix 2: Liver Chemistry  Stoppi[INVESTIGATOR_424311] A lgorithm
Phase III -IV Liver Chemistry Stoppi[INVESTIGATOR_424312]≥2x
ULN (>35% 
direct) or plus
INR>1.5, if 
measur ed*
Possi ble  
Hy’sLawALT≥3xULNALT
≥8xULNPlus
Sympt oms of 
liver injury
or 
hyper sensitivityNo
Yes
Yes YesNo No NoSee algorithm 
for continued 
therapy with 
increase d liver 
chemist ry 
moni toring
Yes
*INR value not applicable to subjects on anticoagu lants ALT 
≥3xULN 
but 
<8xULNYes
Must  refer to Liver Safety Requi red Actions and Follow up Asses sments section in the Appendi x
Repor t as an SAE if po ssible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5, if measur ed*
Liver Safet y Requ ired Actions and Follow up Assessments Section can be found in 
Appendix 3 .
2015N231308_03 CONFIDENTIA L
201832
75Phase III -IV Liver Chemistry Increased Monitoring Algorithm with Continued 
Therapy for ALT 3xULN but <8xULN
Cont inue Study Treatm ent   and   Monitor Liver Chem istry
Discontinue Study Treatment ALT≥5xULN 
but <8xULN
+ bili<2xULN +
no symptoms
NoMust  refer to Liver Safety Requi red Actions and Follow up Asses sments section in the Appendi x
YesALT ≥3xULN 
but <5xULN
+ bili<2xULN  +
no symptomsAble to 
monitor   
weekly 
for  ≥2 
weeksPersists for 
≥2 weeks  
or other 
stoppi[INVESTIGATOR_53099]  ≥4 
weeksPersists for 
≥4 weeks  
or other 
stoppi[INVESTIGATOR_131958] ≥5xULN ALT <5xULN 
Yes Yes
*INR value not applicable to subjects on anticoagulants Must  refer to Liver Safety Requi red Actions and Fol low up Asses sments section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5, if measur ed*
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 3 .
2015N231308_03 CONFIDENTIA L
[PHONE_8800].3. Appendix 3: Liver Safety  Required A ctions and Follow up 
Assessments
Phase III -IV liver chemistry stoppi[INVESTIGATOR_301131] y and evaluate liver event etiology (in alignment with the 
FDA premarketing clinical liver safet y guidance).  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf
Phase III -IV liver chemistry stoppi[INVESTIGATOR_90566] - Liver Stoppi[INVESTIGATOR_53053]- absolute ALT  8xULN
ALT Increase ALT  5xULN but <8xULN  persists for 2 weeks
ALT  3xULN but <5xULN  persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2 ALT  3xULN and International normalized ratio (INR)>1.5, if INR measured
Cannot 
MonitorALT  5xULN but <8xULN and cannot be monitored weekly for  2 weeks
ALT  3xULN but <5xULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to  liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue  study treatment 
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2
Perform liver event foll ow up assessments 
Monitor the subject until liver chemistries 
resolve , stabilize, or return to within baseline 
(see MONITORING below)Viral hepatitis serology4
Only in those with underlying chronic 
hepa titis B at study entry (identified by 
[CONTACT_23977] B surface antigen) 
quantitative hepatitis B DNA and hepatitis 
delta antibody5.
Blood sample for pharmacokinetic (PK) 
analysis, obtained within [ADDRESS_536266] dose6
Serum creatine phosphokinase (CPK) and 
2015N231308_03 CONFIDENTIA L
201832
77Do not restart/rechallenge subject with 
study treatment. 
Permanently discontinue study treatment and 
may continue subje ct in the study for any 
protocol specified follow up assessments
MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, 
aspartate aminotransferase [AST], alkaline 
phosphatase, bilirubin) and perform liver 
event follow up ass essments within  24 hrs
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to 
within baseline
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkali ne phosphatase, bilirubin) and perform 
liver event follow up assessments within  24-
72 hrs 
Monitor subjects weekly until liver chemistries 
resolve, stabilize or return to within baselinelactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications on 
the concomitant medications report form
including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form
For bilirub in or INR criteria:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti- liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG or gamma 
globulins).
Serum acetaminophen adduct HPLC 
assay (quantifies potential acetaminop hen 
contribution to liver injury in subjects with 
definite or likely acetaminophen use in the 
preceding week [ James , 2009]). 
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver bi opsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. Allevents of ALT  3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
2015N231308_03 CONFIDENTIA L
201832
78studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)   
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epst ein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. If hepatitis delta antibody assay cannot be performed,, it can be replaced with a PCR of hepatitis D RNA virus 
(wher e needed) [Le Gal , 2005].
6. PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in 
the time per iod indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971].  
Phase III -IV liver chemistry increased monitoring criteria with continued therapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitor ing Event
Criteria Actions
ALT  5xULN and <8xULN and
bilirubin <2xULN without symptoms 
believed to be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 2 weeks.
OR
ALT  3xULN and <5xULN and
bilirubin <2xULN without symptom s 
believed to be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 4 weeks.Notify the [COMPANY_004] medical monitor within [ADDRESS_536267] 
safety. 
Subject can continue study treatment  
Subject must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time subject meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
If ALT decreases from ALT 5xULN and <8xULN 
to ≥3xULN but <5xULN, continue to monitor liver 
chemistries weekly. 
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver chemistries normalize or return to wit hin 
baseline.
2015N231308_03 CONFIDENTIA L
[ADDRESS_536268] in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény P, Gault E.  Quantification 
of Hepatitis Delta Virus RNA in Serum by  [CONTACT_31861] -Time PCR I ndicates 
Different Patterns of Virological Response to Interferon Therap y in Chronically  Infected 
Patie nts.  J Clin Microbiol. 2005;43(5):2363 –2369. 
2015N231308_03 CONFIDENTIA L
[PHONE_8801].4. Appendix 4: Genetic Research
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine, including FF/V I, FP or an y concomitant medicines;
Asthma susceptibility , severity , and progression and related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  An alyses may  be performed using data 
from multiple clinical studies to investigate these research objectives.
Appropriate descriptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be documented in a Rep orting and Analy sis Plan 
(RAP) prior to initiation of the anal ysis. Planned analy ses and results of genetic 
investigations will be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, as appropriate.
Study Population
Any subject who is enrolled in the study  can participate in genetic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key  component of suc cessful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response.  
A 2 ml saliva sample will be taken for Deox yribonucleic acid (DNA) extraction. 
A saliva sample is collected at the randomisation visit, after the subject has been 
randomized and provided informed consent for genetic research. Instructions for 
collection and shippi[INVESTIGATOR_131977]. The DNA from the saliva sample may  undergo quality  control analy ses to 
confirm the integrit y of the sample. If there are concerns regarding the quality  of 
the sample , then the sample may  be destroy ed. The saliva sample is taken on a 
single occasion unless a duplicate sample is required due to an inabilit y to utilize 
the original sample.  
The genetic sample is labelled (or “coded”) with the same stud y specific number used to 
label other samples and data in the study.  This number can be traced or linked back to 
2015N231308_03 CONFIDENTIA L
[ADDRESS_536269] by  [CONTACT_132018]. Coded samples do not carry  personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stored securel y and may be kept for up to [ADDRESS_536270] 
completes the study , or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other researchers) will only use samples collected from the study  
for the purpose s tated in this protocol and in the informed consent form.  Samples may  be 
used as part of the development of a companion diagnostic to support the [COMPANY_004] medicinal 
product.
Subjects can request their sample to be destro yed at any  time.
Informed Consent
Subject s who do not wish to participate in the genetic research may  still participate in the 
study .  Genetic informed consent must be obtained prior to any  saliva being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research withdraws from the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning the genetic sample, if already  
collected:
Continue to participate in the genetic res earch in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a subject withdraws consent for genetic research or requests sample destruction for an y 
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . 
Genoty pe data may  be generated during the study  or after completion of the study  and
may be anal yzed during the study  or stored for future anal ysis. 
If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.  
Genetic data that has been anal yzed at the time of withdrawn consent will 
continue to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry  criteria for participation in th e study , then the investigator should 
instruct the subject that their genetic sample will be destro yed. No forms are required to 
complete this process as it will be completed as part of the consent and sample 
2015N231308_03 CONFIDENTIA L
[ADDRESS_536271]’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately  and may  publish the results in scientific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the subject, 
family  members, insurers, or employ ers of individual ge notypi[INVESTIGATOR_131978]’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is generall y preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care.
2015N231308_03 CONFIDENTIA L
[PHONE_8802].5. Appendix 5: Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of A dverse Events
13.5.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporally associated with the use of a medicinal product, whe ther or not 
considered related to the medicinal product.
NOTE: An AE can therefore be an yunfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.
Events meeting AE definition include:
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, radiological scans, vital signs 
measurements), including those that worsen from baseline, and felt to be clinically  
significant in the medical and scientific judgement of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after study  treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of seq uelae).
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE.  However, the signs and sy mptoms and/or clinical 
sequelae resulting from lack of efficacy  will be reported if they  fulfil the definition
of an AE or SAE.
The signs and symptoms and/or clinical sequelae resulting from lack of efficacy  will 
be reported if they  fulfil the definition of an AE or SAE.  Also, "lack of efficacy " or 
"failure of expected pharmacological action" also constitutes an AE or SAE.
Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_941] 
2015N231308_03 CONFIDENTIA L
201832
84Events NOT meeting definition of an AE include:
investigator to be more severe than expected for the subject’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition.
Medical or surgical procedure (e .g., endoscopy , appendectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
13.5.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_059] f or signs/symptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
a.Results in death
b.Is life -threatening
NOTE:
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might have caused death, if it were more severe.
c.Requires hospi[INVESTIGATOR_424313]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appro priate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disability/incapacity
2015N231308_03 CONFIDENTIA L
201832
85Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
NOTE:
The term disab ility means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea , influen za, 
and accidental trauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_424314].  These should also be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse
g. Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin  2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form.
See Appendix 3 for the required liver chemistry  follow -up instructions
2015N231308_03 CONFIDENTIA L
[PHONE_8803].5.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
13.5.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the CRF
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical 
records to [COMPANY_004] in lieu of completion of the [COMPANY_004], AE/SAE CRF page.
There may be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004].  In this instance, all subject identifiers, with the exception of the 
subject number, will be blinded on the copi[INVESTIGATOR_424315] K.
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/sy mptoms.
Subject -completed Valu e Evidence and Outcomes questionnaires and the collection 
of AE data are independent components of the study .
Responses to each question in the Value Evidence and Outcomes questionnaire will 
be treated in accordance with standard scoring and statistical pr ocedures detailed b y 
the scale’s developer.
2015N231308_03 CONFIDENTIA L
201832
87The use of a single question from a multidimensional health survey  to designate a 
cause -effect relationship to an AE is inappropriate.
13.5.5. Evaluating AEs and SA Es
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by  [CONTACT_423], causing minimal discomfort 
and not interfering with every day activities.
Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Severe:  An event that prevents normal every day activities. -an AE that is assessed 
as severe will not be confused with an SAE. Severity  is a category  utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least one of the pre -defined 
outcomes as described in the definition of an SAE.
Assessment of Causality
The i nvestigator is obligated to assess the relationship between stud y treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relation ship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors, and the temporal relationship of the event to the study  
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Brochure (IB) and/or Product 
Information, for marketed products, in the determination of his/her assessment.
For each AE/SAE the investigator mustdocument in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004].  Howev er, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to [COMPANY_004].
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information, amen ding the SAE data collection tool accordingl y.
2015N231308_03 CONFIDENTIA L
201832
88The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supp lemental 
measurements and/or evaluations as may  be indicated or as requested by  [CONTACT_90648]/or causality  of the AE or SAE.
The investigator is obligated to assist.  This may  include additional laboratory  tests 
or investigations, histopathological examinations or consultation with other health 
care professionals.
If a subject dies during participation in the study  or during a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  post -mortem findings, 
including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames.
13.5.6. Reporting of SA Es to [COMPANY_004]
SAE reporting to [COMPANY_004] via electronic data collection tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic data collection 
tool
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the Medical Monitor 
Site will enter the serious adverse event data into the electronic s ystem as soon as it 
becomes available.
The investigator will be required to confirm review of the SAE causality  by [CONTACT_90649] ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the electronic data collection tool (e.g., 
InForm s ystem) will be taken off- line to prevent the entry  of new data or changes to 
existing data
If a site receives a report of a new SAE from a study  subject or receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, the site can report this information on a paper SAE form or to the Medical 
Monitor by  [CONTACT_756].
Contacts for SAE receipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
2015N231308_03 CONFIDENTIA L
201832
89SAE reporting to [COMPANY_004] via paper CRF
Facsimile transmission of the SAE paper CRF is the preferred method to tran smit 
this information to the Medical Monitor 
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_72031], with a cop y of the SAE data collection tool sent by 
[CONTACT_9338]
Initial notification via the telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE receipt can be found at this beginning of the protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
2015N231308_03 CONFIDENTIA L
[PHONE_8804].6. Appendix 6: Modified List of Highly  Effective Methods for 
Avoiding Pregnancy  in Females of Reproductive Potential 
(FRP) and Collection of Pregnancy  Information
This list does not apply  to FRP with same sex partners, when this is their preferred and
usual lifesty le or for subjects who are and will continue to be abstinent from penile -
vaginal intercourse on a long term and persistent basis. 
Contraceptive subdermal implant 
Intrauterine device or intrauterine s ystem 
Oral Contraceptive, either combine d or progestogen alone [ Hatcher , 2007 ] 
Injectable progestogen [ Hatcher , 2007 ]
Contraceptive vaginal ring [ Hatcher , 2007 ]
Percutaneou s contraceptive patches [ Hatcher , 2007 ]
Male partner sterilization with documentation of azoospermia prior to the female 
subject's entry  into the study , and this male is the sole partner for that subject 
[Hatcher , 2007 ].  
Male condom plus partner use of one of the contraceptive options below:
oContraceptive subdermal implant 
oIntrauterine device or intrauterine s ystem 
oOral Contraceptive, either combined or progestogen alone [ Hatcher , 2007 ]
Injectable progestogen [ Hatcher , 2007 ]
oContraceptive vaginal ring [ Hatcher , 2007 ]
oPercutaneous contraceptive patches [ Hatcher , 2007 ]
This is an all inclusive list of those methods that meet the [COMPANY_004] definition of highl y 
effective: having a failure rate of less than 1% per y ear when used consistently  and, 
correctly  and, when applicable, in accordance with the product label.  For non -product 
methods (e.g.  male sterility ), the investigator determines what is consistent and correct 
use. The [COMPANY_004] definition is based on the definition provided b y the ICH [ ICH, M3 (R2) 
2009].
The investigator is responsible for ensuring that subjects understand how to properl y use 
these methods of contraception.
13.6.1. Collection of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who b ecomes 
pregnant while participating in this study
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within [ADDRESS_536272]'s pregnancy .
2015N231308_03 CONFIDENTIA L
201832
91Subject will be followed to determine the outcome of the pregnancy . The 
investi gator will collect follow up information on mother and infant, which will be 
forwarded to [COMPANY_004].  Generall y, follow-up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date. 
Any termination of pregnancy  will be reported, regar dless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to [COMPANY_004] 
as described in Appendix [ADDRESS_536273] who becomes pregna nt while participating
Will discontinue study  medication andbe withdrawn from the study .
2015N231308_03 CONFIDENTIA L
[PHONE_8805].7. Appendix 7 -Country  Specific Requirements
No country -specific requirements exist.
2015N231308_03 CONFIDENTIA L
[PHONE_8806].8. Appendix 8 –Protocol Changes
13.8.1. Protocol A mendment [ADDRESS_536274] dose of double- blinded study  medication in each 
Treatment Period. The purpose is to demonstrate that inhaled FF/VI 100/[ADDRESS_536275] been made.
Method of A mendment
Original and amended texts are specified as follows:
Original text: as written in the original protocol
Revised text: as written in Amendment No. 01 with revisio ns in bold font.
Amendment Details
Protocol title 
Original title:
201832: A Double- Blind, Double -Dumm y Comparison of Fluticasone Furoate/Vilanterol 
100/25 mcg Once Daily  Versus Fluticasone Propi[INVESTIGATOR_16847] 250 mcg Twice Daily  in 
Adolescent and Adult Subjects with Asthma and Exercise -Induced Bronchoconstriction
Revised title:
201832: A Randomised , Double -Blind, Double -Dummy  Crossover Comparison of 
Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily  Versus Fluticasone Propi[INVESTIGATOR_16847] 
250 mcg Twice Daily in Adolescent and Adult Subjects with Asthma and Exercise -
Induced Bronchoconstriction
Protocol Sy nopsis: Overall Design
Original text:
This is a multicenter, randomized, double -blind, double -dummy , crossover study  with 
two [ADDRESS_536276] evening dose at Visits 3 and 5. Spi [INVESTIGATOR_424274] (Visit 1), 
2015N231308_03 CONFIDENTIA L
201832
94and pre -dose at Visit 4, and prior to each exercise challenge at Visits 2, 3 and 5. Serial 
spi[INVESTIGATOR_038]  (6 time points over 60 minutes) as FEV 1only will be conducted after each 
exercise challenge test. Subje cts should be monitored until they  reach a recovery  level 
where their FEV 1value represents a 95% recovery  of the pre -exercise FEV 1 result.  
Additional spi[INVESTIGATOR_424275] .
A Pre -Screening Visit (Visit 0) is included to obtain a signed Informed Consent and to 
review concomitant medications, and may  be conducted on the same day  as Visit 1, if 
appropriate. At Visit 1, subjects meeting eligibility criteria and will enter a 4 week single -
blinded run- in period on fluticasone propi[INVESTIGATOR_16847] (FP) 250 mcg twice dail y (BD). 
Albuterol/salbutamol will be issued for rescue use during the run -in, wash -out and 
treatment periods as needed.  Subjects will be instructed to contact [CONTACT_424352].  
A screening electrocardiogram (ECG) and a complete phy sical examination will be 
conducted at Visit 1. Vital signs will be collected at each visit prior to spi[INVESTIGATOR_424316].
Physical activity  levels will be monitored wit h the use of a ph ysical activity monitor to 
assess activity  outside the clinic worn for 7 day s prior to Visit 2 (baseline), for [ADDRESS_536277] at Visits 2 through 5. 
A follow up phone call wi ll be conducted approximately  7 day s after Visit 5.
Revised text:
This is a multicenter, randomized, double -blind, double -dummy , crossover study  with 
two 2 -week treatment periods separated b y a 2 -week wash- out period. Subjects will 
attend up to eight visits over the course of the study. Standardized exercise challenge 
testing will be conducted at Visit 2 for eligibility  determination, Visit 3 and Visit 6 
(after [ADDRESS_536278] treatment dose in each Treatment Period); and at [ADDRESS_536279] eve ning dose at Visits 4 and 7 . Spi[INVESTIGATOR_424317] 
(Visit 1), and pre -dose at Visit 5, and prior to each exercise challenge at Visits 2, 3, 4, 6
and 7 . Serial spi[INVESTIGATOR_038]  (6 time points over 60 minutes) as FEV 1only will be conducted 
after each exercise challenge test. Subjects should be monitored until they  reach a 
recovery  level where their FEV 1value represents a 95% recovery  of the pre -exercise 
FEV 1 result.  Additional spi[INVESTIGATOR_424318].
A Pre -Screening Visit (Visit 0) is included to obtain a signed Informed Consent and to 
review concomitant medications, and may  be conducted on the same day  as Visit 1, if 
appropriate. At Visit 1, subjects meeting eligibility criteria and will enter a 4 week single -
blinded run-in period on fluticasone propi[INVESTIGATOR_16847] (FP) 250 mcg twice dail y (BD). 
2015N231308_03 CONFIDENTIA L
201832
95Albuterol/salbutamol will be issued for rescue use during the run -in, wash -out and 
treatment periods as needed.  Subjects will be instructed to contact [CONTACT_424352].  
A screening electrocardiogram (ECG) and a complete phy sical examination will be 
conducted at Visit 1. Vital signs will be collected at each visit prior to spi[INVESTIGATOR_424316].
Physical activity  levels will be monitored with the use of a ph ysical activity monitor to 
assess activity  outside the clinic worn for 7 day s prior to Visit 2 (baseline), for [ADDRESS_536280] at Visits 2 ,4, 5 and 7. 
A follow up phone call will be conducted approximately  7 day s after Visit 7.
Protocol sy nopsis: Secondary  and Other Endpoints
Original text:
Secondary  Endpoints
Maximal percent decrease from pre -exercise FEV 1following exercise challenge a t 
[ADDRESS_536281] evening dose at the end of the 2 -week treatment period
Time required for recovery  to within 5% of pre -exercise FEV 1from the time of the 
maximal percentage decrease from pre -exercise FEV [ADDRESS_536282] evening dose
Area under the curve for percentage decrease from pre- exercise FEV 1following 
exercise challenge at [ADDRESS_536283] evening dose (AUC 0- 60 min)
Other Endpoints
Categorical treatment response evaluation of the percentage of subjects who
demonstrate a decrease from pre- exercise challenge FEV 1(at [ADDRESS_536284] evening dose) of:
o<10%, 
o≥10% to <20%, 
o≥20% 
Maximal percent decrease from pre -exercise baseline FEV 1following exercise 
challenge at [ADDRESS_536285] evening dose at the end of the 2 -week 
treatment period  
Mean change from baseline in ACT score at the end of the treatment period
Percentage of subjects controlled defined as an Asthma Control Test (ACT) score ≥20 
at the end of the treatment pe riod
2015N231308_03 CONFIDENTIA L
201832
96Change in ph ysical activity  measures as assessed by  a biosensor (SenseWear 
Armband) in terms of physical activity endpoints (e.g. dail y step count, METs, sleep 
duration)
Revised text:
Secondary  Endpoints
Maximal percent decrease from pre -exercise F EV 1following exercise challenge at 
[ADDRESS_536286] evening dose at the end of the 2 -week treatment period
Time required for recovery  to within 5% of pre -exercise FEV 1from the time of the 
maximal percentage decrease from pre -exercise FEV [ADDRESS_536287] evening dose at the end of the 2 -week 
treatment period
Area under the curve for percentage decrease from pre- exercise FEV 1following 
exercise challenge at [ADDRESS_536288] evening dose (AUC 0- 60 min) at 
the end of the 2- week treatment period
Other Endpoints
Categorical treatment response evaluation of the percentage of subjects who
demonstrate a decrease from pre- exercise challenge FEV 1(at [ADDRESS_536289] evening dose at the end of the 2 -week treatment period ) of:
o<10%, 
o≥10% to <20%, 
o≥20% 
Maximal percent decrease from pre -exercise baseline FEV 1following exercise 
challenge at [ADDRESS_536290] evening dose at the end of the 2-week
treatment period  
Mean change from baseline in ACT score at the end of the 2- week treatment period
Percentage of subjects controlled defined as an Asthma Control Test (ACT) score ≥20 
at the end of the 2-week treatment period
Change in ph ysical activity  measures as assessed by  a biosensor (SenseWear 
Armband) in terms of phy sical activity  endpoints (e.g. dail y step count, METs, sleep 
duration)
2015N231308_03 CONFIDENTIA L
201832
97Section 4.2: Secondary  Endpoints
Original text:
Maximal percent decrease from pre -exercise FEV 1following exercise challenge at 
[ADDRESS_536291] evening dose at the end of the 2 -week treatment period
Time required for recovery  to within 5% of pre -exercise FEV 1from the time of the 
maximal percentage decrease from pre -exercise FEV [ADDRESS_536292] evening dose
Area under the curve for percentage decrease from pre -exercise FEV 1following 
exercise challenge at [ADDRESS_536293] evening dose (AUC 0 -60 min)
Revised text:
Maximal percent decrease from pre -exercise FEV 1following exercise challenge at 
[ADDRESS_536294] evening dose at the end of the 2 -week treatment period
Time required for recovery  to within 5% of pre -exercise FEV 1from the time of the 
maximal percentage decrease from pre -exercise FEV 1following the exercise 
challenge at [ADDRESS_536295] evening dose at the end of the 2 -week
treatment period.
Area under the curve for percentage decrease from pre- exercise FEV 1following 
exercise challenge at [ADDRESS_536296] evening dose (AUC 0 -60 min) at 
the end of the 2- week treatment period.
Section 4.3: Other Endpoints
Original text:
Categorical treatment response evaluation of the percentage of subjects who
demonstrate a decrease from pre- exercise challenge FEV 1(at [ADDRESS_536297] evening dose) of:
o<10%, 
o≥10% to <20%, 
o≥20% 
Maximal percent decrease from pre -exercise baseline FEV 1following exercise 
challenge at [ADDRESS_536298] evening dose at the end of the 2 -week 
treatment period
Mean change from baseline in ACT score at the end of the treatm ent period
Percentage of subjects controlled defined as an Asthma Control Test (ACT) score ≥20 
at the end of the treatment period
Change in ph ysical activity  measures as assessed by  a biosensor (SenseWear 
Armband) in terms of physical activity  endpoints (e .g. dail y step count, METs, sleep 
duration)
2015N231308_03 CONFIDENTIA L
201832
98Revised text:
Categorical treatment response evaluation of the percentage of subjects who
demonstrate a decrease from pre- exercise challenge FEV 1(at [ADDRESS_536299] evening dose at the end of the 2 -week treatment period ) of:
o<10%, 
o≥10% to <20%, 
o≥20% 
Maximal percent decrease from pre -exercise baseline FEV 1following exercise 
challenge at [ADDRESS_536300] evening dose at the end of the 2 -week 
treatment period
Mean change from baseline in ACT score at the end of the 2-week treatment period
Percentage of subjects controlled defined as an Asthma Control Test (ACT) score ≥20 
at the end of the 2-week treatment period
Change in ph ysical activity  measures as assessed by  a biosensor (SenseWear 
Armband) in terms of physical activit y endpoints (e.g. dail y step count, METs, sleep 
duration)
Section 5.1: Overall Design
Original text:
This is a multicenter, randomized, double -blind, double -dummy , crossover study  with 
two [ADDRESS_536301] ed at Screening (Visit 1), 
and pre -dose at Visit 4, and prior to each exercise challenge at Visits 2, 3 and 5. Serial 
spi[INVESTIGATOR_038]  (6 time points over 60 minutes) as FEV 1only will be conducted after each 
exercise challenge test. Subjects should be monitored until they  reach a recovery  level 
where their FEV 1value represents a 95% recovery  of the pre -exercise FEV 1 result.  
Additional spi[INVESTIGATOR_424275] .
2015N231308_03 CONFIDENTIA L
201832
99
A Pre -Screening Visit (Visit 0) is included to obtain a signed Informed Consent (I CF) 
and to review concomitant medications, and may  be conducted on the same day  as Visit 
1, if appropriate. At Visit 1, subjects meeting eligibility  criteria will enter a 4 -week 
single -blinded run -in period on fluticasone propi [INVESTIGATOR_16847] (FP) 250 mcg twice daily  (BD). 
Albuterol will be issued for rescue use during the run -in, wash- out and treatment periods 
as needed.  Subjects will be instructed to contact [CONTACT_424367].  
All subjects will be given a pap er diary  during the run- in, washout and treatment periods 
to record an y medical problems experienced during the stud y, an y medications taken, and 
rescue medication usage.
A screening electrocardiogram (ECG) and a complete phy sical examination will be 
condu cted at Visit 1. Vital signs will be collected at each visit prior to spi[INVESTIGATOR_038] , and 
before and after exercise challenge testing.  
Asthma control will be assessed using the Asthma Control Test (ACT) at Visits 2 through 
5.
Physical activity  levels will be monitored to assess activity  outside the clinic [Mitchell, 
2014] using a phy sical activity  monitor (SenseWear Armband accelerometer) worn for 7 
days prior to Visit 2 (baseline), for 7 day s prior to Visit 3 (during the last week of 
Treatment Period 1), for 7 day s prior to Visit 4, and for 7 day s prior to Visit 5 (during the 
last week of Treatment Period 2). Subjects unwilling or unable to participate in daily  
physical activity  monitoring may  still participate in the study , if appropriate. See Study  
Referenc e Manual (SRM) for additional details.
A follow up phone call will be conducted approximately  7 day s after Visit 5.
2015N231308_03 CONFIDENTIA L
201832
100Revised text:
This is a multicenter, randomized, double -blind, double -dummy , crossover study  with 
two 2 -week treatment periods separated b y a 2 -week wash- out period. Subjects will 
attend up to eight visits over the course of the study . Standardized exercise challenge 
testing will be conducted at Visit 2 for eligibility  determination , Visit 3 and Visit 6 
(after [ADDRESS_536302] dose in e ach Treatment Period); and at [ADDRESS_536303] evening dose at Visits 4 and 7. Spi[INVESTIGATOR_424274] (Visit 1), 
and pre -dose at Visit 5and prior to each exercise challenge at Visits 2, 3, 4, 6 and 7. 
Serial spi[INVESTIGATOR_038]  (6 time point s over 60 minutes) as FEV 1only will be conducted after 
each exercise challenge test. Subjects should be monitored until they  reach a recovery  
level where their FEV 1value represents a 95% recovery  of the pre -exercise FEV 1 result.  
Additional spi[INVESTIGATOR_424275] .
A Pre -Screening Visit (Visit 0) is included to obtain a signed Informed Consent (I CF) 
and to review concomitant medications, and may  be conducted on the same day  as Visit 
1, if appropriate. At V isit 1, subjects meeting eligibility  criteria will enter a 4 -week 
single -blinded run -in period on fluticasone propi[INVESTIGATOR_16847] (FP) 250 mcg twice daily  (BD). 
Albuterol will be issued for rescue use during the run -in, wash- out and treatment periods 
as needed.  S ubjects will be instructed to contact [CONTACT_424367].  
All subjects will be given a paper diary  during the run- in, washout and treatment periods 
to record an y medical problems experienced during the stud y, an y medications taken, and 
rescue medication usage.
2015N231308_03 CONFIDENTIA L
201832
101A screening electrocardiogram (ECG) and a complete phy sical examination will be 
conducted at Visit 1. Vital signs will be collected at each visit prior to spi[INVESTIGATOR_038] , and 
before and after exercise challenge testing.  
Asthma c ontrol will be assessed using the Asthma Control Test (ACT) at Visits 2 , 4, 5 
and 7.
Physical activity  levels will be monitored to assess activity  outside the clinic [Mitchell, 
2014] using a phy sical activity  monitor (SenseWear Armband accelerometer) worn for 7 
days prior to Visit 2 (baseline), for 7 day s prior to Visit 4 (during the last week of 
Treatment Period 1), for 7 day s prior to Visit 5
, and for 7 day s prior to Visit 7 (during the 
last week of Treatment Period 2). Subjects unwilling or unable to par ticipate in daily  
physical activity  monitoring may  still participate in the study , if appropriate. See Study  
Reference Manual (SRM) for additional details.
A follow up phone call will be conducted approximately  7 day s after Visit 7.
Section 7.8: Treatment after the End of the Study
Original text:
Subjects will not receive any additional treatment from [COMPANY_004] after completion of the 
study  as other treatment options are available for persistent asthma. The investigator is 
responsible for ensuring that considera tion has been given to the post -study  care of the 
subject’s medical condition, whether or not [COMPANY_004] is providing specific post -study  
treatment. At the end of Visit 5, investigators should prescribe asthma medication 
appropriate to the severity  of the subject ’s asthma in accordance with asthma guidelines 
[GINA, 2015; NIH, 2007]. Do not record asthma medications started on or after the final 
clinic visit in the eCRF.
Revised text:
Subjects will not receive any additional treatment from [COMPANY_004] after completion of t he 
study  as other treatment options are available for persistent asthma. The investigator is 
responsible for ensuring that consideration has been given to the post -study  care of the 
subject’s medical condition, whether or not [COMPANY_004] is providing specific post -study  
treatment. At the end of Visit [ADDRESS_536304]’s asthma in accordance with asthma guidelines 
[GINA, 2015; NIH, 2007]. Do not record asthma medications started on or after the final 
clinic visit in the eCRF.
2015N231308_03 CONFIDENTIA L
201832
102Section 8: Study  Assessments and Procedures – Table 3 Time and Events Table
Original table:
ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 211
Randomization311 411 511
Week -4 0 2 4 6 7
Treatment Day -26 to -30 
days1 14 (-2/+2) 
days28 (-2/+2) 
days42 (-2/+2) 
days47 to [ADDRESS_536305] Demography X
Medical History (including CV) X
Disease (Asthma) History X
Medication History X X
Inclusion/Exclusion Criteria X
Efficacy Assessments
Spi[INVESTIGATOR_038] (full FEV 1 and FVC) X X2 X2 X2 X2 X
Exercise Challenge Testing (Tread mill) X3 X4 X4
Post-Challenge Serial FEV [ADDRESS_536306] SenseWear accelerometer X X
Safety Assessments
Concomitant Medication X X X X X X X6
Physical Examination X
Vital Signs X X7 X7 X X7 X
12-lead ECG X
Adverse Event Assessment X8 X8 X X X X X X
2015N231308_03 CONFIDENTIA L
201832
103ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 211
Randomization311 411 511
Week -4 0 2 4 6 7
Treatment Day -26 to -30 
days1 14 (-2/+2) 
days28 (-2/+2) 
days42 (-2/+2) 
days47 to [ADDRESS_536307] IP X X X X
2015N231308_03 CONFIDENTIA L
[PHONE_8807]. Genetics saliva sample collected at Visit 2 (following Randomization) or at any scheduled visit thereafter. Genetics consent MUST be obtained PRIOR to collec tion of the Genetics 
sample.  
2. Pre-exercise spi[INVESTIGATOR_038] (full FEV 1 and FVC testing), conducted immediately pre -exercise, if applicable. Subject should have withheld albuterol within previous [ADDRESS_536308] -exercise challenges. Longer monitoring may be required for those subjects who do not return to 
5% of baseline FEV 1values within [ADDRESS_536309].
8. Adverse Event and Serious Adverse Events to be collected from the start of study Drug (Visit 1) until the follow up co ntact. However, any SAE related to study participation will be     
recorded from the time of Informed Consent 
9. Review medical conditions diary card, including an assessment of any potential change in exercise capacity
10. An unblinding card will be dispensed a long with double blind IP.
11. Subjects will be contact[CONTACT_5143] [ADDRESS_536310].
2015N231308_03 CONFIDENTIA L
201832
105Revised table:
ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 212
Randomization3 412 512 6 712
Week -4 0 0 2 4 4 6 7
Treatment Day -26 to -30 
days1 2 14 (-2/+2) 
days28 (-2/+2) 
days29 (-2/+2) 42 (-2/+2) 
days47 to 
[ADDRESS_536311] Demography X
Medical History (including CV) X
Disease (Asthma) History X
Medication History X X
Inclusion/Exclusion Criteria X
Evidence of EIB X
Efficacy Assessments
Spi[INVESTIGATOR_038] (full FEV 1 and FVC) X X2 X2 X2 X2 X2 X2 X
Exercise Challenge Testing 
(Treadmill)X3 X4 X5 X4 X5
Post-Challenge Serial FEV [ADDRESS_536312] SenseWear accelerometer X X
Safety Assessments
Concomitant Medi cation X X X X X X X X X7
Physical Examination X
Vital Signs X X8 X8 X8 X X8 X8 X
2015N231308_03 CONFIDENTIA L
201832
106ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 212
Randomization3 412 512 6 712
Week -4 0 0 2 4 4 6 7
Treatment Day -26 to -30 
days1 2 14 (-2/+2) 
days28 (-2/+2) 
days29 (-2/+2) 42 (-2/+2) 
days47 to 
[ADDRESS_536313] IP X X X X
2015N231308_03 CONFIDENTIA L
[PHONE_8808]. Genetics saliva sample collected at Visit 2 (following Randomization) or at any schedul ed visit thereafter. Genetics consent MUST be obtained PRIOR to 
collection of the Genetics sample.  
2. Pre-exercise spi[INVESTIGATOR_038] (full FEV 1 and forced vital capacity (FVC) testing), conducted immediately pre -exercise, if applicable. Subject should have withhel d 
albuterol within previous [ADDRESS_536314] 
demonstrate a decrease in FEV 1of 20% at one time point within [ADDRESS_536315] -exercise challenges. Longer monitoring may be required for those subjects 
who do not return to 5% of baseline FEV 1values within [ADDRESS_536316].
9. Adverse Event and Serious Adverse Events to be collected from the start of study Drug (Visit 1) until the follow up contact. However, any S AE related to study 
participation will be     recorded from the time of Informed Consent 
10. Review medical conditions diary card, in cluding an assessment of any potential change in exercise capacity
11. An unblinding card will be dispensed along with double blind IP.
12. Subjects will be contact[CONTACT_5143] [ADDRESS_536317].
2015N231308_03 CONFIDENTIA L
201832
108Section 8.2.1: Spriometry
Original text:
FEV 1and FVC will be conducted at Visit 1, and pre -dose at Visit 4, and prior to each 
exercise challenge at Visits 2, 3 and 5. For full FEV 1/FVC testing, at least 3 valid and 2 
repeatable (with no more than 8) efforts should be obtained using ATS/ERS guidelines. 
At each time point, the largest FEV 1and FVC s hould be recorded, even if they  do not 
come from the same effort. 
Serial FEV 1 measurements only  (not FVC) will be conducted serially  as described in 
Table [ADDRESS_536318] FEV 1
will be selected.
Revised text:
FEV 1and FVC will be conducted at Visit 1, and pre -dose at Visit 5, and prior to each 
exercise challenge at Visits 2, 3, 4, 6 and 7. For full FEV 1/FVC testing, at least 3 valid 
and 2 repeatable (with no more than 8) efforts should be obtained using ATS/ERS 
guidelines. At each time point, the largest FEV 1and FVC should be recorded, even if 
they do not come from the same effort. 
Serial FEV 1 measurement s only  (not FVC) will be conducted serially  as described in 
Table [ADDRESS_536319] FEV 1will be se lected.
Section [IP_ADDRESS]: Visit 3 and Visit 6 ([ADDRESS_536320] Dose Exercise 
Challenge)
New text:
Visit 3 and Visit 6 begin between 5 PM and 11 PM and should begin at 
approximately the same time as Visit 1 (±1 hour).  These visits should begin prior to 
the subject’s evening dose on that visit day.
Pre-exercise FEV 1: Spi[INVESTIGATOR_424319] 3 and 6 at approximately 
the same time as at Visit 1 (±1 hour). The FEV 1should be measured approximately 
[ADDRESS_536321] two adequate and 
repeatable spi[INVESTIGATOR_424307] 1and FVC maneuvers should be 
obtained before the exercise challenge.
Exercise Challenge: After the pre -exercise FEV [ADDRESS_536322]-exercise Serial Spi[INVESTIGATOR_038]: Following the exercise challenge, serial spi[INVESTIGATOR_424320] 5, 10, 15, 30, [ADDRESS_536323]-challenge. Two FEV 1efforts (not full FVC maneuvers) will be performed at 
each time point.
Medication Dosing: At the end of Visits [ADDRESS_536324] evening dose exercise 
challenge/serial spi[INVESTIGATOR_038], and prior to the subject’s leaving the clinic.
Section [IP_ADDRESS]: Visit 3 and Visit 5 (Blinded Treatment Exercise 
Challenge)
Original text:
Visit 3 and Visit 5 begin between 5 PM and 11 PM and are conducted over 
approximately  24 hours. These visits should begin at approxi mately  the same time as 
Visit 1 (±1 hour) and approximately  at the end of the dosing period for each I P.  
Dosing: At the beginning of Visit 3 and Visit 5, subjects will administer their evening 
doses of double -blinded study  medication in the clinic and th e time of dosing will be 
recorded. Subjects will return to the clinic 12 (±1) hours and 23 (±1) hours after dosing 
for exercise challenge testing.
Pre-exercise FEV 1:At least two adequate and repeatable spi[INVESTIGATOR_424321] 1and FVC maneuvers should be obtained just prior to EACH exercise challenge.
From this spi[INVESTIGATOR_68333], the target FEV 1 values #2 and #3 (Section [IP_ADDRESS]) should 
be determined based on the pre -exercise FEV 1. 
Exercise challenge testing: Exercise challenge testing will occ ur at 12 (±1) hours and 23 
(±1) hours after administering the evening dose. (The 12 -hour exercise challenge and 
spi[INVESTIGATOR_424322].) 
Following each challenge, serial spi[INVESTIGATOR_424323] 5, 10, 15, 30, [ADDRESS_536325]-challenge. Two FEV 1efforts (not full FVC 
maneuvers) will be performed at each time point. 
Washout Medication Dosing: At the end of Visit 3, the washout medication should be 
dispens ed and first evening dose administered following completion of the [ADDRESS_536326] 
evening dose exercise challenge/serial spi[INVESTIGATOR_038] , and prior to the subject’s leaving the 
clinic.
2015N231308_03 CONFIDENTIA L
201832
110Revised text:
Section [IP_ADDRESS]: Visit 4 and Visit 7 (Blinded Treatment Exercis e 
Challenge)
Visit 4 and Visit 7 begin between 5 PM and 11 PM and are conducted over 
approximately  24 hours. These visits should begin at approximately  the same time as 
Visit 1 (±1 hour) and approximately  at the end of the dosing period for each I P.  
Dosing: At the beginning of Visit 4and Visit 7, subjects will administer their evening 
doses of double -blinded study  medication in the clinic and the time of dosing will be 
recorded. Subjects will return to the clinic 12 (±1) hours and 23 (±1) hours after do sing 
for exercise challenge testing.
Pre-exercise FEV 1:At least two adequate and repeatable spi[INVESTIGATOR_424321] 1and FVC maneuvers should be obtained just prior to EACH exercise challenge.
From this spi[INVESTIGATOR_68333], the target FEV 1 values #2 and #3 (Section [IP_ADDRESS]) should 
be determined based on the pre -exercise FEV 1. 
Exercise challenge testing: Exercise challenge testing will occur at 12 (±1) hours and 23 
(±1) hours after administering the evening dose. (The 12 -hour exercise challenge an d 
spi[INVESTIGATOR_424322].) 
Following each challenge, serial spi[INVESTIGATOR_424323] 5, 10, 15, 30, [ADDRESS_536327]-challenge. Two FEV 1efforts (not ful l FVC 
maneuvers) will be performed at each time point. 
Washout Medication Dosing: At the end of Visit 4, the washout medication should be 
dispensed and first evening dose administered following completion of the [ADDRESS_536328] 
evening dose exercise challeng e/serial spi[INVESTIGATOR_038] , and prior to the subject’s leaving the 
clinic.
Section [IP_ADDRESS]: Visit 5 
Original text:
Period 2 pre -exercise baseline FEV 1:Spi[INVESTIGATOR_424300] 4 at 
approximately  the same time as at Visit 1 (±1 hour). The FEV 1should be measured 
approximately  [ADDRESS_536329] two adequate 
and repeatable spi[INVESTIGATOR_424324] 1and FVC maneuvers should be obtained.
Dosing: Subjects will administer their evening doses of double- blinded study  medication 
following the spi[INVESTIGATOR_038] .
2015N231308_03 CONFIDENTIA L
201832
111Revised text:
Period 2 pre -exercise baseline FEV 1:Spi[INVESTIGATOR_424300] 5 at 
approximately  the same time as at Visit 1 (±1 hour). The FEV 1should be measured 
approximately  [ADDRESS_536330] two adequate 
and repeatable spi[INVESTIGATOR_424324] 1and FVC maneuvers should be obtained.
Dosing: Subjects will administer their evening doses of double- blinded study  medication 
following the spi[INVESTIGATOR_038] .
Section 8.2.4 Phy sical A ctivity Monitor
Original text:
Subjects should refrain from significant changes in their exercise level (e.g., joining a 
gym), except as instructed by  [CONTACT_093], for the duration of the study .
A clinically  validated phy sical activity  monitor (accelerometer) will be used to measure 
specific levels of ph ysical activity . There will be 4 assessment periods, including an 
initial baseline assessment in order to provide a reliable estimate of habitual phy sical 
activity .The ph ysical activity  monitor will be worn by  [CONTACT_424361] 2, Visit 3, Visit 4 and Visit 5. Further details will be provided in the 
SRM.
Subjects will be contact[CONTACT_424362] 8- 9 day s prior to Visits 2, 3, 4 and 5 and 
reminded to wear the SenseWear Armband accelerometer for the 7 day s preceeding these 
visits.
Revised text:
Subjects should refrain from significant changes in their exercise level (e.g., joining a 
gym), except as instructed by  [CONTACT_093], for the duration of the study .
A clinically  validated phy sical activity  monitor (accelerometer) will be used to measure 
specific levels of ph ysical activity . There will be 4 assessment periods, including an 
initial baseline assessment in order to provide a reliable estimate of habitual phy sical 
activity .The ph ysical activity  monitor will be worn by  [CONTACT_424361] 2, Visit 4, Visit 5 and Visit 7. Further details will be provided in the 
SRM.
Subjects will be contact[CONTACT_424362] 8- 9 day s prior to Visits 2, 4, 5and 7and 
reminded to wear the SenseWear Armband accelerometer for the 7 day s preceeding these 
visits.
Section 10.1 Hy potheses
Original text:
If the primary  hypothesis on the primary  endpoint for the ITT population is rejected then 
the following hierarch y of tests will be performed using the ITT population; 
2015N231308_03 CONFIDENTIA L
[PHONE_8809].Test at the 5% level the null hy pothesis that the true population difference 
between the treatment group means in maximal percent decrease in FEV 1from 
pre-exercise at [ADDRESS_536331] at the 5% level the null hy pothesis that the true 
probability  distributions for the treatment groups for not recovering to within 5% 
of pre -exercise FEV 1at [ADDRESS_536332] -dose (i.e. the “survival” distributions f or the 
endpoint time to recovery to within 5% of pre -exercise FEV 1at [ADDRESS_536333] -dose) 
are equal.
3.If [ADDRESS_536334] at the 5% level the null hy pothesis that the true 
population probability  distributions for the treatment groups for not recover ing to 
within 5% of pre -exercise FEV 1at [ADDRESS_536335] -dose (i.e. the “survival” 
distributions for the endpoint time to recovery  to within 5% of pre -exercise FEV [ADDRESS_536336] -dose) are equal.
4.If [ADDRESS_536337] at the 5% level the null hy pothes is that the true 
population difference between the treatment group means in AUC for percentage 
decrease in FEV 1from pre -exercise FEV 1at [ADDRESS_536338] at the 5% level the null hy pothesis that the true 
population difference between the treatment group means in AUC for percentage 
decrease in FEV 1from pre -exercise FEV 1at [ADDRESS_536339] -dose is zero.
Revised text:
If the primary  hypothesis on the primary  endpoint for the ITT population is rejected then 
the following h ierarchy  of tests will be performed using the ITT population; 
1.Test at the 5% level the null hy pothesis that the true population difference 
between the treatment group means in maximal percent decrease in FEV 1from 
pre-exercise at [ADDRESS_536340] at the 5% level the null hy pothesis that the true 
probability  distributions for the treatment groups for not recovering to within 5% 
of pre -exercise FEV 1at [ADDRESS_536341] -dose at the en d of the 2- week treatment 
period (i.e. the “survival” distributions for the endpoint time to recovery  to within 
5% of pre -exercise FEV 1at [ADDRESS_536342] -dose) are equal.
3.If [ADDRESS_536343] at the 5% level the null hy pothesis that the true 
populati on probability  distributions for the treatment groups for not recovering to 
within 5% of pre -exercise FEV 1at [ADDRESS_536344] -dose at the end of the 2- week 
treatment period (i.e. the “survival” distributions for the endpoint time to 
recovery  to within 5% of pr e-exercise FEV 1at [ADDRESS_536345] -dose) are equal.
2015N231308_03 CONFIDENTIA L
[PHONE_8810].If [ADDRESS_536346] at the 5% level the null hy pothesis that the true 
population difference between the treatment group means in AUC for percentage 
decrease in FEV 1from pre -exercise FEV 1at [ADDRESS_536347] at the 5% level the null hy pothesis that the true 
population difference between the treatment group means in AUC for percentage 
decrease in FEV 1from pre -exercise FE V1at [ADDRESS_536348] -dose at the end of the 2-
week treatment period is zero.
Section 10.2.1: Sample Size A ssumptions
Original text:
For the primary  efficacy  endpoint of maximal percent decrease in FEV 1following 
exercise challenge at [ADDRESS_536349]- dose, given an assumed 10% screen failure rate, a 
55% run -in failure rate, and a 15% withdrawal rate post -randomisation, a total of 
approximately  [ADDRESS_536350] 148 subjects will enter the run-in period, of which 66 subjects will be 
randomized, of which 56 subjects will be evaluable, that is completing the exercise 
challenges and the FEV 1evaluations at the end of both treatment periods. With 56 
evaluable subjects this study has approximatel y 90% power assuming a true population 
difference of 5% in maximal percent decrease in FEV 1between the two treatment groups.  
This assumes a within-subject standard deviation (SD) of 8% where significance is 
declared at the two -sided 5% significance level . 
Revised text:
For the primary  efficacy  endpoint of maximal percent decrease in FEV 1following 
exercise challenge at [ADDRESS_536351]- dose at the end of the 2 -week treatment period , 
given an assumed 10% screen failure rate, a 55% run -in failure rate, and a 15% 
withdrawal rate post -randomisation, a total of approximately  [ADDRESS_536352] 148 subjects will 
enter the run -in period, of which 66 subjects will be randomized, of which 56 sub jects 
will be evaluable, that is completing the exercise challenges and the FEV 1evaluations at 
the end of both treatment periods. With 56 evaluable subjects this study  has 
approximately  90% power assuming a true population difference of 5% in maximal 
percent decrease in FEV 1between the two treatment groups.  This assumes a within-
subject standard deviation (SD) of 8% where significance is declared at the two -sided 5% 
significance level. 
2015N231308_03 CONFIDENTIA L
201832
114Section [IP_ADDRESS]: Primary  Comparisons of Interest
Original text:
The primary  treatment comparison is the comparison of group means for the FF/VI 
combination and FP for the primary  endpoint of maximal percent decrease in FEV 1from 
pre-exercise at [ADDRESS_536353] -evening dose. This comparison is to be performed using the 
ITT P opulation.
Revised text:
The primary  treatment comparison is the comparison of group means for the FF/VI 
combination and FP for the primary  endpoint of maximal percent decrease in FEV 1from 
pre-exercise at [ADDRESS_536354] -evening dose at the end of the 2- week treatment period . 
This comparison is to be performed using the ITT Population.
Section 10.3.5: Key  Elements of A nalysis Plan
Original text:
Any tests for interactions will be 2 -sided at the 10% level of significance.  In all cases, if 
any assumptions of the proposed methods of analyses are not met, alternative methods of 
analyses will be used.
The baseline FEV 1for all endpoints will be the pre- treatment FEV 1value obtained at the 
start of each Treatment Period (Visit 2 or Visit 4).
Revised text:
Any tests for interactions will be 2 -sided at the 10% level of significance.  In all cases, if 
any assumptions of the proposed methods of analy ses are not met, alternative methods of 
analyses will be used.
The baseline FEV 1for all endpoints will be the pre- treatment FEV 1value obtained at the 
start of each Treatment Period (Visit 2 or Visit 5).
Section [IP_ADDRESS].2: Secondary  Analyses
Original text:
Summaries and anal yses for secondary  endpoints will be provided for the ITT population.  
Maximal percent decreas e from pre -exercise FEV 1following exercise challenge (at [ADDRESS_536355] -dose):
2015N231308_03 CONFIDENTIA L
[ADDRESS_536356]-
dose. 
Time required for recovery to within 5% of the pre -exercise FEV 1from the time of the 
maximal percentage decrease from pre -exercise FEV 1following the challenge (at [ADDRESS_536357] -dose):
The time required for recovery  to within 5% of the pre -exercise FEV 1from the time of 
the maximal percentage decrease from pre -exercise FEV 1following exercise challenge at 
[ADDRESS_536358] ratio, confidence 
interval and p -value will be presented. Kaplan -Meier plots showing the cumulative 
incidence curves for each treatment group wi ll be produced. 
AUC ( 0-60 min) for percentage decrease from pre -exercise FEV 1after exercise (at [ADDRESS_536359] -dose):
A comparison will be made of the estimated means of the two treatment groups in AUC 
of the percentage decrease in FEV 1from pre-exercise at [ADDRESS_536360] for covariate effects. The LMM will include the following covariates: 
treatment, subject -level mean of the pre -treatment FEV 1 period baselines (mean of the [ADDRESS_536361]), centered period- level baseline FEV 1(period baselines 
centered using subject- level mean of the pre -treatment FEV 1period baselines),  gender, 
age, treatment period and smoking history  as fixed effects, and a random intercept for 
each subject.  
Revised text:
Summaries and anal yses for secondary  endpoints will be provided for the ITT population.  
Maximal percent decrease from pre -exercise FEV 1following exercise challenge (at [ADDRESS_536362] -dose at the end of the 2- week treatment period):
This endpoint will be summarized and anal yzed as for the primary  endpoint of maximal 
percent decrease from pre- exercise FEV 1following exercise challenge at [ADDRESS_536363]-
dose.  
Time required for recovery to within 5% of the pre- exercise FEV 1from the time of the 
maximal perce ntage decrease from pre -exercise FEV 1following the challenge (at [ADDRESS_536364] -dose at the end of the 2- week treatment period):
The time required for recovery  to within 5% of the pre -exercise FEV 1from the time of 
the maximal percentage decre ase from pre -exercise FEV 1following exercise challenge at 
[ADDRESS_536365] ratio, confidence 
2015N231308_03 CONFIDENTIA L
201832
116interval and p -value will be presented. Kaplan -Meier plots showing the cumulative 
incidence curves for each treatment group will be produced. 
AUC ( 0-60 min) for percentage decrease from pre -exercise FEV 1after exercise (at [ADDRESS_536366] -dose at the end of the 2- week treatment period):
A comparison will be made of the estimated means of the two treatment groups in AUC 
of the percentage decrease in FEV 1from pre -exercise at [ADDRESS_536367] for covariate effects. The LMM will include the following covariates: 
treatment, subject -level mean of the pre -treatment FEV 1 period baselines (mean of the [ADDRESS_536368]), centered period -level baseline FEV 1(period baselines 
centered using subject- level mean of the pre -treatment FEV 1period baselines),  gender, 
age, treatment period and smoking history  as fixed effects, and a random intercept for 
each subject.  
13.8.2. Protocol A mendment 02
This amendm ent applies to all trial centres participating in study  201832.
This protocol is being amended to make the following changes:
Increase the screen failure rate to 20% (from 10%) and the run -in failure rate to 70% 
(from 55%). This takes into consideration t he challenge of enrolling EIB subjects 
with sy mptomatic allergic rhinitis (SAR) at screening and also the challenge for 
subjects to demonstrate a decrease in FEV1 of ≥20% at one time point within 30 
minutes of the end of the exercise challenge at Visit 2; after taking fluticasone 
propi[INVESTIGATOR_424270]- in period. 
Allow subjects with sy mptomatic allergic rhinitis at screening to be treated for up to 
four weeks with intranasal corticosteroids followed by  a repeat screening vis it to 
determine eligibility  prior to entry  into the study . Subjects that continue to be 
symptomatic after up to four weeks of treatment will be excluded. Eligible subjects 
will enter the run -in phase for [ADDRESS_536369] exercise challenge at
Visit 2.
Allow subjects who are asy mptomatic at screening, who become s ymptomatic during 
the study  to remain in the study  and be treated with intranasal corticosteroids at a 
constant dose for the duration of the study. Therefore, the randomisation exclusi on 
criterion 6 (s ymptomatic allergic rhinitis) has been deleted. 
Include tobacco/marijuana use and pregnancy  (which were omitted in error in the 
original protocol) as exclusion criteria.
Clarify  the expectations for subjects for Visits 4 and 7 with regards to the number of 
anticipated clinic visits (and procedures) over the 24 -hour period for both visits.
Extend the time window for the repeat exercise challenge from 24 -48 hours to up to 
one week; taking into consideration the challenge for subjects to retu rn within 48 
hours for a repeat procedure.
Replace the ACT questionnaire with the ACQ -[ADDRESS_536370] will not clearly  represent asthma control fo r the specific treatment 
periods.
Increase the restriction period for caffeinated beverages to 4 hours prior to 
spi[INVESTIGATOR_424325] (previously  2 hours prior to 
spi[INVESTIGATOR_038] ) due to the possibility  of inducing refractoriness. 
Thetime to recovery  endpoint (time to recovery  to within 5% of pre -exercise FEV [ADDRESS_536371]- exercise FEV 1) has been 
changed to a binary  endpoint defining recovery  as those subjects who have a [ADDRESS_536372] -exercise FEV 1measurement that is no more than 5% lower than their 
pre-exercise FEV 1. This binary  endpoint has also been included in the “other 
endpoints” at all the remaining post- exercise spi[INVESTIGATOR_424326].
The statistical testing hierarch y has been changed to prioritise the maximal 
percentage FEV 1reduction (primary  endpoint) and binary  recovery  endpoints 
following the [ADDRESS_536373] -dose exercise challenge.
Other edits and minor corrections have been made.
Method of Amendment
Original and amended texts are s pecified as follows:
Original text: as written in the Protocol Amendment No. 01
Revised text: as written in Amendment No. 02 with revisions in bold font.
Amendment Details
Protocol Sy nopsis and Section 4.2: Secondary  Endpoints
Original text:
Maximal pe rcent decrease from pre -exercise FEV 1following exercise challenge at 
[ADDRESS_536374] evening dose at the end of the 2 -week treatment period
Time required for recovery  to within 5% of pre -exercise FEV 1from the time of the 
maximal percentage decrease from pr e-exercise FEV [ADDRESS_536375] evening dose at the end of the 2 -week 
treatment period.
Area under the curve for percentage decrease from pre- exercise FEV 1following 
exercise challenge at [ADDRESS_536376] evening dose (AUC 0- 60 min) at 
the end of the 2-week treatment period.
Revised text:
Maximal percent decrease from pre -exercise FEV 1following exercise challenge at 
[ADDRESS_536377] evening dose at the end of the 2 -week treatment period
2015N231308_03 CONFIDENTIA L
201832
118Proportion of subjects with a [ADDRESS_536378]- challenge FEV 1that was no more 
than 5% lower than their pre -exercise FEV 1following the exercise challenge at 
[ADDRESS_536379] evening dose at the end of the 2- week treatment 
period 
Weighted mean for percentage d ecrease from pre -exercise FEV 1following exercise 
challenge at [ADDRESS_536380] evening dose (weighted mean 0-60 min) at 
the end of the 2-week treatment period
Protocol Sy nopsis and Section 4.3: Other Endpoints
Original text:
Categorical trea tment response evaluation of the percentage of subjects who 
demonstrate a decrease from pre-exercise challenge FEV1 (at [ADDRESS_536381] evening dose at the end of the 2 -week treatment period) of:
o<10%, 
o≥10% to <20%,
o≥20%
Maximal percent decreas e from pre -exercise baseline FEV1 following exercise 
challenge at [ADDRESS_536382] evening dose at the end of the 2 -week 
treatment period  
Mean change from baseline in ACT score at the end of the 2- week treatment period
Percentage of subjects controlled defined as an Asthma Control Test (ACT) score ≥20 
at the end of the 2 -week treatment period
Change in ph ysical activity  measures as assessed by  a biosensor (SenseWear 
Armband) in terms of physical activity endpoints (e.g. dail y step count, METs, sleep 
duration)
Revised text:
Categorical treatment response evaluation of the percentage of subjects who
demonstrate a decrease from pre- exercise challenge FEV 1(at [ADDRESS_536383] evening dose at the end of the 2- week treatment period) of:
o<10% , 
o≥10% to <20%,
o≥20%
Maximal percent decrease from treatment period baseline FEV1 following exercise 
challenge at [ADDRESS_536384] evening dose at the end of the 2 -week 
treatment period.
Mean change from baseline in Asthma Control Questionnaire -5 (ACQ -5) score 
at the end of the 2- week treatment period. 
2015N231308_03 CONFIDENTIA L
201832
119Percentage of subjects controlled, defined as an ACQ- 5 score ≤0.75, at the end 
of the 2- week treatment period. 
Percentage of subjects achieving an improvement of ≥0.5 or greater in ACQ -5 
score at t he end of the 2 -week treatment. 
Change in ph ysical activity  measures as assessed by  a biosensor (SenseWear 
Armband) in terms of physical activity endpoints (e.g. dail y step count, Metabolic 
Equivalent of Tasks (METs), sleep duration).
Proportion of subjec ts with a [ADDRESS_536385] -challenge FEV 1that was no more 
than 5% lower than their pre -exercise FEV 1following the exercise challenge at 
[ADDRESS_536386] evening dose at the end of the 2- week treatment 
period. Repeat for the 10, 15, 45 and 60 minut e time points. 
Protocol Sy nopsis: Overall Design
Original text:
This is a multicenter, randomized, double -blind, double -dummy , crossover study  with 
two 2 -week treatment periods separated b y a 2 -week wash- out period. Subjects will 
attend up to eight visi ts over the course of the study . Standardized exercise challenge 
testing will be conducted at Visit 2 for eligibility  determination, Visit 3 and Visit 6 (after 
[ADDRESS_536387] treatment dose in each Treatment Period); and at [ADDRESS_536388] evening dose at Visits 4 and 7. Spi[INVESTIGATOR_424274] (Visit 1), 
and pre -dose at Visit 5, and prior to each exercise challenge at Visits 2, 3, 4, 6 and 7. 
Serial spi[INVESTIGATOR_038]  (6 time points over 60 minutes) as FEV 1only will be conducted afte r 
each exercise challenge test. Subjects should be monitored until they  reach a recovery  
level where their FEV 1value represents a 95% recovery  of the pre -exercise FEV 1 result.  
Additional spi[INVESTIGATOR_424327].
A Pre -Screening Visit (Visit 0) is included to obtain a signed Informed Consent and to 
review concomitant medications, and may  be conducted on the same day  as Visit 1, if 
appropriate. At Visit 1, subjects meeting eligibility criteria and will enter a 4 week single -
blinded run-in period on fluticasone propi[INVESTIGATOR_16847] (FP) 250 mcg twice dail y (BD). 
Albuterol will be issued for rescue use during the run -in, wash- out and treatment periods 
as needed.  Subjects will be instructed to contact [CONTACT_424368].  
A screening electrocardiogram (ECG) and a complete phy sical examination will be 
conducted at Visit 1. Vital signs will be collected at each visit prior to spi[INVESTIGATOR_424316].
Physical activity  levels will be monitored with the use of a phy sical activity  monitor to 
assess activity  outside the clinic worn for 7 day s prior to Visit 2 (baseline), for [ADDRESS_536389] at Visits 2, 4, 5 and 7 . 
A follow up phone call will be conducted approximately  7 day s after Visit 7.
Revised text:
This is a multicenter, randomized, double -blind, double -dummy , crossover study  with 
two 2 -week treatment periods separated b y a 2 -week wash- out period. Subjects will
participate in up to eight study visits (Visit 0 to Visit 7) over the course of the study 
and a follow up phone call approximately a week after Visit 7. Visits 1, 2, 3, 5 and 6 
are evening visits that will be conducted between 5PM and 11PM. Visit 4 an d Visit 7 
are also evening visits that will begin between 5PM and 11PM and continue over a 
period of approximately 24 hours. Subjects will be required to attend three clinic 
visits during this 24 -hour period.
Standardized exercise challenge testing (using a treadmill) will be conducted at Visit 2 
for eligibility  determination, Visit 3 and Visit 6 (after [ADDRESS_536390] treatment dose 
in each Treatment Period); and at [ADDRESS_536391] evening dose at Visits 4 and 7. 
Spi[INVESTIGATOR_424274] (Visit 1), and pre -dose at Visit 5, and prior to 
each exercise challenge at Visits 2, 3, 4, 6 and 7. Serial spi[INVESTIGATOR_038]  (6 time points over 60 
minutes) as FEV 1only will be conducted after each exercise challenge test. At Visit 2, 
subjects must d emonstrate a decrease in FEV 1of ≥20% when compared to the FEV [ADDRESS_536392] -challenge.  Subjects who achieve a decrease 
in FEV 1of 15% to <20% ma y continue taking their daily run -in medication and 
repeat the eligibility exercise challenge and associated procedures once within a 
week of the original procedure. Subjects should be monitored until they  reach a 
recovery  level where their FEV 1value repr esents a 95% recovery  of the pre -exercise 
FEV 1 result.  Additional spi[INVESTIGATOR_424318] .
A Pre -Screening Visit (Visit 0) is included to obtain a signed Informed Consent, 
demography and to review concomitant medications, and may  be conducted on the same 
day as Visit 1, if appropriate. 
At Visit 1, subjects meeting eligibility  criteria and will enter a 4 week single- blinded run-
in period on fluticasone propi[INVESTIGATOR_16847] (FP) 250 mcg twice dail y (BD). Subjects with 
symptomatic allergic rhinitis at Visit 1 (screening) may be treated for up to four 
weeks with intranasal corticosteroids followed by a repeat screening visit to 
determine eligibility prior to entry into the study. Only one repeat screening visit 
will be perf ormed following treatment with intranasal corticosteroids. Subjects that 
continue to be symptomatic after up to four weeks of treatment will be excluded. 
Eligible subjects will enter the run- in period. Subjects who are asymptomatic at 
screening, who become symptomatic during the study will remain in the study and 
may be treated with intranasal corticosteroids at a constant dose for the duration of 
the study.
2015N231308_03 CONFIDENTIA L
201832
121Albuterol /salbutamol will be issued for rescue use during the run -in, wash -out and 
treatment periods as needed.  Subjects will be instructed to contact [CONTACT_424352].  
All subjects will be given a paper diary during the run -in, washout and treatment 
periods to record any medical problems experienced during the study, any 
medi cations taken, and rescue medication usage.
A screening electrocardiogram (ECG) and a complete phy sical examination will be 
conducted at Visit 1. Vital signs including pulse rate and systolic and diastolic blood 
pressure will be obtained at each clinic vis it, including any Early Withdrawal visit. 
At all time points where both vital signs and spi[INVESTIGATOR_424328], vital signs 
will be done before the spriometry measurement. At visits where the exercise 
challenge is performed, vitals will be measured befor e (prior to the pre -exercise 
spi[INVESTIGATOR_038]) and after the exercise challenge .
Asthma control will be assessed using the ACQ -5at Visits 2, 4, 5 and 7. 
Physical activity  levels will be monitored to assess activity outside the clinic with the 
use of a ph ysicalactivity  monitor (SenseWear Armband accelerometer) worn for 7 
days prior to Visit 2 (baseline), for 7 day sprior to Visit 4 ( during the last week of 
Treatment Period 1), for 7 day s prior to Visit 5, and for 7 day sprior to Visit 7 ( during 
the last week of Treatment Period 2 ). Subjects unwilling or unable to participate in daily 
physical activity  monitoring may  still participate in the study , if appropriate.
A follow up phone call will be conducted approximately  7 day s after Visit 7.
Section 2.2: Study  rationale
Original text:
In patients with persistent asthma, improvements in protection from exercise -induced 
bronchoconstriction (EIB) with I CS/LABA combination product FP/salmeterol 
(Advair®) have been demonstrated [Murray , 2011; Pearlman, 2009; Weiler, 2005]. 
However, differences between FP/salmeterol and FP monotherap y have not consistently  
been observed [Murray , 2011; Weiler, 2005]. I n a study  that evaluated the effect of 
FP/salmeterol compared to FP over the 12 hour dosing interval [Weiler, 2005], a la rge 
percentage of subjects in both the FP/salmeterol (18%) and FP (36% and 33% at Day  1 
and Week 4, respectivel y) treatment arms failed to complete the second exercise 
challenge test 8.[ADDRESS_536393] EIB towards
the end of the 12 hour dosing interval
Revised text:
In patients with persistent asthma, improvements in protection from exercise -induced 
bronchoconstriction (EIB) with I CS/LABA combination product Fluticasone propi[INVESTIGATOR_16847]
(FP)/salmeterol (Advair®) have be en demonstrated [Murray , 2011; Pearlman , 2009; 
Weiler, 2005]. However, differences between FP/salmeterol and FP monotherap y have 
2015N231308_03 CONFIDENTIA L
201832
122not consistently  been observed [Murray , 2011; Weiler, 2005]. I n a stud y that evaluated 
the effect of FP/salmeterol compared to FP over the 12 hour dosing interval [Weiler, 
2005], a large percentage of subjects in both the FP/salmeterol (18%) and FP (36% and 
33% at Day  1 and Week 4, respectivel y) treatment arms failed to complete the second 
exercise challenge test 8.[ADDRESS_536394] EIB 
towards the end of the 12 hour dosing interval.
Protocol Sy nopsis and Section 5.2: Treatment A rms and Duration
Original text:
Two treatment arms will be employ ed for the study : 
FF/V I 100/25 mcg QD via ELLI PTA + Placebo BD via Diskus
FP 250 mcg BD via Diskus + Placebo QD via ELLIPTA
As this is a [ADDRESS_536395] 
approximately  7-days after completing Treatment Period 2. The total duration of study  
participation is approximately 11 weeks.
Revised text:
Two treatment arms will be employ ed for the study : 
FF/V I 100/25 mcg QD via ELLIPTA + Placebo BD via Diskus
FP 250 mcg BD via Diskus + Placebo QD via ELLIPTA
As this is a [ADDRESS_536396] udy participation is approximately  11 weeks ; 
and up to 15 weeks for subjects with SAR at screening who may need to be treated 
with intranasal corticosteroids followed by [CONTACT_424369].
2015N231308_03 CONFIDENTIA L
201832
123Protocol Sy nopsis and Section 5.3: Type and Number of Subjects
Original text:
Approximately  165 subjects with persistent asthma with evidence of EIB and current use 
of a low -to moderate -dose inhaled corticosteroid (I CS) will be screened in order to 
randomize 66 subjects, assuming a 10% screen failure rate and 55% run-in failure rate. 
This is to achieve 56 evaluable subjects completing the exercise challenges and the FEV 1
evaluations at the end of both treatment periods. This calculation assumes a 15% 
withdrawal rate during the study .  
Revised text:
Approximately 275 subjects with persistent asthma with evidence of EIB and current use 
of a low -to moderate -dose inhaled corticosteroid (I CS) will be screened in order to 
randomize 66 subjects, assuming a 20% screen failure rate and 70% run -in failure rate. 
This is to achieve 56 evaluable subjects completing the exercise challenges and the FEV 1
evaluations at the end of both treatment periods. This calculation assumes a 15% 
withdrawal rate during the study .  
Protocol Sy nopsis: A nalysis
Original text:
The primary  treatment comparison will be between the FF/VI combination and FP and 
will be performed using the ITT Population. Demonstration of efficacy  for the treatments 
will be based on a h ypothesis testing approach whereb y the null h ypothesis is that there is 
no diffe rence between the population treatment groups and the alternative hy pothesis is 
that there is a difference between the population treatment groups.  
Revised text:
The primary  treatment comparison will be between the FF/VI combination and FP and 
will be p erformed using the intent -to-treat (ITT) Population. Demonstration of efficacy  
for the treatments will be based on a h ypothesis testing approach whereb y the null 
hypothesis is that there is no difference between the population treatment groups and the 
alternative h ypothesis is that there is a difference between the population treatment 
groups
Section 5.1: Overall Design
Original text:
This is a multicenter, randomized, double -blind, double -dummy , crossover study  with 
two 2 -week treatment periods separate d by a 2-week wash- out period. Subjects will 
2015N231308_03 CONFIDENTIA L
201832
124attend up to eight visits over the course of the study. Standardized exercise challenge 
testing will be conducted at Visit 2 for eligibility  determination, Visit 3 and Visit 6 (after 
[ADDRESS_536397] dose i n each Treatment Period); and at [ADDRESS_536398] evening 
dose at Visits 4 and 7. Spi[INVESTIGATOR_424274] (Visit 1), and pre -dose 
at Visit 5 and prior to each exercise challenge at Visits 2, 3, 4, 6 and 7. Serial spi[INVESTIGATOR_038]  
(6 time points over 60 minutes) as FEV 1only will be conducted after each exercise 
challenge test. Subjects should be monitored until they  reach a recovery  level where their 
FEV 1value represents a 95% recovery  of the pre -exercise FEV 1 result.  Additional 
spi[INVESTIGATOR_424329] .
A Pre -Screening Visit (Visit 0) is included to obtain a signed Informed Consent (I CF) 
and to review concomitant medications, and may  be conducted on the same day  as Visit 
1, if appropriate. A t Visit 1, subjects meeting eligibility  criteria will enter a 4 -week 
single -blinded run -in period on fluticasone propi[INVESTIGATOR_16847] (FP) 250 mcg twice daily  (BD). 
Albuterol will be issued for rescue use during the run -in, wash- out and treatment periods 
as needed.   Subjects will be instructed to contact [CONTACT_424367].  
All subjects will be given a paper diary  during the run- in, washout and treatment periods 
to record an y medical problems experienced during the stud y, an y medications tak en, and 
rescue medication usage.
A screening electrocardiogram (ECG) and a complete phy sical examination will be 
conducted at Visit 1. Vital signs will be collected at each visit prior to spi[INVESTIGATOR_038] , and 
before and after exercise challenge testing.  
2015N231308_03 CONFIDENTIA L
[ADDRESS_536399] (ACT) at Visits 2, 4, 5 
and 7.
Physical activity  levels will be monitored to assess activity  outside the clinic [Mitchell, 
2014] using a phy sical activity  monitor (SenseWear Armband accelerometer) wo rn for 7 
days prior to Visit 2 (baseline), for 7 day s prior to Visit 4 (during the last week of 
Treatment Period 1), for 7 day s prior to Visit 5, and for 7 day s prior to Visit 7 (during the 
last week of Treatment Period 2). Subjects unwilling or unable to participate in daily  
physical activity  monitoring may  still participate in the study , if appropriate. See Study  
Reference Manual (SRM) for additional details.
A follow up phone call will be conducted approximately  [ADDRESS_536400] completed 
the study  upon completion of Visit 7. For entry  into the electronic case report form 
(eCRF), stud y completion will be defined as completion of the follow up contact.
There are no plans to routinely  provide any  of the study  treatments for compassionate use 
following stud y completion, as asthma treatments including ICS/L ABA combination 
products are available worldwide.
Supplementary  study  conduct information not mandated to be present in this protocol is 
provided in the SRM. The SRM will provide the site personnel with administrative and 
detailed technical information that does not impact subject safet y.
Revised text:
This is a multicenter, randomized, double -blind, double -dummy , crossover s tudy with 
two 2 -week treatment periods separated b y a 2 -week wash- out period. Subjects will
participate in up to eight study visits (Visit 0 to Visit 7) over the course of the study
and a follow up phone call approximately a week after Visit 7. Visits 1, 2 , 3, 5 and 6 
are evening visits that will be conducted between 5PM and 11PM. Visit 4 and Visit 7 
are also evening visits that will begin between 5PM and 11PM and continue over a 
period of approximately 24 hours. Subjects will be required to attend three cl inic 
visits during this 24 -hour period.
Standardized exercise challenge testing (using a treadmill) will be conducted at Visit 2 
for eligibility  determination, Visit 3 and Visit 6 (after [ADDRESS_536401] dose in each 
Treatment Period); and at [ADDRESS_536402] evening dose at Visits 4 and 7. 
Spi[INVESTIGATOR_424274] (Visit 1), and pre -dose at Visit 5 and prior to 
each exercise challenge at Visits 2, 3, 4, 6 and 7. Serial spi[INVESTIGATOR_038]  (6 time points over 60 
minutes) as FEV 1only will be conducted after each exercise challenge test. At Visit 2, 
subjects must demonstrate a decrease in FEV 1of ≥20% when compared to the FEV [ADDRESS_536403] -challenge.  Subjects who achieve a decrease 
in FEV 1of 15% to <20% may continue taking their daily run- in medication and 
2015N231308_03 CONFIDENTIA L
201832
126repeat the eligibility exercise challenge and associated procedures once within a 
week of the original procedure. Subjects should be monitored until they  reach a 
recovery  level where their FEV 1value represents a 95% recovery  of the pre-exercise 
FEV 1 result.  Additional spi[INVESTIGATOR_424318] . 
A Pre -Screening Visit (Visit 0) is included to obtain a signed Informed Consent (I CF), 
demography and to review concomitant medications, and m ay be conducted on the same 
day as Visit 1, if appropriate. 
At Visit 1, subjects meeting eligibility  criteria will enter a 4- week single -blinded run- in 
period on fluticasone propi[INVESTIGATOR_16847] (FP) 250 mcg twice dail y (BD). Subjects with 
symptomatic allergic rhin itis at Visit 1 (screening) may be treated for up to four 
weeks with intranasal corticosteroids followed by a repeat screening visit to 
determine eligibility prior to entry into the study. Only one repeat screening visit 
will be performed following treatment with intranasal corticosteroids. Subjects that 
continue to be symptomatic after up to four weeks of treatment will be excluded. 
Eligible subjects will enter the run- in period. Subjects who are asymptomatic at 
screening, who become symptomatic during the study will remain in the study and 
may be treated with intranasal corticosteroids at a constant dose for the duration of 
the study.
Albuterol /salbutamol will be issued for rescue use during the run -in, wash -out and 
treatment periods as needed.  Subjects w ill be instructed to contact [CONTACT_424352].  
2015N231308_03 CONFIDENTIA L
[ADDRESS_536404] an y medical problems experienced during the stud y, an y medications taken, and 
rescue medication usage.
A screening electrocardiogram (ECG) and a complete phy sical examination will be 
conducted at Visit 1. Vital signs including pulse rate and systolic and diastolic blood 
pressure will be obtained at each clinic visit, including any Early Withdrawal visit. 
At all time points where both vital signs and spi[INVESTIGATOR_424328], vital signs 
will be done before the spriometry measurement. At visits where the exercise 
challenge is performed, vitals will be measured before (prior to the pre -exercise 
spi[INVESTIGATOR_038]) and after the exercise challenge.
Asthma control will be assessed using the ACQ -5at Visits 2, 4, 5 and 7.
Physical activity  levels will be monitored to assess activity  outside the clinic [Mitchell, 
2014] using a phy sical activity  monitor (SenseWear Armband accelerometer) worn for 7 
days prior to Visit 2 (baseline), for 7 day s prior to Visit 4 (during the last week of 
Treatment Period 1), for 7 day s prior to Visit 5, and for 7 day s prior to Visit 7 (during the 
last week of Treatment Period 2). Subjects unwilling or unable to participate in daily  
physical activity  monitoring may  still participate in the study , if appropriate. See Study  
Reference Manual (SRM) for additional details.
A follow up phone call will be conducted approximately  [ADDRESS_536405] a repeat screening 
visit after treatment with intranasal corticosteroids.
There are no plans to routinely provide any  of the study  treatments for compassionate use 
following stud y completion, as asthma treatments including ICS/L ABA combination 
products are available worldwide.
Supplementary  study  conduct information not mandated to be present in this protocol is 
provided in the SRM. The SRM will provide the site personnel with administrative and 
detailed technical information that does not impact subject safet y.
Section 6.1.2: Exclusion Criteria #4
Original text:
Symptomatic Allergic Rhinitis:  Subjects with symptomatic allergic rhinitis within the 
past two weeks are excluded from the stud y.  
Revised text:
Symptomatic Allergic Rhinitis:  Subjects with sy mptomatic allergic rhinitis at Visit 1 
may be treated for up to four weeks with intranasal c orticosteroids followed by a 
2015N231308_03 CONFIDENTIA L
201832
128repeat screening visit to determine eligibility prior to entry into the study. Subjects 
that continue to be symptomatic after up to four weeks of treatment will be 
excluded.
Section 6.1.2: Screening Exclusion Criteria #5
Original text:
12-Lead Electrocardiogram (ECG):  A subject is not eligible if he/she has an abnormal, 
clinically  significant ECG at the Screening Visit . 
Revised text:
12-Lead Electrocardiogram (ECG):  A subject is not eligible if he/she has an abnormal, 
clinically  significant ECG as determined by [CONTACT_424370] V isit. 
Section 6.1.2: New Screening Exclusion Criterion 
Pregnancy: Women who are pregnant or lactating or are planning on becoming 
pregnant during the study.
Section 6.1.2: Screening Exclusion Criteria #10
Original text:
Allergies:
a)Drug Allergy:   Any adverse reaction including immediate or delay ed 
hypersensitivity  to an y beta 2-agonist, sy mpathomimetic drug, or any  intranasal, 
inhaled, or s ystemic corticosteroid therap y, or exc ipi[INVESTIGATOR_424330]/V I 100/25 or 
FP 250 (i.e., drug, lactose or magnesium stearate).
b)Milk Protein Allergy: History  of severe milk protein allergy .
Revised text:
a)Drug Allergy:   Any adverse reaction including immediate or delay ed 
hypersensitivity  to an ybeta 2-agonist, sy mpathomimetic drug, or any  intranasal, 
inhaled, or s ystemic corticosteroid therapy, or excipi[INVESTIGATOR_424330]/V I 100/25 or 
FP 250 (i.e., drug, lactose or magnesium stearate).
b)Milk Protein Allergy: History  of severe milk protein allergy .
c)Latex Allergy: History of allergy or sensitivity to latex that in the opi[INVESTIGATOR_424331]’s participation in the study.
2015N231308_03 CONFIDENTIA L
201832
129Section 6.1.2: New Screening Exclusion Criterion 
Tobacco/Marijuana Use: Current tobacco smoker or has a smoking history of ≥10 
pack- years (20 cigarettes/day for 10 years). A subject may not have used inhaled 
tobacco products or inhaled marijuana within the past 3 months (e.g., cigarettes, 
cigars, electronic cigarettes, or pi[INVESTIGATOR_28303])
Section 6.2.1: Randomisation Inclusion C riteria #2
Original text:
FEV 1Target : Subjects must demonstrate a decrease in FEV 1of 20% at one time point 
within 30 minutes of the end of a standardized exercise challenge.  Subjects who achieve 
a decrease in FEV 1of 15% to <20% may  continue taking t heir daily  run-in medication 
and repeat the eligibility  exercise challenge once within 24 to 48 hours.   
Revised text:
FEV 1Target : Subjects must demonstrate a decrease in FEV 1of 20% at one time point 
within 30 minutes of the end of a standardized exercise challenge.  Subjects who achieve 
a decrease in FEV 1of 15% to <20% may  continue taking their daily  run-in medication 
and repeat the eligibility  exercise challenge and associated procedures once within a 
week of the original procedure.    
Section 6.2. 2: Randomisation Exclusion Criteria 
Original text:
1.Pregnancy: Positive urine pregnancy  test at Visit 2.
2.Asthma Medication Changes:  Changes in asthma medication after Visit 1 
(excluding albuterol inhalation aerosol provided at Visit 1) are not permitted .
3.Prohibited Medication:   No use of an y prohibited medications (Section 7.10.2) 
during the run- in period or at Visit 2.
4.Respi[INVESTIGATOR_83078]:  Occurrence of a culture -documented or suspected bacterial 
or viral infection of the upper or lower respi[INVESTIGATOR_53121], sinus or middle ear during 
the run- in period that led to a change in asthma management or, in the opi[INVESTIGATOR_1070], is expected to affect the subject’s asthma status or the subject’s ability  
to participate in the study.
5.Asthma Exacerbati on:  Evidence of a severe exacerbation, defined as deterioration 
of asthma requiring the use of s ystemic corticosteroids (tablets, suspension, or 
injection) for at least 3 day s or an in -patient hospi[INVESTIGATOR_424332] 
(ED) visit due to asthma that required s ystemic corticosteroids between Visits 1 and 
2.
2015N231308_03 CONFIDENTIA L
[PHONE_8811].Symptomatic Allergic Rhinitis: Subjects with sy mptoms of allergic rhinitis within 
the 2 weeks prior to the randomization visit (Visit 2). 
Revised text:
1.Pregnancy: Positive urine pregnanc y test at Visit 2.
2.Asthma Medication Changes:  Changes in asthma medication after Visit 1 
(excluding albuterol/salbutamol inhalation aerosol provided at Visit 1) are not 
permitted.
3.Prohibited Medication:   Use of an y prohibited medications (Section 7.9.2) 
during the run -in period or at Visit 2.
4.Respi[INVESTIGATOR_83078]:  Occurrence of a culture -documented or suspected 
bacterial or viral infection of the upper or lower respi[INVESTIGATOR_53121], sinus or middle 
ear during the run -in period that led to a change in asthm a management or, in the 
opi[INVESTIGATOR_871], is expected to affect the subject’s asthma status or the 
subject’s ability  to participate in the study .
5.Asthma Exacerbation :  Evidence of a severe exacerbation, defined as 
deterioration of asthma requir ing the use of s ystemic corticosteroids (tablets, 
suspension, or injection) for at least 3 days or an in- patient hospi[INVESTIGATOR_424288] (ED) visit due to asthma that required s ystemic 
corticosteroids between Visits 1 and 2.
Section 6.3: S creening/Baseline/Run-in Failures
Original text:
Screen failures are defined as subjects who consent to participate in the clinical trial but 
are never subsequently  randomized. I n order to ensure transparent reporting of screen 
failure subjects, meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements, and respond to queries from Regulatory  authorities, a minimal 
set of screen failure information is required including Demograph y, Screen Failure reason 
details, Eligibility  Criteria, and any Serious Adverse Events.
A subject who is assigned a subject number, has signed the informed consent, and has 
completed at least one study  procedure, but does not enter the run- in period of the study  
is considered a ‘screen failure’.  
A subje ct who completes the screening visit and is dispensed FP [ADDRESS_536406] who has entered the run -in period, but is not randomized to study  treatmen t 
medication, is classified as a ‘run -in failure’.  
At a minimum, the following information will be collected for subjects who fail 
screening or run- in:
2015N231308_03 CONFIDENTIA L
[PHONE_8812]. Demographic information for race, age and gender
2.Reason for screen/run -in failure (screen/run- in failu re eCRF page, 
inclusion/exclusion criteria eCRF page, and randomization criteria eCRF page 
[if applicable])
3. SAE information
4.Investigator signature [CONTACT_424375]: 
In order to ensure transparent reporting of screen failure subjects, meet the Consolid ated 
Standards of Reporting Trials (CONSORT) publishing requirements, and respond to 
queries from Regulatory  authorities, a minimal set of screen failure information is 
required including Demograph y, Screen Failure reason details, Eligibility Criteria, and
any Serious Adverse Events.
A subject who is assigned a subject number, has signed the informed consent, and has 
completed at least one study  procedure, but does not enter the run- in period of the study  
is considered a ‘screen failure’.  
A subject who completes the screening visit and is dispensed FP 250 mcg, 
albuterol/salbutamol for rescue use, and a medical conditions diary  card is considered to 
have entered the run -in period.  A subject who has entered the run -in period, but is not 
randomized to study  treatment medication, is classified as a ‘run -in failure’.  
At a minimum, the following information will be collected for subjects who fail 
screening or run- in:
1. Demographic information for race, age and gender
2.Reason for screen/run -in failure (screen/run-in failure eCRF page, 
inclusion/exclusion criteria eCRF page, and randomization criteria eCRF page 
[if applicable])
3. SAE information
4.Investigator signature [CONTACT_424376]-screening of subjects is not allowed in this study with the exception of subjects 
with sympt omatic allergic rhinitis at screening who may have a repeat screening 
visit after treatment with intranasal corticosteroids.
2015N231308_03 CONFIDENTIA L
201832
132Section 6.4.2: Reasons for Study  Withdrawal
Original text:
The primary  reason for Study  Withdrawal will be recorded in the eCRF a nd any  data 
collected up until the point of withdrawal will be used in the data analy ses.
General reasons for withdrawal may  include: 
1.Adverse event 
2.Withdrew consent
3.Lost to follow -up 
4.Protocol violation impacting safet y
5.Lack of efficacy
6.Subject reached p rotocol -defined withdrawal criteria
Liver function
Asthma Exacerbation
Asthma Worsening
Pregnancy
ECG
7.Non-compliance 
8.Injury  during the exercise challenge
9.Study  closed/terminated
Revised text:
The primary  reason for Study  Withdrawal will be recorded in t he eCRF and any  data 
collected up until the point of withdrawal will be used in the data analy ses.
General reasons for withdrawal may  include: 
1.Adverse event 
2.Withdrew consent
3.Lost to follow -up 
4.Protocol deviation impacting safet y
5.Lack of efficacy
6. Subject reached protocol -defined withdrawal criteria
Liver function
2015N231308_03 CONFIDENTIA L
201832
133Asthma Exacerbation
Asthma Worsening
Pregnancy
ECG
7.Non-compliance 
8.Injury  during the exercise challenge
9.Study  closed/terminated
Section 7: Study  Treatment
Original text:
Albuterol will be given to all subjects to use throughout the study  to treat acute asthma 
symptoms as needed per product label. Onl y stud y-supplied albuterol should be used for 
rescue during the study . Rescue usage will be recorded twice daily  in the subject’s paper 
diary . Do not record albuterol use in the eCRF.
Revised text:
Albuterol /salbutamol will be given to all subjects to use throughout the study  to treat 
acute asthma s ymptoms as needed per product label. Only  study -supplied 
albuterol /salbutamol should be used for rescue d uring the study . Rescue usage will be 
recorded once daily  in the subject’s paper diary . Do not record albuterol/salbutamol 
use in the eCRF.
Section 7.1: New sub -title included
Section 7.1: Investigational product and other study  treatment
Section 7.2.1: A ssignment of Subject Number
Original text:
At Visit 1, a unique Subject Number (CRF number) will be assigned to any  subject who 
has at least one Visit [ADDRESS_536407] Number will be used to identify  individual subjects during the course of the 
study . 
Revised text:
At Visit 1, a unique Subject Number (CRF number) will be assigned to any  subject who 
has at least one Visit [ADDRESS_536408] number assigned at the 
original screeni ng visit.
Section [IP_ADDRESS]: Permitted Non -Asthma Medications
Original text:
The following non -asthma medications are permitted. This list is not all inclusive. For 
any questions contact [CONTACT_1689].
Cardioselective beta- blockers (stable dose) and ophthalmic beta- blockers: 
Administer with caution as they  may  block bronchodilatory  effects of beta -agonists 
and produce severe bronchospasm.
Strong cytochrome P450 3A4 inhibitors (e.g. ketoconazole, ritonavir, 
clarithromycin): Use with caution . May  cause systemic corticosteroid and 
cardiovascular effects.
Tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs):
Administer with extreme caution as they  may  potentiate the effects of beta -
agonists on the vascular system.
Diuretics: Caution is advis ed in the co -administration of beta -agonists with non 
potassium –sparing diuretics.
Decongestants: Subjects may  take decongestants during the study  except during the 
24 hours prior to ECG measurements.
Antihistamines: Short -acting and long -acting antihistam ines are allowed to control 
symptoms of allergic disorders, however are not permitted the week prior to 
exercise testing. In addition, antihistamine ey e drops are allowed during the study . 
Intranasal corticosteroids: Subjects may  take intranasal corticost eroids to control 
symptoms of allergic disorders as long as the dose remains constant for the duration 
of the study .
Topi[INVESTIGATOR_11930]: Subjects may  use topi[INVESTIGATOR_11930] ( ≤ 1% 
hydrocortisone) for dermatological diseases.
Revised text:
The following non -asthma medications are permitted. This list is not all inclusive. For 
any questions contact [CONTACT_1689].
2015N231308_03 CONFIDENTIA L
201832
135Cardioselective b eta-blockers (stable dose) and ophthalmic beta -blockers: 
Administer with caution as they  may  block bronchodilatory  effects of beta -agonists 
and produce severe bronchospasm.
Strong cytochrome P450 3A4 inhibitors (e.g. ketoconazole, ritonavir, 
clarithromycin ):Use with caution . May  cause sy stemic corticosteroid and 
cardiovascular effects.
Tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs):
Administer with extreme caution as they  may  potentiate the effects of beta -
agonists on the vascular syste m.
Diuretics: Caution is advised in the co -administration of beta -agonists with non 
potassium –sparing diuretics.
Decongestants: Subjects may  take decongestants during the study  except during the 
24 hours prior to ECG measurements.
Antihistamines: Short -acting and long-acting antihistamines are allowed to control 
symptoms of allergic disorders, however are not permitted the week prior to 
exercise testing. In addition, antihistamine ey e drops are allowed during the study . 
Subjects should be reminded to avoid taking any antihistamines a week before 
each exercise challenge procedure.
Intranasal corticosteroids: Subjects may  take intranasal corticosteroids to control 
symptoms of allergic disorders as long as the dose remains constant for the duration 
of the study .
Topi[INVESTIGATOR_11930]: Subjects may  usetopi[INVESTIGATOR_11930] ( ≤ 1% 
hydrocortisone) for dermatological diseases.
Influenza and/or pneumonia vaccination.
All medications for other disorders as long as the dose remains constant 
wherever possible and their use is not expected to affect the subje cts’ lung 
function or safety assessments.
2015N231308_03 CONFIDENTIA L
201832
136Section 8: A ssessments and Procedures – Table 3 Time and Events Table
Original table:
Table 7 Time and Events Table
ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 212
Randomization3 412 512 6 712
Week -4 0 0 2 4 4 6 7
Treatment Day -26 to -30 
days1 2 14 (-2/+2) 
days28 (-2/+2) 
days29 (-2/+2) 42 (-2/+2) 
days47 to 
[ADDRESS_536409] Demography X
Medical History (including CV) X
Disease (Asthma) History X
Medication History X X
Inclusion/Exclusion Criteria X
Evidence of EIB X
Efficacy Asses sments
Spi[INVESTIGATOR_038] (full FEV 1 and FVC) X X2 X2 X2 X X2 X2 X
Exercise Challenge Testing 
(Treadmill)X3 X4 X5 X4 X5
Post-Challenge Serial FEV [ADDRESS_536410] SenseWear accelerometer X X
2015N231308_03 CONFIDENTIA L
201832
137ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 212
Randomization3 412 512 6 712
Week -4 0 0 2 4 4 6 7
Treatment Day -26 to -30 
days1 2 14 (-2/+2) 
days28 (-2/+2) 
days29 (-2/+2) 42 (-2/+2) 
days47 to 
[ADDRESS_536411] IP X X X X
2015N231308_03 CONFIDENTIA L
[PHONE_8813]. Genetics saliva sample collected at Visit 2 (following Randomization) or at any scheduled visit thereafter. Genetics consent MUST be obtained PRIOR to 
collection of the Genetics sample.  
2. Pre-exercise spi[INVESTIGATOR_038] (full FEV 1 and FVC testing), conducted immediately pre -exercise, if applicable. Subject should have withheld albuterol within previous [ADDRESS_536412] demo nstrate a 
decrease in FEV 1of 20% at one time point within [ADDRESS_536413] -exercise challenges. Longer monitoring may be required for those subjects 
who do not return to 5% of baseline FEV 1values within [ADDRESS_536414].
9. Adverse Event and Serious Adverse Events to be collected from the start of study Drug (Visit 1) until the follow up contact. However, any SAE related to study 
participation will be     recorded from the time of Informed Consent 
10. Review medical conditions diary card, including an assessment of any potential change in exercise capacity
11. An unblinding card will be dispensed along with double blind IP.
12. Subjects will be contact[CONTACT_5143] [ADDRESS_536415].
2015N231308_03 CONFIDENTIA L
201832
139Revised table:
Section 8.1: Time and Events Table
Table 8 Time and Events Table
ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 212
Randomization3 412; 14 512 6 712; 14
Week -4 0 0 2 4 4 6 7
Treatment Day -26 to -30 
days1 2 14 (-2/+2) 
days28 (-2/+2) 
days29 (-2/+2) 42 (-2/+2) 
days47 to 
[ADDRESS_536416] Demography X
Medical History (including CV) X
Disease (Asthma) History X
Medication History X X
Smoking history/status X
Inclusion/Exclusion Criteria X
Evidence of EIB X
Efficacy Assessments
Spi[INVESTIGATOR_038] (full FEV 1 and FVC) X X2 X2 X2 X X2 X2 X
Exerci se Challenge Testing 
(Treadmill)X3, [ADDRESS_536417]-Challenge Serial FEV 1 
MeasurementsX3 X6 X6 X6 X6
Asthma Control Questionnaire -5 X X X X X
2015N231308_03 CONFIDENTIA L
201832
140ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 212
Randomization3 412; 14 512 6 712; 14
Week -4 0 0 2 4 4 6 7
Treatment Day -26 to -30 
days1 2 14 (-2/+2) 
days28 (-2/+2) 
days29 (-2/+2) 42 (-2/+2) 
days47 to 
[ADDRESS_536418] Fluticaso ne Propi[INVESTIGATOR_16847] X X
Dispense Rescue16
Albuterol/salbutamolX X X X X X
Collect Rescue 
Albuterol/salbutamolX X X X
Dispense IP X11 X
Assess study drug  compliance X X X X X X X
Collect IP X X X
2015N231308_03 CONFIDENTIA L
[PHONE_8814]. Genetics saliva sam ple collected at Visit 2 (following Randomization) or at any scheduled visit thereafter. Genetics consent MUST be obtained PR IOR to 
collection of the Genetics sample.  
2. Pre-exercise spi[INVESTIGATOR_038] (full FEV 1 and FVC testing), conducted immediately pre -exercise (and after vital signs), if applicable. Subject should have withheld 
albuterol/salbutamol within previous [ADDRESS_536419] demonstrate a 
decrease in FEV 1of 20% at one time point within [ADDRESS_536420] -exercise challenges. Longer monitoring may be required for those subjects 
who do not return to 5% of baseline FEV 1values within [ADDRESS_536421]. 
8. Vital signs will be collected before (prior to the pre- exercise spi[INVESTIGATOR_038]) and after each exercise challenge test.
9. Adverse Event and Serious Adverse Events to be collected from the start of study Drug (Visit 1) until the follow up contact. However, any SAE related to study 
participation will be     recorded from the time of Informed Consent 
10. Review medical conditions diary card, including an assessment of any potential change in exercise capacity
11. An unblinding card will be dispensed along with double blind IP.
12. Subject s will be contact[CONTACT_5143] [ADDRESS_536422].
14. Visit 4 and Visit 7 will begin between 5PM and 11PM and continue over a period of approximately 24 hours. After the evening v isit, subjects will 
return to the clinic at 12 hours and 23 hours (after the evening dose of study medication) for an exercise challenge procedure.
15. Subjects will be contact[CONTACT_5143] [ADDRESS_536423] and re- dispense rescue as needed from Visit 1
17.   Subjects who achieve a decrease in FEV 1of 15% to <20% may continue taking their daily run -in medication and repeat the eligibility exercise 
challenge and associated procedures once within a week of the original procedure.
2015N231308_03 CONFIDENTIA L
201832
142Section 8.2: Screen ing and Critical Baseline A ssessments
Original text:
The following data will be captured at Visit 1:
1.Demographic parameters for year of birth, sex, race and ethnicit y 
2.Medical/medication/family  history  will be assessed as related to the 
inclusion/exclusi on criteria listed in Section 6.1. 
3.Asthma history  (including duration of asthma)
4.Evidence of E IB questions
5.Asthma and non-asthma concurrent medications
6.Concurrent medical conditions
7.Cardiovascular medical history /risk factors (as detailed in the eCRF) wil l be assessed 
at screening.
8.Reason for screen failure (if applicable)
9.Screening lung function
10. Vital signs (including height and weight)
11.Serious Adverse Events related to study  participation
Revised text:
Critical Baseline A ssessments
During the pre- screening visit (Visit 0); each subject will have the following 
information collected:
1.Demographic history (including gender, ethnic origin and date of birth)
2.Concomitant medication review
3. Adverse event assessment
The following data will be captured at Visit 1:
1.Medical/medication/family  history  will be assessed as related to the 
inclusion/exclusion criteria listed in Section 6.1. 
2. Smoking history 
3.Asthma history  (including duration of asthma)
4.Evidence of E IB questions
5.Asthma and non-asthma concurrent medications
2015N231308_03 CONFIDENTIA L
[PHONE_8815].Concurrent medical conditions
7.Cardiovascular medical history /risk factors (as detailed in the eCRF) will be assessed 
at screening.
8.Reason for screen failure (if applicable)
9.Screening lung function
10. Vital signs (including height and weight)
11.Serious Advers e Events related to study  participation
Section 8.3.1: Spi[INVESTIGATOR_424333]:
Subjects will be required to withhold their rescue medication (albuterol) for at least 6 
hours before each visit . 
Exercise challenges should not be performed within 24 hou rs of exercise in cold air. 
Subjects should abstain from smoking or drinking beverages with high caffeine content 
such as tea or coffee for 2 hours prior to pulmonary  function testing. 
The FEV 1should be measured using spi[INVESTIGATOR_424334] y (ATS)/European 
Respi[INVESTIGATOR_21584] y (ERS) [Miller, 2005]. All sites will use standardized spi[INVESTIGATOR_424335] b y an external vendor. 
FEV 1and FVC will be conducted at Visit 1, a nd pre -dose at Visit 5, and prior to each 
exercise challenge at Visits 2, 3, 4, 6 and 7. For full FEV 1/FVC testing, at least 3 valid 
and 2 repeatable (with no more than 8) efforts should be obtained using ATS/ERS 
guidelines. At each time point, the largest FEV 1and FVC should be recorded, even if 
they do not come from the same effort. 
Serial FEV 1 measurements only  (not FVC) will be conducted serially  as described in 
Table [ADDRESS_536424] FEV 1will be selected.
Revised text:
Subjects should abstain from drinking beverages with high caffeine content such as 
tea or coffee for 4 hours prior to the spi[INVESTIGATOR_230159]. 
FEV 1should be measured using spi[INVESTIGATOR_424297]  (ATS)/European Respi[INVESTIGATOR_21584] y 
(ERS) [Miller, 2005]. All sites will use standardized spi[INVESTIGATOR_424336] b y 
an external vendor. Full FEV 1and FVC will be conducted at Visit 1, and pre -dose at Visit 
5, and prior to each exercise challenge at Visits 2, 3, 4, 6 and 7. 
2015N231308_03 CONFIDENTIA L
201832
144For full FEV 1and FVC testing at Screening and at randomisation (Visit 2), at le ast two
valid and two repeatable (with no more than 8) efforts should be obtained using 
ATS/ERS guidelines. For all other visits where full FEV 1and FVC testing is performed 
(prior to each exercise test at visits 3, 4, 6 and 7), at least two valid efforts should be 
obtained.  At each time point, the largest FEV 1and FVC should be recorded, even if they  
do not come from the same effort. 
Serial FEV 1 measurements only  (not FVC) will be conducted serially  as described in 
Table [ADDRESS_536425] 70% of their predicted normal value to be 
eligible to take part in the study at Visit 1.
After Visit 1, subjects will always be required to withhold their albuterol/salbutamol 
for at least [ADDRESS_536426] not administer study drug prior to coming to the clinic on study visit 
days.
Section 8.3.2: Exercise Challenge Testing
Original text:
The exercise challenge test is a stepped challenge on a treadmill at a speed and incline 
that will allow the subject’s heart rate to reach between 80% to 95% of their maximum 
heart rate. All exercise challenges will be performed on a treadmill. During the exercise 
challenge, subjects will breathe medical grade dry  air at am bient temperature from a 
reservoir using a two -way non-rebreathing valve.
Subjects will exercise sufficiently  to attain a heart rate between 80 to 95% of their 
predicted maximum within 4 minutes and maintain this heart rate with exercise for an 
additional 6 minutes for a total of 10 minutes of exercise. The challenge will be followed 
immediately  by [CONTACT_28424][INVESTIGATOR_038]  (FEV 1efforts only ) at 6 time points over 60 minutes ( 5, 
10, 15, 30, [ADDRESS_536427]- exercise) . The information gained from the eligibil ity 
challenge(s) regarding incline and speed will be used to obtain the target heart rate in the 
subsequent exercise challenges.
Additional instructions on exercise challenge testing can be found in the SRM.
Revised text:
The exercise challenge test is a stepped challenge on a treadmill at a speed and incline 
that will allow the subject’s heart rate to reach between 80% to 95% of their maximum 
heart rate. All exercise challenges will be performed on a treadmill. During the exercise 
challenge, subjects will breathe medical grade dry  air at ambient temperature from a 
reservoir using a two -way non-rebreathing valve.
2015N231308_03 CONFIDENTIA L
201832
145Subjects will exercise sufficiently  to attain a heart rate between 80 to 95% of their 
predicted maximum within 4 minutes and maintain this heart r ate with exercise for an 
additional 6 minutes for a total of 10 minutes of exercise. The challenge will be followed 
immediately  by [CONTACT_28424][INVESTIGATOR_038]  (FEV 1efforts only ) at 6 time points over 60 minutes ( 5, 
10, 15, 30, [ADDRESS_536428]- exercise) . The information gained from the eligibility  
challenge(s) regarding incline and speed will be used to obtain the target heart rate in the 
subsequent exercise challenges.
Exercise challenges should not be performed within 24 hours of exercise in cold air. 
Subje cts should abstain from drinking beverages with high caffeine content such as 
tea or coffee for 4 hours prior to the exercise challenge. 
Additional instructions on exercise challenge testing can be found in the SRM.
Section [IP_ADDRESS]: Visit 1 (Screening)
Original text:
Spi[INVESTIGATOR_424300] 1 between 5:00 PM and 11:[ADDRESS_536429] pre- bronchodilator FEV 1of ≥ 70% of their pr edicted normal 
value to be eligible to take part in the study .  
Revised text:
Spi[INVESTIGATOR_424300] 1 between 5:00 PM and 11:[ADDRESS_536430] pre -bronchodilator FEV 1of ≥70% of their predicted normal value to be 
eligible to take part in the study .  
Section [IP_ADDRESS]: Visit 2 (Randomization)
Original text:
Pre-exercise baseline (Period 1 baseline) FEV 1:Spi[INVESTIGATOR_424300] 
2 at approximately  the same time as at Visit 1 (±1 hour). The FEV 1should be measured 
approximately  12 hours after dosing with run-in medication (FP 250 mcg). At least two 
adequate and repeatable spi[INVESTIGATOR_424324] 1and FVC maneuvers should be 
obtained before the first exercise challenge.
From this spi[INVESTIGATOR_68333], the target FEV 1 values (Section [IP_ADDRESS]) should be 
determined based on the pre- exercise FEV 1. 
Eligibility Exercise Challenge: After the pre -exercise baseline FEV [ADDRESS_536431]-exercise Serial Spi[INVESTIGATOR_038]: Following the eligibility  exercise challenge, two FEV 1
efforts (not full FVC maneuvers) will be performed at 5, 10, 15, 30, [ADDRESS_536432] demonstrate a decrease in FEV 1of ≥20% 
when compared to the FEV 1obtained immediately pre -exercise for at least one of the 
post-exercise spi[INVESTIGATOR_424303] [ADDRESS_536433] -challenge.  Subjects 
who achieve a decrease in FEV 1of 15% to <20% may  continue taking their daily run-in 
medication and repeat the eligibility  exercise challenge once within 24 to 48 hours. 
Dosing: Eligible subjects will administer their evening doses of double- blinded study  
medication following the eligibility  exercise challenge/serial spi[INVESTIGATOR_038] . Evening dosing 
should occur between 5 PM and 11PM.
Revised text:
Treatment period 1 baseline FEV 1:Spi[INVESTIGATOR_424300] 2 at 
approximately  the same time as at Visit 1 (±1 hour). The FEV 1should be measured 
approximately  12 hours after dosing with run-in medication (FP 250 mcg). At least two 
valid and tworepeatable spi[INVESTIGATOR_424337].
From this spi[INVESTIGATOR_68333], the target FEV 1 values #2 and #3 (Section [IP_ADDRESS]) should 
be determined based on the pre -exercise FEV 1. 
Eligibility Exercise Challenge: After the pre -exercise baseline FEV [ADDRESS_536434]-exercise Serial Spi[INVESTIGATOR_038]: Following the eligibility  exercise challenge, serial 
spi[INVESTIGATOR_038]  (FEV 1) will be performed at 5, 10, 15, 30, [ADDRESS_536435] demonstrate a decrease in FEV 1of ≥20% 
when compared to the FEV 1obtained immediatel y pre-exercise for at least one of the 
post-exercise spi[INVESTIGATOR_424303] [ADDRESS_536436] -challenge.  Subjects 
who achieve a decrease in FEV 1of 15% to <20% may  continue taking their daily  run-in 
medication and repeat the eligibility  exercise challenge once within a week. In the event 
where a repeat visit is required for the exercise challenge, spi[INVESTIGATOR_424338] -and post - exercise challenge as detailed in 
Table 3. In addition, ACQ- 5 and a review of concomitant medication and adverse 
events will be performed at the repeat visit. 
Dosing: Eligible subjects will administer their evening dose of double- blinded study  
medication following the eligibility  exercise challenge/serial spi[INVESTIGATOR_038] . Evening dosing
should occur between 5 PM and 11PM.
2015N231308_03 CONFIDENTIA L
201832
147Section [IP_ADDRESS]: Visit 3 and Visit 6 ([ADDRESS_536437] Dose Exercise 
Challenge)
Original text:
Visit 3 and Visit 6 begin between 5 PM and 11 PM and should begin at approximately  
the same time as Visit 1 (±1 hour). These visits should begin prior to the subject’s 
evening dose on that visit day .
Pre-exercise FEV 1:Spi[INVESTIGATOR_424305] 3 and 6 at approximately  the 
same time as at Visit 1 (±1 hour). The FEV 1should be measured approximately  [ADDRESS_536438] two adequate and repeatable 
spi[INVESTIGATOR_424324] 1and FVC maneuvers should be obtained before the 
exercise challenge.
Exercise Challenge: After the pre -exercise FEV [ADDRESS_536439]-exercise Serial Spi[INVESTIGATOR_038]: Following the exercise challenge, serial spi[INVESTIGATOR_424320] 5, 10, 15, 30, 45 and 60 minutes pos t-
challenge. Two FEV 1efforts (not full FVC maneuvers) will be performed at each time 
point.
Medication Dosing: At the end of Visits [ADDRESS_536440] evening dose exercise 
challenge/serial spi[INVESTIGATOR_038] , and prior to the subject’s leaving the clinic.
Revised text:
Visit 3 and Visit 6 begin between 5 PM and 11 PM and should begin at approximately  
the same time as Visit 1 (±1 hour).  These visits should begin prior to the subject’s 
evening dose on that visit day .
Pre-exercise FEV 1:Spi[INVESTIGATOR_424305] 3 and 6 at approximately  the 
same time as at Visit 1 (±1 hour). The FEV 1should be measured approximately  [ADDRESS_536441] tw o valid spi[INVESTIGATOR_424339].
From this spi[INVESTIGATOR_68333], the target FEV 1 values #2 and #3 (Section [IP_ADDRESS]) 
should be determined based on the pre- exercise FEV 1. 
Exercise Challenge: After the pre -exercise FEV [ADDRESS_536442]-exercise Serial Spi[INVESTIGATOR_038]: Following the eligibility exercise challenge at each
visit, serial spi[INVESTIGATOR_038]  (FEV 1)will be performed at 5, [ADDRESS_536443]-
exercise.
2015N231308_03 CONFIDENTIA L
201832
148Medication Dosing: At the end of Visits [ADDRESS_536444] evening 
dose exercise challenge/serial spi[INVESTIGATOR_038] , and prior to the subject’s leaving the clinic.
Section [IP_ADDRESS]: Visit 4 and Visit 7 (Blinded Treatment Exercise 
Challenges)
Original text:
Visit 4 and Visit 7 begin between 5 PM and 11 PM and are conducted over 
approximately  24 hours. These visits should begin at approximately  the same time as 
Visit 1 (±1 hour) and approximately  at the end of the dosing period for each I P.  
Dosing: At the beginning of Visit 4 and Visit 7, subjects will administer their evening 
doses of double -blinded study  medication in the clinic and the time of dosing will be 
recorded. Subjects will return to the clinic 12 (±1) hours and 23 (±1) hours after dosing 
for exercise challenge testing.
Pre-exercise FEV 1:At least two adequate and repeatable spi[INVESTIGATOR_424321] 1andFVC maneuvers should be obtained just prior to EACH exercise challenge.
From this spi[INVESTIGATOR_68333], the target FEV 1 values #2 and #3 (Section [IP_ADDRESS]) should 
be determined based on the pre -exercise FEV 1. 
Exercise challenge testing: Exercise challenge testing will occur at 12 (±1) hours and 23 
(±1) hours after administering the evening dose. (The 12 -hour exercise challenge and 
spi[INVESTIGATOR_424322].) 
Following each challenge, serial spi[INVESTIGATOR_424340] 5, 10, 15, 30, [ADDRESS_536445]-challenge. Two FEV 1efforts (not full FVC 
maneuvers) will be performed at each time point. 
Washout Medication Dosing: At the end of Visit 4, the washout medication s hould be 
dispensed and first evening dose administered following completion of the [ADDRESS_536446] 
evening dose exercise challenge/serial spi[INVESTIGATOR_038] , and prior to the subject’s leaving the 
clinic.
Revised text:
Visit 4 and Visit 7 begin between 5 PM and 11 P M and are conducted over 
approximately  24 hours. Subjects will be required to attend three clinic visits during 
each 24- hour period for Visit 4 and Visit 7. The evening visit should begin at 
approximately  the same time as Visit 1 (±1 hour).  
Dosing: At th e beginning of Visit 4 and Visit 7, subjects will administer their evening 
doses of double -blinded study  medication in the clinic and the time of dosing will be 
recorded. In addition to administering the evening dose, vital signs will be measured 
and a rev iew of concomitant medication and AEs performed.
2015N231308_03 CONFIDENTIA L
201832
149Subjects will return to the clinic 12 (±1) hours and 23 (±1) hours after evening 
dosing for exercise challenge testing.
Pre-exercise FEV 1:At least two valid spi[INVESTIGATOR_424307] 1and FVC 
maneuve rs should be obtained just prior to each exercise challenge.
From this spi[INVESTIGATOR_68333], the target FEV 1 values #2 and #3 (Section [IP_ADDRESS]) should 
be determined based on the pre -exercise FEV 1. 
Exercise challenge testing: Exercise challenge testing will occur at 12 (±1) hours and 23 
(±1) hours after administering the evening dose. (The 12 -hour exercise challenge and 
spi[INVESTIGATOR_424341]). 
Post-exercise Serial Spi[INVESTIGATOR_038]: Following the eligibility  exercise challenge at each 
visit, serial spi[INVESTIGATOR_038]  (FEV 1) will be performed at 5, 10, 15, 30, [ADDRESS_536447]-
exercise.
Washout Medication Dosing: At the end of Visit 4, the washout medication should be 
dispensed and first evening dose administered following completion of the [ADDRESS_536448] 
evening dose exercise challenge/serial spi[INVESTIGATOR_038] , and prior to the subject’s leaving the 
clinic.
Section [IP_ADDRESS]: Visit 5 
Original text:
Period 2 pre -exercise baseline FEV 1:Spi[INVESTIGATOR_424300] 5 at 
approximately  the same time as at Visit 1 (±1 hour). The FEV 1should be measured 
approximately  [ADDRESS_536449] two adequate 
and repeatable spi[INVESTIGATOR_424324] 1and FVC maneuvers should be obtai ned.
Dosing: Subjects will administer their evening doses of double- blinded study  medication 
following the spi[INVESTIGATOR_038] .
Revised text:
Treatment period 2 baseline FEV 1:Spi[INVESTIGATOR_424300] 5 at 
approximately  the same time as at Visit 1 (±1 hour). The FEV 1should be measured 
approximately  [ADDRESS_536450] two valid 
spi[INVESTIGATOR_424309].
Dosing: Subjects will administer their evening doses of double- blinded study  medication 
following the spi[INVESTIGATOR_038] .
2015N231308_03 CONFIDENTIA L
201832
150Section 8.3.5: A sthma Control Test (ACT) 
Original text:
The ACT is a five -item questionnaire developed as a measure of subjects’ asthma control 
that can be quickl y and easily  completed in clinical practice. The questions are designed 
tobe self -completed b y the subject. It is recommended that the ACT be administered at 
the same time during each visit. To avoid biasing responses, the subjects should not be 
told the results of diagnostic tests prior to completing the questionnaire and shou ld be 
completed before an y procedures are performed on the subject to avoid influencing the 
subject’s response. Adequate time should be allowed to complete all items on the ACT.
The subject should be given a quiet area in which to complete the questionnair e.
The investigator should ask the subject to complete the questions as accurately  as 
possible. I f the subject requests help or clarification with any of the questions, he/she will 
be asked to re -read the instructions and give the answer that best reflects how he/she felt 
over the previous [ADDRESS_536451] with an y answer or 
attempt to interpret an y portion of a question.
Revised text:
Asthma Control Questionnaire -5 (A CQ-5) (New text)
The ACQ -[ADDRESS_536452]’ asthma control that can be 
quickly and easily completed [Juniper, 2005].
The questions are designed to be self -completed by [CONTACT_423]. The five questions 
enquire about the frequency and/or severity of symptoms (nocturnal awakening on 
waking in the morning, activity limitation, a nd shortness of breath, wheeze). The 
response options for all these questions consist of a zero (no impairment/limitation) 
to six (total impairment/ limitation) scale.
The subject should be given a quiet area in which to complete the questionnaire. 
The in vestigator should ask the subject to complete the questions as accurately as 
possible. If the subject requests help or clarification with any of the questions, 
he/she will be asked to re -read the instructions and give the answer that best reflects 
how he/ she felt over the previous week. The subject should be reassured that there 
are no right or wrong answers. The investigator should not provide the subject with 
any answer or attempt to interpret any portion of a question.
It is recommended that the ACQ -5be administered at the same time during each 
visit. To avoid biasing responses, the subjects should not be told the results of 
diagnostic tests prior to completing the questionnaire and should be completed 
2015N231308_03 CONFIDENTIA L
[ADDRESS_536453]’s response. Adequate time should be allowed to complete all items on the 
ACQ -5.
Section 8.4: Safety  
Original text:
Safety  will be assessed, as indicated in the Time and Events Time andEvents Table 
Table 3, by  [CONTACT_424371], a ph ysical examination at screening, and vital signs 
(systolic and diastolic blood pressure and heart rate [pulse] at each visit. A screening 12 -
ECG will be conducted.
Planned time points for all safety  assessments are listed in the Time and Events Table 
(Time and Events Table Table 3). 
Revised text:
Safety  will be assessed, as indicated in the Time and Events Time andEvents Table 
Table 3
, by [CONTACT_324332], a ph ysical examination at screening, and vital signs 
(systolic and diastolic blood pressure and heart rate [pulse] at each visit. A screening [ADDRESS_536454] x
-ray should be conducted 
within 48 hours.
Planned time points for all safety  assessments are listed in the Time and Events Table 
(Time and Events Table Table 3).
Section 8.4.5: Vital Signs
Original text:
Vital signs will be measured in semi -supi[INVESTIGATOR_55848] [ADDRESS_536455] prior to 
spi[INVESTIGATOR_424342], s ystolic and diastolic blood pressure and 
pulse rate. 
Vital signs (s ystolic and diastolic blood pressure and pulse rate) will be measured 
again before and after each exercise challenge and recorded in the eCRF. Heart 
rate and ox ygen saturation will be measured during each exercise challenge.
If there are an y clinicall y significant abnormalities noted, further examinations 
must be performed until the abnormalit y is resolved.  
2015N231308_03 CONFIDENTIA L
201832
152Revised text:
Vital signs including pulse rate and systolic and diastolic blood pressure will be 
obtained at each c linic visit, including any Early Withdrawal visit. 
Vital signs will be obtained after subjects have rested for approximately 5 
minutes in a semi -supi[INVESTIGATOR_2547].
At all time points where vital signs and spi[INVESTIGATOR_424328], vital signs 
will be done b efore the spriometry measurement. . 
Heart rate will be measured during each exercise challenge. 
If there are an y clinicall y significant abnormalities noted, further examinations 
must be performed until the abnormalit y is resolved.  
Section 8.4.6: Elect rocardiogram (ECG)
Original text:
A pre -dose, 12- lead ECG will be performed and interpreted b y the investigator or 
his/her suitably  qualified designee at Visit 1. The ECG will be recorded after [ADDRESS_536456] prior to performing spi[INVESTIGATOR_038] .
Investigators will use a site ECG machine and perform a manual reading of the 
ECG parameters to determine whether a subject meets the eligibility  criteria for 
enrolment in the study  at screening (Visit 1). 
The ECG interpretation including the paper trace will be maintained at the site 
within the source documentation.
Revised text:
A 12 -lead ECG will be performed and interpreted by  [CONTACT_15009]/her 
suitably  qualified designee at Visit 1. The ECG will be recorded after [ADDRESS_536457] after vital signs and prior to performing spi[INVESTIGATOR_038] .
Investigators will use a site ECG machine and perform a manual reading of the 
ECG parameters to determine whether a subject meets the eligibility  criteria for 
enrolment in the study  at screening (Visit 1). 
The ECG interpretation including the paper trace will be maintained at the site 
within the source documentation.
2015N231308_03 CONFIDENTIA L
201832
153Section 10.1: Hy potheses
Original text:
The primary  endpoint is the maximal percent decrease in FEV 1following exercise 
challenge at [ADDRESS_536458] -dose at the en d of the 2 -week treatment period.  
The treatment comparison is the FF/VI combination versus FP.  Demonstration of 
efficacy  for this treatment comparison will be based on a hy pothesis testing approach 
whereb y the null hy pothesis is that there is no differe nce between treatment groups and 
the alternative h ypothesis is that there is a difference between treatment groups.  
A 2-sided 5% probability associated with incorrectly  rejecting the null hy pothesis 
(significance level) is considered acceptable for this study . In order to account for 
multiplicity , this primary hy pothesis test on the primary  endpoint for the ITT ( Intent -to-
Treat) population will act as a gatekeeper for all other hy pothesis tests using the 
secondary  endpoints, where these tests will proceed in a pre -defined order.
If the primary  hypothesis on the primary  endpoint for the ITT population is rejected then 
the following hierarch y of tests will be performed using the ITT population; 
1.Test at the 5% level the null hy pothesis that the true populati on difference 
between the treatment group means in maximal percent decrease in FEV1 from 
pre-exercise at [ADDRESS_536459] at the 5% level the null hy pothesis that the true 
probability  distributions for the treatment groups for not recovering to within 5% 
of pre -exercise FEV1 at [ADDRESS_536460]- dose at the end of the 2 -week treatment 
period (i.e. the “survival” distributions for the endpoint time to recovery  to within 
5% of pre -exercise FEV1 at [ADDRESS_536461] -dose) are equal.
3.If [ADDRESS_536462] at the 5% level the null hy pothesis that the true 
population probability  distributions for the treatment groups for not recovering to 
within 5% of pre -exercise FEV1 at [ADDRESS_536463] -dose at the end of the 2 -week 
treatment period (i.e. the “survival” distributions for the endpoint time to recovery  
to within 5% of pre -exercise FEV1 at [ADDRESS_536464]- dose) are equal.
4.If [ADDRESS_536465] at the 5% level the null hy pothesis that the tru e 
population difference between the treatment group means in AUC for percentage 
decrease in FEV1 from pre -exercise FEV1 at [ADDRESS_536466] at the 5% level the null hy pothesis that the true 
population difference between the treatment group means in AUC for percentage 
decrease in FEV1 from pre -exercise FEV1 at [ADDRESS_536467] -dose at the end of the 2-
week treatment period is zero.
2015N231308_03 CONFIDENTIA L
201832
154Revised text:
The primary endpoint is the maximal percent decrease in FEV 1following exercise 
challenge at [ADDRESS_536468] -dose at the end of the 2-week treatment period.  
The treatment comparison is the FF/VI combination versus FP.  Demonstration of 
efficacy  for this treatment comparison will be based on a hypothesis testing approach 
whereb y the null hy pothesis is that there is no difference between treatment groups and 
the alternative h ypothesis is that there is a difference between treatment groups.  
A 2-sided 5% probability associated with incorrectly  rejecting the null hy pothesis 
(significance level) is considered acceptable for this study . In order to account for 
multiplicity , this primary hy pothesis test on the primary  endpoint for the ITT ( Intent -to-
Treat) population will act as a gatekeeper for all other h ypothesis tests using the 
secondary  endpoints, where these tests will proceed in a pre -defined order.
If the primary  hypothesis on the primary  endpoint for the ITT population is rejected then 
the following hierarch y of tests will be performed using the ITT population; 
1.Test at the 5% level the null hypothesis that the true odds ratio between the 
two treatment groups of recovering to within 5% of pre -exercise FEV 1at the 
[ADDRESS_536469] at the 5% level the null hypothesis that the true population difference 
between the treatment group means in maximal percent decrease in FEV [ADDRESS_536470] at the 5% level the null hypothesis that the true odds ratio between the 
two treatment groups of recovering to within 5% of pre -exercise FEV 1at the 
[ADDRESS_536471] at the 5% level the null hypothesis that the true 
population difference between the treatment group means in weighted mean 
0-[ADDRESS_536472] at the 5% level the null hypothesis that the true 
population difference between the treatment group means in weighted mean 
0-[ADDRESS_536473] -dose at the end of the 2- week treatment period is zero.
2015N231308_03 CONFIDENTIA L
201832
155Section 10.2.1: Sample Size A ssumptions
Original text:
For the primary  efficacy  endpoint of maximal percent decrease in FEV 1following 
exercise challenge at [ADDRESS_536474] -dose at the end of the 2 -week treatment period , given 
an assumed 10% screen failure rate, a 55% run- in failure rate, and a 15% withdrawal rate 
post-randomisation, a total of approximately  [ADDRESS_536475] 148 subjects will enter the run -in period, 
of which 66 subjects will be randomized, of which 56 subjects will be evaluable, that is 
completing the exercise challenges and the FEV 1evaluations at the end of both treat ment 
periods. With 56 evaluable subjects this study  has approximately  90% power assuming a 
true population difference of 5% in maximal percent decrease in FEV 1between the two 
treatment groups.  This assumes a within- subject standard deviation (SD) of 8% w here 
significance is declared at the two- sided 5% significance level. 
Subjects will be centrall y randomized to one of the two treatment sequences shown 
below in Table 4 in a 1:1 ratio:
Revised text:
For the primary  efficacy  endpoint of maximal percent decrease in FEV 1following 
exercise challenge at [ADDRESS_536476]- dose at the end of the 2 -week treatment period , given 
an assumed 20% screen failure rate, a 70% run- in failure rate, and a 15% withdrawal rate 
post-randomisation, a total of approximately  [ADDRESS_536477] 220subjects will enter the run- in period, 
of which 66 subjects will be randomized, of which 56 subjects will be evaluable, that is 
completing the exercise challenges and the FEV 1evaluations at the end of both treatment 
periods. With 56 evaluable subjects this study  has approximately  90% power assuming a 
true population difference of 5% in maximal percent decrease in FEV 1between the two 
treatment groups.  This assumes a wit hin-subject standard deviation (SD) of 8% where 
significance is declared at the two- sided 5% significance level. 
Subjects will be centrall y randomized to one of the two treatment sequences shown 
below in Table 4 in a 1:1 ratio:
Other measures of efficacy  include the evaluation of a categorical treatment response 
evaluating the percentage of subjects who demonstrate a decrease from pre -exercise 
challenge FEV 1<10%, a decrease 10% to <20%, or a decrease 20%, and an evaluation 
of maximal percent decrease fro m pre -treatment baseline in FEV 1(period baseline) 
following exercise challenge (at [ADDRESS_536478]- dose) .  Additional endpoints 
include evaluation of ph ysical activity monitoring and Asthma Control Test.  All 
endpoints will be described further in the RAP.  
2015N231308_03 CONFIDENTIA L
201832
156Section [IP_ADDRESS]: Secondary  Analyses
Original text:
Summaries and anal yses for secondary  endpoints will be provided for the ITT population.  
Maximal percent decrease from pre -exercise FEV 1following exercise challenge (at [ADDRESS_536479] -dose at the end of the 2 -week treatment period):
This endpoint will be summarized and anal yzed as for the primary  endpoint of maximal 
percent decrease from pre- exercise FEV 1following exercise challenge at [ADDRESS_536480]-
dose.  
Time required for recovery to within 5% of the pre -exercise FEV 1from the time of the 
maximal percentage decrease from pre -exercise FEV 1following the challenge (at [ADDRESS_536481] -dose at the end of the 2- week treatment period):
The time required for recovery  to within 5% of the pre -exercise FEV 1from the time of 
the maximal percentage decrease from pre -exercise FEV 1following exercise challenge at 
[ADDRESS_536482] ratio, confidence 
interval and p -value will be presented. Kaplan -Meier plots showing the cumulative 
incidence curves for each treatmen t group will be produced. 
AUC ( 0-60 min) for percentage decrease from pre -exercise FEV 1after exercise (at [ADDRESS_536483] -dose at the end of the 2- week treatment period):
A comparison will be made of the estimated means of the two treatment gr oups in AUC 
of the percentage decrease in FEV 1from pre -exercise at [ADDRESS_536484] for covariate effects. The LMM will include the following covariates: 
treatment, subject -level mean of the pre -treatment FEV 1 period baselines (mean of the [ADDRESS_536485]), centered period -level baseline FEV 1(period baselines 
centered using subject- level mean of the pre -treatment FEV 1period baselines),  gender, 
age, treatment period and smoking history  as fixed effects, and a r andom intercept for 
each subject.  
Revised text:
Summaries and anal yses for secondary  endpoints will be provided for the ITT population.  
Maximal percent decrease from pre -exercise FEV 1following exercise challenge (at [ADDRESS_536486] -dose at the end of t he 2-week treatment period):
This endpoint will be summarized and anal yzed as for the primary  endpoint of maximal 
percent decrease from pre- exercise FEV 1following exercise challenge at [ADDRESS_536487] -challenge FEV 1that was no more than 
5% lower than their pre -exercise FEV 1following the exercise challenge at [ADDRESS_536488] evening dose at the end of the 2 -week treatment period
This endpoint will be analy sed using a logistic regression model s eparatel y for the 12 and 
23 hour challenges using the covariates baseline FEV 1, treatment group, gender, age, and 
smoking history .
Weighted mean 0 -60 minutes for percentage decrease from pre- exercise FEV 1after 
exercise (at [ADDRESS_536489] -dose at the end of the 2 -week treatment 
period):
A comparison will be made of the estimated means of the two treatment groups in for 
weighted mean 0- [ADDRESS_536490] for covariate effects. The LMM will 
include the following covariates: treatment, subject -level mean of the pre -treatment FEV 1 
period baselines (mean of the [ADDRESS_536491]), centered period -level 
baseline FEV 1(period baselines centered using subject -level mean of the pre -treatment 
FEV 1period baselines),  gender, age, treatment period and smoking history as fixed 
effects, and a random intercept for each subject.  
Section [IP_ADDRESS].1: Other Efficacy  Analyses
Original text:
Other measures of efficacy  include the evaluation of a categorical treatment response 
evaluating the percentage of subjects who demonstrate a decrease from pre -exercise 
challenge FEV 1<10%, a decrease 10% to <20%, or a decrease 20%, and an evaluation 
of maximal percent d ecrease from pre -treatment baseline in FEV 1(period baseline) 
following exercise challenge (at [ADDRESS_536492]- dose) .  Additional endpoints 
include evaluation of ph ysical activity monitoring and Asthma Control Test.  All 
endpoints will be descri bed further in the RAP.  
Revised text:
Other measures of efficacy  include the evaluation of a categorical treatment response 
evaluating the percentage of subjects who demonstrate a decrease from pre -exercise 
challenge FEV 1<10%, a decrease 10% to <20%, o r a decrease  20%, and an evaluation 
of maximal percent decrease from treatment period baseline in FEV 1(period baseline) 
following exercise challenge (at [ADDRESS_536493]- dose) .  Additional 
endpoints include evaluation of physical activity monit oring the ACQ -[ADDRESS_536494]- challenge FEV 1that was no more 
than 5% lower than their pre -exercise FEV 1following the exercise challenge at [ADDRESS_536495] evening dose at the end of the 2 -week treat ment period 
(repeat for the 10, 15, 45 and 60 minute time points).
2015N231308_03 CONFIDENTIA L
201832
158Section 12: References
Original text:
European Medicines Agency  (EMA). Note for guidance on clinical investigation of 
medicinal products for treatment of asthma. 27Jun2013. CHMP/EWP/2922 /01 Rev.1.
FDA Guidance for Industry : Exercise Induced Bronchospasm (EIB)—Development of 
Drugs to Prevent EIB, February  2002.
Global I nitiative for Asthma (GINA). Global Strategy for Asthma Management and 
Prevention. GI NA, www.ginasthma.org; 2015.
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, editors. 
Contraceptive Technology . 19th edition. [LOCATION_001]: Ardent Media, 2007(a): 24. Table 3 -
2.
ICH guideline M3(R2) on non -clinical safety  studies for the conduct of human clinical 
trials and mar keting authorisation for pharmaceuticals, 2009; EMA/CPMP/ICH/286/1995
Jones A, Fay  JK, Burr ML, Stone M, Hood K, Roberts G. Inhaled Corticosteroids Effects 
on Bone Metabolism in Asthma and Mild Chronic Obstructive Pulmonary Disease. 
Cochrane Database of Sy stemic Reviews. 2002;1:1 -21. 
König P, Hillmana L, Cervantesa C, Levinea C, et al. Bone Metabolism in Children with 
Asthma Treated with Inhaled Beclomethasone Dipropi[INVESTIGATOR_16847]. The Journal of Paediatrics. 
1993;122:219-226. 
McFadden ER, Gilbert IA. Exercise- induced asthma. N Engl J Med 1994;330:1362 -1367.
McMahon AW, Levenson MS, McEvoy  BW, Mosholder AD, Murphy  D. Age and risks 
of FDA -approved long -acting 2-adrenergic receptor agonists. Pediatrics. 
2011;Nov;128(5):e1147 -54. 
Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spi[INVESTIGATOR_038] . Eur Respir J. 
2005;26:319 -338. 
Mitchell KE, Johnson- Warrington V, Apps LD, Bankart LS, Williams JE, Rees K, Jolly  
K, Steiner M, Morgan M, Singh SJ. A Self -Management Programme for COPD: a 
Randomised Controlled Trial. Eur Respir J. 2014;44:1538 -1547. 
Murray  JJ, Waitkus- Edwards KR, Yancey  SW. Evaluation of Fluticasone Propi[INVESTIGATOR_424310]/Salmeterol Combination on Exercise in Pediatric and Adolescent 
Patients with Asthma. Open Resp Med J, 2011, 5, 11 -18.
National Institutes of Health (NIH). Guidelines for the Diagnosis and Management of 
Asthma - Expert Panel Report 3 2007 . U.S. Department of Health and Human Services, 
Bethesda, MD; 2007. NIH Publication No. 07-4051.
2015N231308_03 CONFIDENTIA L
201832
159Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky  DA, Rundell KW, et al. An 
Official American Thoracic Societ y Clinical Practice Guideline: Exercise -induced 
Bronchoconstriction. Am J Respir Crit Care Med 2013;187:1016–1027.
Pearlman D, Qaqundah P, Matz J, Yancey  SJ, Stempel DA, Ortega HG. F luticasone 
Propi[INVESTIGATOR_16847]/Salmeterol and Exercise -Induced Asthma in Children With Persistent 
Asthma. Pediatric Pulm 2009;44:429 –435.
Poppi[CONTACT_3019] H, Muittari A, Kreus KE, Korhonen O, Vilhanen A. Exercise Asthma and 
Disodium Cromogly cate. Br Med J 1970;4:337- 339.
Quanjer P, Stanojevic S, Cole T, Baur X., Hall G, Enright P, et al. on behalf of the ERS 
Global L ung Function Initiative.  Multi -ethnic reference values for spi[INVESTIGATOR_105221] 3 -
95 year age range: the global lung function 2012 equations. Eur Respir J , 2012; 40: 
1324 –1343.
Turpeinen M, Pelkonen AS, Nikander K, Sorva R, Selroos O, Juntunen -Backman K, 
Haahtela T. Bone mineral density  in children treated with daily  or periodical inhaled 
budesonide: the Helsinki Earl y Intervention Childhood Asthma study . Paediatri c 
Research. 2010;68(2):169-173. 
Weiler J, et al. Pathogenesis, prevalence, diagnosis, and management of exercise -induced 
bronchoconstriction: a practice parameter. Ann Allerg Asthma Immunol 2010;105 (6 
Supp): S1- S47. 
Weiler J, Nathan RA, Rupp NT, Kalberg CJ; Emmett A, Dorinsky  PM. Effect of 
fluticasone/salmeterol administered via a single device on exercise -induced 
bronchospasm in patients with persistent asthma. Ann. Allergy Asthma Immunol. 
2005;94:65-72.
Revised text:
European Medicines Agency  (EMA). No te for guidance on clinical investigation of 
medicinal products for treatment of asthma. 27Jun2013. CHMP/EWP/2922/01 Rev.1.
FDA Guidance for Industry : Exercise Induced Bronchospasm (EIB)—Development of 
Drugs to Prevent EIB, February  2002.
Global I nitiative for Asthma (GINA). Global Strategy for Asthma Management and 
Prevention. GI NA, www.ginasthma.org; 2015.
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, editors. 
Contraceptive Technology . 19th edition. [LOCATION_001]: Ardent Media, 2007(a): 24 . Table 3-
2.
ICH guideline M3(R2) on non -clinical safety  studies for the conduct of human clinical 
trials and marketing authorisation for pharmaceuticals, 2009; EMA/CPMP/ICH/286/1995
2015N231308_03 CONFIDENTIA L
201832
160Jones A, Fay  JK, Burr ML, Stone M, Hood K, Roberts G. Inhaled Corticoster oids Effects 
on Bone Metabolism in Asthma and Mild Chronic Obstructive Pulmonary Disease. 
Cochrane Database of Systemic Reviews. 2002;1:1 -21. 
Juniper EF, Svensson K, Mörk AC, Ståhl E. Modification of the Asthma Quality of 
Life Questionnaire (standardised) in patients 12 years and older. Health and Quality 
of Life Outcomes. 2005; 3:58.
König P, Hillmana L, Cervantesa C, Levine C, Maloney C , Douglass B ,et al. Bone 
Metabolism in Children with Asthma Treated with Inhaled Beclomethasone 
Dipropi[INVESTIGATOR_16847]. The Journ al of Paediatrics. 1993;122:219-226. 
McFadden ER, Gilbert IA. Exercise- induced asthma. N Engl J Med 1994;330:1362 -1367.
McMahon AW, Levenson MS, McEvoy  BW, Mosholder AD, Murphy  D. Age and risks 
of FDA -approved long -acting 2-adrenergic receptor agonists. Pediatrics. 
2011;Nov;128(5):e1147 -54. 
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi F, Coates A, et al. 
Standardisation of spi[INVESTIGATOR_038] . Eur Respir J. 2005;26:319 -338. 
Mitchell KE, Johnson- Warrington V, Apps LD, Bankart LS, Williams JE, Rees K,et al. . 
A Self- Management Programme for COPD: a Randomised Controlled Trial. Eur Respir 
J. 2014;44:1538-1547. 
Murray  JJ, Waitkus- Edwards KR, Yancey  SW. Evaluation of Fluticasone Propi[INVESTIGATOR_424310]/Salmeterol Combination on Exercise in Ped iatric and Adolescent 
Patients with Asthma. Open Resp Med J, 2011, 5, 11 -18.
National Institutes of Health (NIH). Guidelines for the Diagnosis and Management of 
Asthma - Expert Panel Report 3 2007 . U.S. Department of Health and Human Services, 
Bethesda, MD ; 2007. NIH Publication No. 07 -4051.
Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky  DA, Rundell KW, Hull JH, et al. 
An Official American Thoracic Societ y Clinical Practice Guideline: Exercise -induced 
Bronchoconstriction. Am J Respir Crit Care Med 2013 ;187:1016 –1027.
Pearlman D, Qaqundah P, Matz J, Yancey  SJ, Stempel DA, Ortega HG. Fluticasone 
Propi[INVESTIGATOR_16847]/Salmeterol and Exercise -Induced Asthma in Children With Persistent 
Asthma. Pediatric Pulm 2009;44:429 –435.
Poppi[CONTACT_3019] H, Muittari A, Kreus KE, Korhonen O, Vilhanen A. Exercise Asthma and 
Disodium Cromogly cate. Br Med J 1970;4:337- 339.
Quanjer P, Stanojevic S, Cole T, Baur X., Hall G, Enright P, et al. on behalf of the ERS 
Global L ung Function Initiative.  Multi -ethnic reference values for spi[INVESTIGATOR_105221] 3-
95 year age range: the global lung function 2012 equations. Eur Respir J , 2012; 40: 
1324 –1343.
2015N231308_03 CONFIDENTIA L
201832
161Turpeinen M, Pelkonen AS, Nikander K, Sorva R, Selroos O, Juntunen -Backman K,et al. 
Bone mineral density in children treated with daily  or periodical inhaled budesonide: the 
Helsinki Early  Intervention Childhood Asthma study . Paediatric Research. 
2010;68(2):169 -173. 
Weiler J, Anderson SD , Randolph C , Bonini S , Craig TJ, Pearlman DS ,et al. 
Pathogenesis, prevalence, diagnosis, and management of exercise -induced
bronchoconstriction: a practice parameter. Ann Allerg Asthma Immunol 2010;105 (6 
Supp): S1- S47. 
Weiler J, Nathan RA, Rupp NT, Kalberg CJ; Emmett A, Dorinsky PM. Effect of 
fluticasone/salmeterol administered via a single device on exercise -induced 
broncho spasm in patients with persistent asthma. Ann. Allergy Asthma Immunol. 
2005;94:65-72.
2015N231308_03 CONFIDENTIA L
201832
[ZIP_CODE].8.3. Protocol A mendment 03 (25-MAY-2016 ) from Protocol 
Amendment 02 (16 -DEC -2015)
Amendment 3is appli cable to all investigator sites in study  201832.
This amendment has been written to clarify  text regarding timing of visits to ensure that 
the intention of the protocol is correctly  reflected.  Other amendments were made where 
deemed necessary .
Method of Amendment
Original and revised texts are specified as follows:
Original t ext: as written in the Amendment No. 2
Revised text : as written in Amendment No. 03 with additional or revised text 
indicated b ybold font ,or bold underline (Time and Events Table) .
Amendment Details
Section 5.1  Ov erall Design
Original text:

2015N231308_03 CONFIDENTIA L
201832
163Revised text:
Rationale:
Day [ADDRESS_536496] the intention of the protocol to ensure that the 
two treatment periods are 14 day s in length .
Section 6.2 Randomisation Criteria
Original text:
At the end of the run -in period, a subject will be eligible for Randomization to double -
blinded study  treatment if he/she meets all the following criteria at Visit 2. Visit 2 may  be 
conducted over the course of 48 hours (within the designated window), if the eligibility 
exercise challenge is repeated.
Revised Text:
At the end of the run -in period, a subject will be eligible for Randomization to double-
blinded study  treatment if he/she meets all the following criteria at Visit 2 .
Rationale:
Visit [ADDRESS_536497] and Other Study  Treatment
Original text:
Albuterol/salbutamol inhalation aerosol will be supplied by  [CONTACT_23983]
2015N231308_03 CONFIDENTIA L
201832
164Revised Text:
Albuterol/salbutamol inhalation aerosol will be supplied as detailed in the SRM .
Rationale:
Change in strategy  for rescue medication suppl y.
Section 7.2.[ADDRESS_536498] Number
Original text:
At Visit1 , a unique Subject Number (CRF number) will be assigned to any  subject who 
hasat least one Visit [ADDRESS_536499] Number will be used to identify  individual subjects during the course of the 
study .
Revised Text:
At the Pre-screen visit, a unique Subject Number (CRF number) will be assigned to 
any subject who has given informed consent. The unique Subject Number will be used to 
identify  individual subjects during the course of the study .
Rationale:
Subject numbers must be assigned as soon as informed consent is given and the informed 
consent form signed, regardless of study  procedures.
Section 7.10.2  Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_424343]:
The following asthma medications are prohibited during the conduct of the study  or 
within the specified time frame:
Within 12 weeks of Visit 1 and during the study:
Systemic (oral, parenteral or depot) corticosteroids
Anti- IgE (e.g. Xolair )
Revised Text:
The following asthma medications are prohibited during the conduct of the study  or 
within the specified time frame:
Within 12 weeks of Visit 1 and during the study:
Systemic (oral, parenteral or depot) corticosteroids
Anti- IgE (e.g. Xolair , Nucala™)
Rationale:
Nucala has recentl y received a license for asthma and should be excluded.
2015N231308_03 CONFIDENTIA L
201832
165Table 3  Time and Events Table
Original text:
ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 212
Randomization3 412, 14 512 6 712, 14
Week -4 0 0 2 4 4 6 7
Treatment Day -26 to -30 
days1 2 14 (-2/+2) 
days28 (-2/+2) 
days29(-2/+2) 42 (-2/+2) 
days47 to 
[ADDRESS_536500] Demography X
Medical History (including CV) X
Disease (Asthma) History X
Medication History X X
Smoking history/status X
Inclusion/Exclusion Criteria X
Evidence of EIB X
Efficacy Assessments
Spi[INVESTIGATOR_038] (full FEV 1 and FVC) X X2 X2 X2 X X2 X2 X
Exercise Challenge Testing 
(Treadmill)X3, [ADDRESS_536501] SenseWear accelerometer X X
Safety Assessments
Concomitant Medication X X X X X X X X X X7
Physical Examination X
2015N231308_03 CONFIDENTIA L
201832
166ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 212
Randomization3 412, 14 512 6 712, 14
Week -4 0 0 2 4 4 6 7
Treatment Day -26 to -30 
days1 2 14 (-2/+2) 
days28 (-2/+2) 
days29(-2/+2) 42 (-2/+2) 
days47 to 
[ADDRESS_536502] Fluticasone Propi[INVESTIGATOR_16847] X X
Dispense Rescue16
Albuterol/salbutamolX X X X X X
Collect Rescue 
Albuterol/salbutamolX X X X
Dispense IP X11 X
Assess study drug  compliance X X X X X X X
Collect IP X X X
2015N231308_03 CONFIDENTIA L
[PHONE_8816]. Genetics saliva sample collected at Visit 2 (following Randomization) or at any scheduled visit thereafter. Genetics consent MUST be obtained PRIOR to 
collection of the Genetics sam ple.  
2. Pre-exercise spi[INVESTIGATOR_038] (full FEV 1 and forced vital capacity (FVC) testing), conducted immediately pre -exercise (and after vital signs), if applicable. Subject 
should have withheld albuterol/salbutamol within previous [ADDRESS_536503] demonstrate a 
decrease in FEV 1of 20% at one time point within [ADDRESS_536504] -exercise challenges. Longer monitoring may be required for those subjects 
who do not return to 5%of baseline FEV 1values within [ADDRESS_536505]. 
8. Vital signs will be collected before (prior to the pre -exercise spi[INVESTIGATOR_038]) and after each exercise challenge test.
9. Adverse Event and Serious Adverse Events to be collected from the start of study Drug (Visit 1) until the follow up contact. However, any SAE related to study 
participation will be     recorded from the time of Informed Consent 
10. Review medical conditions diary card, including an assessment of any potential change in exercise capacity
11. An unblinding card will be dispensed along with double blind IP.
12. Subjects will be contact[CONTACT_5143] [ADDRESS_536506].
14. Visit 4 and Visit 7 will begin between 5PM and 11PM and continue over a period of approximately 24 hours. Subjects will r eturn to the clinic at 12 hours and 23 
hours (after the evening dose of study medication from the evening visit) for an exercise challenge procedure.
15. Subjects will be contact[CONTACT_5143] [ADDRESS_536507] and re -dispense rescue as needed from Visit 1
17.   Subjects who achieve a decrease in FEV 1of 15 % to <20% may continue taking their daily run -in medication and repeat the eligibilit y exercise challenge and 
associated procedures once within a week of the original procedure.
2015N231308_03 CONFIDENTIA L
201832
168Revised Text:
ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 212
Randomization3 412, 14 512 6 712, 14
Week -4 0 0 2 4 4 6 7
Treatment Day -26 to -30 
days0 118 14 (-2/+2) 
days28 (-2/+2) 
days2918 42 (-2/+2) 
days47 to 
[ADDRESS_536508] Demograph y X
Medical History (including CV) X
Disease (Asthma) History X
Medication History X X
Smoking history/status X
Inclusion/Exclusion Criteria X
Evidence of EIB X
Efficacy Assessments
Spi[INVESTIGATOR_038] (full FEV 1 and FVC) X X2 X2 X2 X X2 X2 X
Exercise Challenge Testing 
(Treadmill)X3, [ADDRESS_536509] SenseWear accelerometer X X
Safety Assessments
Concomitant Medication X X X X X X X X X X7
Physical Examination X
Vital Signs X X8 X8 X8 X X8 X8 X
2015N231308_03 CONFIDENTIA L
201832
169ProceduresPre-Screen Screen/
Run-inTreatment Period 1 Treatment Period 2 Early
Withdrawal
VisitFollow -
up
Phone 
Call
Visit/Contact 0 1 212
Randomization3 412, 14 512 6 712, 14
Week -4 0 0 2 4 4 6 7
Treatment Day -26 to -30 
days0 118 14 (-2/+2) 
days28 (-2/+2) 
days2918 42 (-2/+2) 
days47 to 
[ADDRESS_536510] Fluticasone Propi[INVESTIGATOR_16847] X X
Dispense Rescue16
Albuterol/salbutamolX X X X X X
Collect Rescue 
Albuterol/salbutamolX X X X
Dispense IP X11 X
Assess study drug  compliance X X X X X X X
Collect IP X X X
2015N231308_03 CONFIDENTIA L
[PHONE_8817]. Genetics saliva sample collected at Visit 2 (following Randomization) or at any scheduled visit thereafter. Genetics consent MUST be obtained PRIOR to 
collection of the Genetics sample.  
2. Pre-exercise spi[INVESTIGATOR_038] (full FEV 1 and forced vital capacity (FVC) testing), conducted immediately pre -exercise (and after vital signs), if applicable. Subject 
should have withheld albuterol/salbutamol within previous [ADDRESS_536511] demonstrate a 
decrease in FEV 1of 20% at one time point within [ADDRESS_536512] -exercise challenges. Longer monitoring may be required for those subjects 
who do not return to 95%of baseline FEV 1values within [ADDRESS_536513]. 
8. Vital signs will be collected before (prior to the pre -exercise spi[INVESTIGATOR_038]) and after each exercise challenge test.
9. Adverse Event and Serious Adverse Events to be collected from the st art of study Drug (Visit 1) until the follow up contact. However, any SAE related to study 
participation will be recorded from the time of Informed Consent 
10. Review medical conditions diary card, including an assessment of any potential change in exercise c apacity
11. An unblinding card will be dispensed along with double blind IP.
12. Subjects will be contact[CONTACT_5143] [ADDRESS_536514].
14. Visit 4 and Visit 7 will begin between 5PM and 11PM and continue over a period of approximately 24 hours .Subjects will return to the clinic at 12 hours (±1 
hour) and 23 hours (±1 hour) (after the evening dose of study medication from the evening visit) for an exercise challenge procedure.
15. Subjects will be contact[CONTACT_5143] [ADDRESS_536515] and re -dispense rescue as needed from Visit 1
17.   Subjects who achieve a decrease in FEV 1of 15 % to <20% may continue taking their daily run -in medication and repeat the eligibility exercise challen ge and 
associated procedures once within a week of the original procedure.
18.   Visit [ADDRESS_536516] be performed on the day immediately following Vis it 5.
Rationale:
Corresponding Day  for Visit [ADDRESS_536517] the intention of the protocol to ensure that the two treatment periods 
are 14 day s in length.  Other minor adjustments made to clarify  the timing of visits.
2015N231308_03 CONFIDENTIA L
201832
171Section [IP_ADDRESS]  Visit 2 (Randomi zation)
Original text:
Treatment period 1 baseline FEV 1:Spi[INVESTIGATOR_424300] 2 at 
approximately  the same time as at Visit 1 (±1 hour). The FEV 1should be measured 
approximately  12 hours after dosing with run-in medication (FP 250 mcg). At least two 
valid and two r epeatable spi[INVESTIGATOR_424344].
Revised Text:
Treatment period 1 baseline FEV 1:Visit 2 begins between 5 PM and 11 PM and 
should begin at approximately the same time as Visit 1 (±1 hour).   Spi[INVESTIGATOR_424301] 2 at approximately  the same time as at Visit 1 (±1 hour). The FEV 1
should be measured approximately  12 hours (±1 hour) after dosing with run- in 
medication (FP 250 mcg). At least two valid and two repeatable spi[INVESTIGATOR_424345].
Rationale:
To ensure clarity of the timing of visit 2.
Section [IP_ADDRESS] -Visit 3 and Visit 6 ([ADDRESS_536518] Dose Exercise 
Challenge)
Original text:
Pre-exercise FEV 1:Spi[INVESTIGATOR_424305] 3 and 6 at approximately  the 
same time as at Visit 1 (±1 hour). The FEV 1should be measured approximately  [ADDRESS_536519] two valid spi[INVESTIGATOR_424346].
Revised Text:
Pre-exercise FEV 1:Spi[INVESTIGATOR_424305] 3 and 6 at approximately  the 
same time as at Visit 1 (±1 hour). The FEV 1should be measured approximately  23 hours 
(±1 hour) after the first dose in each treatment period. At leas t two valid spi[INVESTIGATOR_424306].
Rationale:
To ensure clarit y of the timing of Spi[INVESTIGATOR_424347] 3 and 6.
Section [IP_ADDRESS] –Visit 5
Original text:
Treatment period 2 baseline FEV 1:Spi[INVESTIGATOR_424348] 5 at 
approximately  the same time as at Visit 1 (±1 hour). The FEV 1should be measured 
approximately  [ADDRESS_536520] two valid 
spi[INVESTIGATOR_424309].
2015N231308_03 CONFIDENTIA L
201832
172Revised Text:
Treatment period 2 baseline FEV 1:Spi[INVESTIGATOR_424300] 5 at 
approximately  the same time as at Visit 1 (±1 hour). The FEV 1should be measured 
approximately  12 hours (±1 hour) after dosing with the washout medication. At least two 
valid spi[INVESTIGATOR_424309].
Rationale:
To ensure clarit y of the timing of Spi[INVESTIGATOR_424349] 5.
Section 8.4.5 
Original Text:
Vital signs will be obtained after subjects have rested for approximately  5 minutes in a 
semi -supi[INVESTIGATOR_2547].
Revised Text:
Vital sig ns will be obtained after subjects have rested for approximately  [ADDRESS_536521] exercise s pi[INVESTIGATOR_424350].
Section 13.1 –Appendix 1 –Abbrev iations and Trademarks -
Original text:
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_424372]/BREO
2015N231308_03 CONFIDENTIA L
201832
173Revised Text:
Trademark Information
Trademarks of the GlaxoSmithKline 
group o f companiesTrademarks not owned by [CONTACT_424372]/BREO
NUCALA
Rationale:
Addition of Trademark to reflect addition of prohibited medication.